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1.  MicroRNAs 
MicroRNAs (miRNAs) are single-stranded RNA molecules of ~22nt (Bartel, 2004) 
that belong to the larger family of non-coding RNAs. MiRNAs inhibit expression 
of genes by repressing their translation or stability (Filipowicz et al., 2008). The 
first miRNA, lin-4, was discovered in Caenorhabditis elegans (C. elegans) in 
1993 (Lee et al., 1993). However, only after the second miRNA, let-7, was 
discovered in 2000 (Reinhart et al., 2000), more attention was paid to miRNAs. 
Since then a substantial number of miRNAs has been identified with, at present, 
more than 25,000 miRNAs in the miRBase database, including over 2,000 
human miRNAs (miRbase Release 19, Kozomara and Griffiths-Jones, 2011). 
MiRNAs have been found in a total number of 193 species, including viruses, 
plants and animals. Approximately 55% of the C. elegans miRNAs have 
homologues in humans indicating that there is high degree of conservation 
during animal evolution (Ibanez-Ventoso et al., 2008). This high degree of 
conservation indicates the importance of miRNAs in cellular functioning.  
Biogenesis of miRNAs 
Genomic locations of miRNAs include introns and exons of protein-coding or 
noncoding genes as well as intergenic regions (Fig.1) (Kim and Nam, 2006). The 
majority of the miRNAs are located in introns of protein-coding genes. MiRNAs 
are transcribed together with their host gene as longer primary miRNA 
transcripts (pri-miRNA) (Cai et al., 2004). The canonical miRNA biogenesis 
pathway consists of two enzymatic steps (Fig. 2). Transcription of pri-miRNAs 
generally involves polymerase II and occasionally polymerase III (Borchert et 
al., 2006; Lee et al., 2004). The pri-miRNA transcripts contain one or more 
hairpin structures. Different miRNAs that are transcribed from one primary 
transcript with multiple hairpin structures are denoted as miRNA clusters (Lee et 
al., 2002). MiRNA clusters are not a rare finding. In fact, miRNA clusters 













FIGURE 1. Genomic localization of miRNAs. (A) MiRNAs can be localized in introns of 
protein-coding or noncoding genes (intronic miRNAs). As an example the miR-31 primary 
transcript with the stem-loop in the intron of the noncoding MIR31HG gene is shown. (B) 
MiRNAs localized in exons of noncoding genes (exonic miRNAs). The location of the miR-
155 stem-loop in exon 3 of the BIC noncoding gene. (C) MiRNAs that have their own 
promoter (intergenic miRNAs), as an example the miR-21 gene is shown. 
 
 
 Biogenesis of miRNAs is tightly regulated resulting in specific miRNA 
expression patterns in certain tissues or at specific developmental stages. 
Hairpin structures are processed by the Microprocessor complex that consists of 
DiGeorge syndrome critical region 8 (DGCR8) and the RNase III endonuclease 
Drosha (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Landthaler et 
al., 2004; Lee et al., 2003). DGCR8 recognizes the hairpin structure by 
interacting with the ssRNA segments flanking the stem-loop structure and 
mediates cleavage of the hairpin structure by Drosha (Han et al., 2006; Zeng 
and Cullen, 2005). The resulting 60-70nt precursor miRNA (pre-miRNA) is 
exported to the cytoplasm by the Exportin 5 – RanGTP complex to be further 
processed by the RNase III endonuclease Dicer to a double stranded ~22nt 
miRNA/miRNA* duplex (Bohnsack et al., 2004; Grishok et al., 2001; Hutvagner 
et al., 2001; Lund et al., 2004; Yi et al., 2003). One strand, denoted as the 
miRNA, is incorporated into the RNA-induced silencing complex (RISC) while the 
other strand, denoted as the miRNA*, is often degraded (Eulalio et al., 2008; 
Filipowicz et al., 2008). Selection of the miRNA that will be retained in the RISC 
complex is thought to depend on the stability of the 5’ends of the 
miRNA/miRNA* duplex (Khvorova et al., 2003; Schwarz et al., 2003). Each of 
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the two strands of the duplex can be incorporated into the RISC complex. 
Therefore, miRNA-5p and -3p nomenclature is now more commonly used.
 
FIGURE 2. Canonical biogenesis of miRNAs. MicroRNAs are transcribed as long 
primary transcripts (pri-miRNA) that are processed by the Drosha-DGCR8 complex to 
precursor miRNA (pre-miRNA). These precursors are exported to the cytoplasm by 
Exportin-5 and further processed by Dicer to a miRNA/miRNA* duplex. The mature miRNA 
is incorporated into the RNA-induced silencing complex (RISC) and this complex binds to 
the 3’UTR of its target genes and inhibits the translation. 
Function of miRNAs 
RISC is a multiprotein complex that includes a miRNA and one of the four 
Argonaute proteins (Gregory et al., 2005; Hutvagner and Zamore, 2002; 
Mourelatos et al., 2002). The miRNA guides the RISC to its target transcripts 
based on partial complementarity between the mRNA and miRNA (Fig. 2). A high 
degree of complementarity of nucleotides 2-7 of the miRNA is the most 
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is referred to as the “seed sequence”. The degree of homology for the remaining 
part of the miRNA may be lower and thus adds to the promiscuous nature of 
single miRNAs that target different mRNAs (Doench and Sharp, 2004). MiRNAs 
that share “seed sequences” belong to the same miRNA seed family and may, at 
least in part, target the same set of genes. MiRNAs usually bind to the 3’UTR of 
the target gene and less frequent to the coding sequence or 5’UTR (Chi et al., 
2009). MiRNA binding affects either mRNA translation or its stability (Pillai et al., 
2007). Both target gene prediction programs and biochemical approaches have 
been widely applied to identify miRNA target genes and they indicated that each 
miRNA can target multiple mRNAs and each mRNA can be targeted by multiple 
miRNAs. It is estimated that more than one third of the genes can be regulated 
by miRNAs (Lewis et al., 2005). This suggests that miRNAs play a role in a large 
variety of cellular processes. Functional studies have indeed indicated that 
miRNAs are involved in virtually all biological processes including programmed 
cell death, proliferation, cell differentiation and metabolic control. In addition, 
miRNAs have been causally linked to many pathological conditions including 
diabetes, cardiovascular disease, autoimmune disorders and, most thoroughly 
investigated, cancer. A substantial number of human miRNAs are located in the 
cancer-associated genomic locations (Calin et al., 2004) and there are numerous 
studies that show altered miRNA levels in various cancer types (Lu et al., 2005; 
Sassen et al., 2008). Alteration of miRNA levels in cancer can be caused by 
genetic aberrations, deregulation of transcription and epigenetic factors, 
alterations in miRNA processing and/or miRNA stability.  
2.  B-cell lymphoma 
The most common B-cell lymphoma subtypes include diffuse large B-cell 
lymphoma (DLBCL), Hodgkin lymphoma (HL), follicular lymphoma (FL), chronic 
lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), marginal zone 
lymphoma (MZL) and Burkitt lymphoma (BL) (Kuppers, 2005). All these 
malignancies display distinct clinical, histological and immunophenotypic 
features, and vary greatly in short-term and long-term response to treatment.  
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 A large proportion of the B-cell lymphomas are derived from B cells at the 
germinal center (GC) stage of maturation (Kuppers et al., 1999). GCs arise from 
foci of mature naïve B cells upon B-cell antigen receptor (BcR) stimulation in 
combination with co-stimulatory signals from T cells (MacLennan, 1994). GCs 
are characterized by proliferating B cells that have an active somatic 
hypermutation (SHM) machinery (Kuppers et al., 1993). During SHM, a high 
rate of mutations is introduced into the functionally rearranged immunoglobulin 
(Ig) genes, affecting their affinity. Fractions of these GC B cells undergo class-
switch recombination, which is mediated by double-strand DNA breaks (Liu et 
al., 1996). These cells may undergo second rounds of affinity maturation and 
selection, after which they may differentiate into memory or plasma cells. Both 
processes are essential for successful antigen-driven maturation of B cells, but 
they also represent important risk factors for malignant transformation. 
Accordingly, an established hallmark of many types of B-cell lymphomas are 
reciprocal translocations involving one of the Ig gene loci (heavy and light chain 
genes) and a proto-oncogene. The result is uncontrolled constitutive expression 
of the translocated gene. Examples of such GC-derived translocations are BCL6-
Ig in DLBCL, MYC-Ig in BL and DLBCL and BCL2-Ig in FL (Baron et al., 1993; 
Dalla-Favera et al., 1983; Ladanyi et al., 1991; Taub et al., 1982; Ye et al., 
1993). The involvement of non-Ig gene loci is partially caused by the somatic 
hypermutation machinery which can also target many non-Ig genes. 
3.  MicroRNAs in B-cell lymphoma 
Several miRNAs have been shown to have tumor suppressive or oncogenic 
activity in B-cell lymphoma. Tumor suppressive miRNAs may target oncogenes, 
and loss of such miRNAs leads to enhanced levels of oncogenic proteins. Tumor 
suppressive miR-15a and miR-16-1 are frequently deleted or downregulated in 
CLL (Calin et al., 2002; Calin et al., 2005). Mice with deletion of the genomic loci 
containing this miRNA locus developed CLL-like disease (Klein et al., 2010). The 
tumor suppressive role of miR-15a and miR-16-1 in CLL has been reported to 
involve inhibition of the anti-apoptotic oncogene Bcl-2 (Cimmino et al., 2005). 
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(Mayr et al., 2007; Sampson et al., 2007). Oncogenic miRNAs may target tumor 
suppressor genes, and enhanced expression of these oncogenic miRNAs may, as 
such, result in reduced levels of tumor suppressor proteins. For example, miR-
21 is upregulated in most cancer types (Buscaglia and Li, 2011). Conditional 
overexpression of miR-21 in mice resulted in formation of tumors with pre-B cell 
malignant lymphoid-like phenotype that regressed completely when miR-21 was 
inactivated (Medina et al., 2010). This indicates that miR-21 is a genuine 
oncogene that plays a key role in tumor growth. Other oncogenic miRNAs 
strongly associated with both B-cell functioning and B-cell lymphoma are miR-
155 and the miR-17~92 cluster (Hayashita et al., 2005; Kluiver et al., 2005; 
Kluiver et al., 2006).  
MiR-155  
MiR-155 is processed from the transcript of a noncoding gene called B-cell 
integration cluster (BIC) (Lagos-Quintana et al., 2002). Several studies have 
shown that BIC and miR-155 play a crucial role in the immune response 
(O'Connell et al., 2009; Rodriguez et al., 2007; Thai et al., 2007). BIC 
expression levels are highly induced in B cells upon stimulation via the B cell 
receptor (van den Berg et al., 2003). BIC and miR-155 are highly expressed in 
normal tonsillar GC B cells indicating a role in B-cell maturation (Kluiver et al., 
2007). This was indeed demonstrated in BIC/miR-155-deficient mice (Rodriguez 
et al., 2007; Thai et al., 2007). These mice showed reduced numbers of 
germinal center B cells and diminished high-affinity IgG1 antibody production. 
Also, in vitro activated miR-155-deficient T cells showed increased tendency to 
differentiate into Th2-type cells (Rodriguez et al., 2007).  
 BIC/miR-155 was one of the first oncogenic miRNAs shown to be 
associated with B-cell lymphoma. Elevated miR-155 levels were observed in 
several B-cell lymphomas, such as HL, DLBCL and PMBL (Eis et al., 2005; 
Kluiver et al., 2005). Further evidence for an oncogenic role for miR-155 came 
from a study demonstrating that Eµ-miR-155 transgenic mice developed 
polyclonal pre-B-cell proliferations leading to B-cell malignancies at later stages 
(Costinean et al., 2006). Myeloproliferative disorders were induced by 
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overexpression of miR-155 in hematopoietic stem cells in a mouse model 
(O'Connell et al., 2008). Recently, Babar et al. showed that induction of miR-155 
caused disseminated lymphoma in mice, characterized by clonal and 
transplantable neoplastic pre-B cells (Babar et al., 2012). Tumor cells were 
shown to be addicted to miR-155, as miR-155 withdrawal lead to rapid tumor 
regression due to increased apoptosis of the malignant cells. These studies 
suggest that inhibition of miR-155 can be used as a therapeutic strategy for 
miR-155-expressing lymphomas.  
 In contrast, to other GC B-cell-derived lymphomas, miR-155 is expressed 
at very low levels in Burkitt lymphoma suggesting that miR-155 may also have a 
tumor suppressive function (Kluiver et al., 2006). Consistent with this putative 
tumor suppressor function, miR-155 has been shown to target activation-
induced cytidine deaminase (AID) (Dorsett et al., 2008). AID promotes 
immunoglobulin gene diversification in normal B cells, but thereby enhances the 
risk of chromosomal translocations involving the immunoglobulin loci (Dorsett et 
al., 2007; Liu et al., 2008; Ramiro et al., 2004). Translocations involving the 
MYC locus and one of the immunoglobulin gene loci are a hallmark of Burkitt 
lymphoma (Taub et al., 1982). Thus, these data indicate that downregulation of 
miR-155 may contribute to the initiation phase of Burkitt lymphoma by 
enhancing the formation of MYC translocations. 
The miR-17~92 cluster  
The miR-17~92 cluster consists of 6 miRNAs that are processed from a single 
primary transcript, C13ORF25 (Figure 3). This miRNA cluster has two paralogs, 
i.e. the miR-106a~363 and miR-106b~25 clusters that share multiple seed 
family members and also some identical miRNAs (Tanzer and Stadler, 2004). 
C13ORF25 is located in the 13q31 region, which is often amplified in B-cell 
lymphoma (Ota et al., 2004; Rinaldi et al., 2007). Mice deficient for miR-17~92 
have a block in pro-B to pre-B-cell development, indicating an important role of 













FIGURE 3. Schematic representation of the miR-17~92 cluster. Each dominant 
miRNA which is derived from the strand -3p or 5p is indicated in red. 
of miR-17~92 in the Eµ-MYC mouse B-cell lymphoma model resulted in 
accelerated B-cell lymphoma development (He et al., 2005). More recently, miR-
19a and miR-19b have been identified as the key oncogenic components 
necessary and sufficient for promoting MYC-induced lymphomagenesis by 
repressing apoptosis (Mu et al., 2009; Olive et al., 2009). Several individual 
members of this miRNA cluster play important roles in proliferation, tumor 
angiogenesis and suppression of apoptosis (Dews et al., 2006; Hayashita et al., 
2005; Li et al., 2012; Matsumura et al., 2003).  
SCOPE OF THE THESIS 
Altered miRNA levels are observed in almost all types of cancer including B-cell 
lymphoma. The aim of this thesis is to investigate possible causes of altered 
miRNA levels and the specific consequences of altered miRNA-155 levels in B-
cell lymphoma.  
 MiRNA levels are regulated at the level of transcription of the primary 
transcripts, miRNA processing and miRNA stability. In this thesis, we focus on 
the regulation of miRNA processing and the consequences of altered miR-155 
levels. In chapter 2, we present an overview of established mechanisms to 
regulate miRNA processing. This chapter serves as an introduction to the 
experimental work described in chapters 3 and 4. In chapter 3, we present our 
results on processing of exonic miRNAs. It is still unclear whether exonic miRNAs 
are processed from unspliced or spliced pri-miRNA transcripts. To study this, we 
assessed the levels and cellular localization of unspliced and spliced pri-miRNA 
Introduction & Scope of the thesis 
 
19 
transcripts of miR-155, miR-146a and miR-22. In addition, we overexpressed 
miR-155 using constructs containing pre-miR-155 and either exonic or intronic 
5’ upstream flanking sequence to determine if these upstream sequences 
affected the processing efficiency to miR-155. In chapter 4, we describe our 
study on processing of the miR-17~92 cluster. We assessed levels of the 
primary miR-17~92 transcript and the six mature miRNAs in normal B cells, 117 
non-Hodgkin lymphoma (NHL) cases and in 21 NHL cell lines. We assessed the 
correlation between the levels of primary miR-17~92 transcripts with each of 
the six mature miRNAs in each NHL subtype. We also compared the levels of the 
individual miR-17~92 cluster members in NHL to the levels in their normal B-cell 
counterparts to identify which miRNAs are induced in NHL.  
 To determine the consequences of altered miRNA expression levels, it is 
crucial to effectively inhibit miRNAs. In chapter 5, we describe a straight-
forward method to inhibit miRNAs using miRNA sponges. We showed how to 
generate retroviral miRNA sponges with variable numbers of miRNA binding 
sites. We confirmed their effectiveness and showed applications for loss-of-
function studies. In chapter 6, we describe the consequence of altered miR-155 
expression in B-cell lymphoma. To this end, we overexpressed miR-155 in 
Burkitt lymphoma cells with very low endogenous levels and determined the 
effect of miR-155 induction on cell growth. We next identified genes that are 
targeted by miR-155 using Ago2-RIP-Chip. We validated six selected genes by 
luciferase reporter assay and assessed whether their inhibition by shRNAs could 
phenocopy the effect of miR-155 induction on the growth of Burkitt lymphoma 
cells. We used a miR-155 sponge to determine whether the six selected targets 
are also regulated by endogenous miR-155 in Hodgkin lymphoma cells with high 
endogenous miR-155 level. Finally, in chapter 7, we summarize and discuss 
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MicroRNAs (miRNAs) are a set of small, non-protein-coding RNAs that regulate 
gene expression at the post-transcriptional level. Maturation of miRNAs 
comprises several regulated steps resulting in ~22-nucleotide single-stranded 
mature miRNAs. Regulation of miRNA expression can occur both at the 
transcriptional level and at the post-transcriptional level during miRNA 
processing. Recent studies have elucidated specific aspects of the well-regulated 
nature of miRNA processing involving various regulatory proteins, editing of 
miRNA transcripts, and cellular location. In addition, single nucleotide 
polymorphisms in miRNA genes can also affect the processing efficiency of 
primary miRNA transcripts. In this review we present an overview of the 
currently known regulatory pathways of miRNA processing and provide a basis 
to understand how aberrant miRNA processing may arise and may be involved in 
pathophysiological conditions such as cancer. 
 




MicroRNAs (miRNAs) are small (22-nucleotide [nt]) noncoding RNA molecules 
that are single-stranded in the functional form (Bartel 2004). Unlike their small 
size, they play an important role in the regulation of gene expression at the 
post-transcriptional level. After their discovery in Caenorhabditis elegans (Lee et 
al. 1993; Wightman et al. 1993), there have been a large number of studies 
identifying miRNAs in animals, plants, and viruses. Their importance was 
confirmed in several cellular processes like development, cell fate determination, 
proliferation, and apoptosis. Moreover, altered miRNA expression profiles have 
been demonstrated in a large number of pathological conditions, such as cancer, 
suggesting that miRNAs are involved in disordered cellular function, such as 
malignant transformation.  
 MiRNAs are located within introns and exons of protein coding genes or in 
intergenic regions (Kim and Nam 2006). They are transcribed as long primary 
miRNA (pri-miRNA) transcripts containing one or more hairpin structures. Each 
hairpin structure consists of a double-stranded stem and a terminal loop. In the 
nucleus, the primary miRNA is cleaved by the Microprocessor complex, which 
consists of Drosha and DGCR8 (Lee et al. 2003; Denli et al. 2004; Gregory et al. 
2004; Han et al. 2004; Landthaler et al. 2004). This cleavage step results in an 
~65-nt precursor miRNA (pre-miRNA), which is exported from the nucleus to the 
cytoplasm in association with Exportin-5 and RanGTP (Yi et al. 2003; Bohnsack 
et al. 2004; Lund et al. 2004) and cleaved by Dicer to an ~22-nt miRNA duplex 
(Grishok et al. 2001; Hutvagner et al. 2001). One of the two strands is 
assembled into the RNA-induced silencing complex (RISC) together with one of 
the Argonaute (Ago) proteins. RISC can bind to the 3’-untranslated region (UTR) 
of the target mRNA based on a partial miRNA–mRNA complementarity. This 
binding causes a translational inhibition and/or degradation of the target mRNA 
(Eulalio et al. 2008; Filipowicz et al. 2008). However, not all miRNAs are 
processed by this so-called canonical biogenesis pathway. Alternatively, miRNAs 
can be generated from short intronic hairpins called mirtrons that are spliced 
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Mirtrons bypass cleavage by Drosha, but nuclear export and further processing 
are common with the canonical miRNA processing pathway (Okamura et al. 
2007; Ruby et al. 2007).  
 Biogenesis of miRNAs is tightly regulated resulting in characteristic miRNA 
expression patterns for different organisms, tissues, cell types, and 
developmental stages. It is known that transcription of miRNA genes can be 
regulated by epigenetic factors (Scott et al. 2006; Lehmann et al. 2007; 
Lujambio et al. 2007) or transcription factors (Xi et al. 2006; He et al. 2007; 
mature miRNA expression levels clearly indicate that the level of mature miRNAs 
can also be regulated at the level of miRNA processing. This review focuses on 
the mechanisms and factors that regulate miRNA processing, for example, 
regulatory proteins, cellular localization, and genetic variation. 
MECHANISMS FOR REGULATING MICRORNA PROCESSING 
Processing of miRNAs can be regulated at multiple steps and leads to either 
elevated or decreased miRNA levels. Altered miRNA levels may be caused by 
regulatory proteins that influence miRNA processing, acquired variations in the 
miRNA transcript, and by changes in the nuclear export efficiency. In addition to 
these regulatory mechanisms, single nucleotide polymorphisms (SNPs) can also 
have a pronounced effect on the efficiency of the miRNA processing machinery.  
Regulatory proteins 
Recently, a number of proteins that regulate miRNA processing have been 
described as key elements in defining the unique expression patterns of miRNAs 
in different cell types, tissues, or in pathological conditions. These proteins can 
be subdivided into three groups, i.e., Drosha binding/associated proteins, Dicer 
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Drosha binding/associated proteins  
The Microprocessor complex consisting of Drosha and DGCR8 is sufficient to 
process pri-miRNA to pre-miRNA (Fig. 1A). However, Drosha was shown to be a 
component of a larger complex containing DEAD-box RNA helicases p68 (DDX5), 
p72 (DDX17), nuclear factor (NF) 90, and NF45 (Gregory et al. 2004). The 
p68/p72 and NF90/NF45 complexes have been shown to alter the miRNA 
processing efficiency for specific miRNAs (Fukuda et al. 2007; Davis et al. 2008; 
Sakamoto et al. 2009; Suzuki et al. 2009; Yamagata et al. 2009). Specifically, it 
has been shown that endogenous p68/p72 facilitate Drosha processing of a 
subset of pri-miRNAs based on reduced mature miRNA levels in both p72- and 
p68-helicase-deficient mouse embryos (Fukuda et al. 2007). Several studies 
showed that interaction of p68/p72 with other proteins also alters processing of 
specific primary miRNAs. Interaction of p68 with SMAD facilitates the processing 
of pri-miR-21 (Fig. 1B; Davis et al. 2008). The interaction of p68 with SMAD was 
induced by transforming growth factor β (TGF-β) and bone morphogenetic 
proteins (BMPs). Similarly, wild-type p53 has been shown to associate with p68 
and enhance processing of several primary miRNAs by Drosha, including pri-
miRNA of miR-16-1, miR-143, and miR-145, in response to DNA damage (Fig. 
1C; Suzuki et al. 2009). Moreover, wild-type p53 positively regulates Drosha-
mediated processing by promoting recruitment of Drosha complex to the target 
pri-miRNAs, whereas mutant p53 hinders assembly of the Drosha complex 
(Suzuki et al. 2009). Drosha-mediated processing can be inhibited by p68/p72-
dependent mechanisms upon stimulation of estrogen receptor alpha (ERα) (Fig. 
1D; Yamagata et al. 2009). This mechanism caused obstructed processing of a 
set of pri-miRNAs including miR-16, miR-125a, miR-143, miR-145, and miR-195 
(Yamagata et al. 2009). Together these studies show that the p68/p72 complex 
is an important mediator of miRNA processing regulation and can direct Drosha 
toward either reduced or enhanced processing of specific miRNAs. The result of 
the interaction between Drosha, p68, and the target pri-miRNA depends on 
proteins interacting with p68 like SMAD, p53, or ERα. This indicates that the 













FIGURE 1. MicroRNA processing regulation by Drosha binding or Drosha-
associated proteins. (A) Primary miRNA transcript (Pri-miRNA) is processed by 
Drosha/DGCR8 complex to precursor miRNA (Pre-miRNA). (B) SMAD associates with pri-
miR-21, p68, and Drosha/DGCR8 complex to enhance pri-miR-21 processing. (C) 
Association of p53 with pri-miR-16-1 and pri-miR-143, p68, and Drosha/DGCR8 enhances 
pri-miR-16-1 and pri-miR-143 processing. (D) p68/p72 complex mediates inhibition of pri-
miR-16, pri-miR-125a, pri-miR-143, pri-miR-145, and pri-miR-195 upon stimulation of 
estrogen receptor α (ERα) by estradiol (E2). (E) Nuclear factor (NF) 90/45 complex inhibits 
Drosha/DGCR8 processing by binding to stem/loop fragment of pri-miR-21, pri-miR-
15~16-1, and pri-let-7a-1. 
 Two other members of the large Drosha-containing complex identified by 
Gregory et al. (2004), i.e., NF90 and NF45, were also shown to be involved in 
the regulation of miRNA processing (Fig. 1E). However, the interaction between 
Drosha and NF90/NF45 has not been confirmed for the endogenous Drosha–
DGCR8 complex (Sakamoto et al. 2009). Nevertheless, overexpression of 
NF90/NF45 in 293T cells caused accumulation of pri-let-7a-1, pri-miR-21, and 
pri-miR-15a~16-1, without affecting the mature miRNA levels (Sakamoto et al. 
2009). This suggests that the decreased processing efficiency induced by 
NF90/NF45 was compensated by other factors. Depletion of NF90 resulted in 
decreased pri-let-7a-1 levels and increased mature let-7a levels (Sakamoto et 
al. 2009). The higher binding affinity of NF90/NF45 to pri-let-7a-1, as compared 
to DGCR8 in vitro, suggested that the reduced miRNA processing efficiency was 
caused by reducing the accessibility for Drosha–DGCR8 (Sakamoto et al. 2009).  
 Current literature shows that regulatory proteins are a dominant factor in 
the regulation of Drosha-mediated pri-miRNA processing. Moreover, various 
signaling pathways enhance or reduce the efficiency of this step. It is likely that 
more Drosha-associated proteins regulate miRNA processing, and, as such, the 
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balance between positive and negative regulators may determine the efficiency 
of miRNA processing. 
Dicer binding proteins 
Dicer interacts with Tar RNA binding protein (TRBP) and protein activator of PKR 
(PACT) and one of the Ago (1–4) proteins, mainly Ago2 (Chendrimada et al. 
2005; Haase et al. 2005; Lee et al. 2006). TRBP and PACT facilitate RISC 
assembly, and they are not essential for miRNA processing (Haase et al. 2005; 
Lee et al. 2006). However, phosphorylated TRBP stabilized the Dicer-containing 
complex (Paroo et al. 2009). Expression of phospho-mimic TRBP resulted in 
increased levels of growth-promoting miRNAs like miR-17, miR-20a, and miR-92 
and decreased the level of the growth-inhibitory miRNA let-7a (Paroo et al. 
2009). However, let-7a level is affected indirectly via a mechanism that may 
involve other proteins like Lin28 (Paroo et al. 2009). TRBP phosphorylation was 
mediated by the mitogen-activated protein kinase (MAPK) signaling pathway. 
Therefore, alteration of miRNA processing by ERK may result in a pro-growth 
phenotype. 
 Ago proteins are important for proper miRNA function. However, they can 
also influence miRNA expression. Ectopically expressed Ago proteins (Ago1–4) 
enhanced expression of some miRNAs including miR-215, miR-17-5p, miR-23b, 
and miR-92 (Diederichs and Haber 2007). Additionally, Ago2, which has intrinsic 
endonuclease activity in mammals (Song et al. 2004), induced cleavage of pre-
miRNAs leading to an alternative processing intermediate with cleaved arms of 
the hairpin (Diederichs and Haber 2007). This intermediate did not change 
processing to mature miRNA, but may facilitate miRNA duplex dissociation and 
formation of RISC complex. Dicer-associated proteins, especially TRBP, clearly 
play a role in the regulation of miRNA processing. However, the mechanisms and 
specificity of this regulation remain unknown. 
Terminal loop binding proteins 
Processing of primary and precursor miRNAs (Fig. 2A) can be regulated by 
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processing efficiency. Members of the let-7 family were shown to be post-
transcriptionally regulated during differentiation of human embryonic stem cells 
(Suh et al. 2004), development of mice (Thomson et al. 2006), and neural 
differentiation of embryocarcinoma cells (Wulczyn et al. 2007). In all cases, 
Lin28, the developmentally regulated RNA binding protein, was shown to inhibit 
pri-let-7 processing (Fig. 2B; Newman et al. 2008; Piskounova et al. 2008; 
Rybak et al. 2008; Viswanathan et al. 2008). Lin28 interacted with the terminal 
loop region via a conserved sequence, inhibiting processing of pri- and pre-
miRNA (Newman et al. 2008; Piskounova et al. 2008; Rybak et al. 2008; 
Viswanathan et al. 2008). Suppression of let-7 in neural stem cells led to 
upregulation of Lin28 and failure of pre-let-7 processing (Rybak et al. 2008). 
These results suggest a feedback loop between let-7 and Lin28. Lin28 causes 
terminal uridylation of pre-let-7 in the cytoplasm (Heo et al. 2008) leading to 
inhibition of Dicer processing and inducing guidance of pre-let-7 to a 
degradation pathway (Fig. 2B). A terminal uridylyl transferase 4 (TUTase 4, 
TUT4) has been shown to be responsible for the pre-let-7 uridylation (Hagan et 
al. 2009; Heo et al. 2009; Lehrbach et al. 2009). Binding of TUT4 to pre-let-7 is 
dependent on the presence of Lin28, confirming that Lin28 is necessary for 
recruiting TUT4.  
 The RNA binding protein heterogeneous nuclear ribonucleoprotein A1 
(hnRNP A1) has been reported to facilitate processing of miR-18a, a member of 
the miR17~92 cluster (Fig. 2C; Guil and Caceres 2007). Knockdown of hnRNP 
A1 resulted in inhibition of pri- to pre-miR-18a processing, but did not affect 
other members of this cluster. This might in part explain variations in levels of 
the individual mature miRNA members of this cluster (Yu et al. 2006; Lu et al. 
2007; Mendell 2008). hnRNP A1 binds to both the terminal loop and a region in 
the stem of pri-miR-18a (Michlewski et al. 2008), causing relaxation of the stem 
and facilitating Drosha/DGCR8 processing. The possible effect of hnRNP A1 
binding on the Dicer processing step has not been investigated for miR-18a. 
hnRNP A1 also binds to the terminal loops of pri-let-7a-1 and pri-miR-101-1, 
indicating that this protein might also regulate processing of other pri-miRNAs. 
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This is consistent with the more general RNA binding properties of hnRNP A1 
(Mayeda and Krainer 1992; Martinez-Contreras et al. 2006).  
 Another RNA binding protein proven to be involved in miRNA processing is 
the KH-type splicing regulatory protein (KSRP). KSRP is known as a key 
mediator of AU-rich element (ARE)-directed mRNA decay that facilitates 
recruitment of the degradation machinery to ARE-containing mRNAs (Gherzi et 
al. 2004; Garcıa-Mayoral et al. 2007). KSRP was shown to be a component of 
both Drosha and Dicer complexes and promoted biogenesis of a cohort of 
miRNAs including let-7a, miR-21, and miR-16 (Fig. 2D; Trabucchi et al. 2009). 
KSRP binds to the terminal loop of its target primary and/or precursor miRNAs 
and induces processing by Drosha and Dicer complexes through protein–protein 
interactions (Trabucchi et al. 2009). Moreover, KSRP mediates induction of miR-  
 
 
FIGURE 2. MicroRNA processing regulation by terminal loop binding proteins. (A) 
Primary miRNA transcript (pri-miRNA) is processed by Drosha/DGCR8 complex to 
precursor miRNA (pre-miRNA) and by Dicer to mature miRNA. Stem and terminal loop (TL) 
regions are assigned within pri-miRNA. (B) Lin28 protein binds to the terminal loop of pri- 
and pre-miRNAs from the let-7 family and impairs processing by reducing Drosha and 
Dicer cleavage and causing uridylation of pre-miR by terminal uridylyl transferase 4 
(TUT4) leading to degradation of pre-miR by an unidentified nuclease. (C) Heterogeneous 
nuclear ribonucleoprotein (hnRNP) A1 binds to the terminal loop and stem of pri-miR-18a 
and facilitates its processing by Drosha. (D) KH-type splicing regulatory protein (KSRP) 
binds to the terminal loop of a set of pri- and pre-miRNAs including let-7a, miR-20, miR-
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155 processing in murine macrophages upon LPS stimulation that is also 
achieved by binding to the terminal loop (Ruggiero et al. 2009).  
 Conservation of terminal loop sequences across vertebrate species can be 
found in ~14% (74 out of 533) of the miRNAs indicating that the loops of these 
miRNAs are functionally important (Michlewski et al. 2008). To analyze the 
relevance of these conserved terminal loop sequences, Michlewski et al. (2008) 
showed that oligonucleotides complementary to the sequence of conserved 
terminal loops abolished the in vitro processing of pri-miR-18a, pri-miR-31, pri-
miR-101-1, pri-miR-379, and pri-let-7a-1. Pri-miRNAs without conserved loops 
(pri-miR-16-1, pri-miR-27a) were not affected by antisense loop oligo’s 
(Michlewski et al. 2008).  
 These studies clearly demonstrate that terminal loop binding proteins play 
an important role in the regulation of miRNA processing. Therefore, it is highly 
likely that other RNA binding proteins may also be involved in the regulation of 
processing of individual miRNAs. 
Cellular location 
Exportin-5 mediates the nuclear export of pre-miRNAs to the cytoplasm and 
protects pre-miRNAs from digestion (Bohnsack et al. 2004; Lund et al. 2004). 
The length of the double-stranded stem and presence of 3’ overhangs but not 
the sequence or the loop structure are important for proper recognition of pre-
miRNAs by Exportin-5 (Lund et al. 2004; Zeng and Cullen 2004).  
 A blockade in the transport of pre-miRNAs from nucleus to cytoplasm was 
suggested to explain the high levels of precursor and lack of mature miR-128a, 
miR-105, and miR-31 in some cancer cell lines. This was supported by the 
predominant nuclear localization of primary/precursors detected by in situ RT-
PCR (Lee et al. 2008). A debatable example for premature nuclear export is BIC 
(pri-miR-155) (van den Berg et al. 2003; Eis et al. 2005; Kluiver et al. 2005). 
RNA in situ hybridization (ISH) using a probe complementary to the 3’ part of 
exon 3 revealed a strong nuclear staining in various lymphoma subtypes and in 
normal B-cells. This exon contains the stem–loop region of miR-155, indicating 
an appropriate location. Eis at al. (2005) showed a cytoplasmic location of 
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spliced BIC transcripts and a nuclear location of the unspliced BIC transcript in 
two lymphoma cell lines by RT-PCR of RNA isolated from purified nuclear and 
cytoplasmic fractions. These data might indicate that the unspliced BIC 
transcript serves as a source for miR-155. However, this does not explain the 
specific nuclear localization for BIC using RNA-ISH. Since both cell lines tested 
by Eis at al. (2005) showed a high level of miR-155, it remains unclear if 
premature export of spliced BIC transcripts explains the low miR-155 levels 
observed in Burkitt lymphoma cell lines after induction of BIC (Kluiver et al. 
2007). Based on current literature, the importance of nuclear export in miRNA 
processing regulation remains uncertain.  
Sequence alterations in DNA/RNA  
Alteration of miRNA processing can be caused not only by changes in the 
processing machinery, but also due to sequence alterations in the miRNA genes 
or RNA transcripts. In 15% of patients with chronic lymphocytic leukemia (CLL), 
but not in healthy controls, mutations were found in five of 42 analyzed miRNA 
genes (Calin et al. 2005). Moreover, a germline mutation located in the miR-
15a~16-1 genomic DNA, 7 bp downstream from pre-miR-16-1, resulted in lower 
levels of the mature miRNAs (Calin et al. 2005). However, it remains to be 
established whether this effect is caused by aberrant transcription or processing.  
 Besides mutations, alterations at the miRNA transcript level caused by 
RNA editing can affect miRNA processing (Fig. 3). RNA editing is conducted by 
adenosine deaminases acting on RNA (ADARs) that convert adenosine (A) to 
inosine (I) in dsRNA structures (Bass 2002; Maas et al. 2003; Amariglio and 
Rechavi 2007). The primary transcript of miR-22 was the first miRNA shown to 
undergo A-to-I editing at positions that surround the Drosha cleavage site 
(Luciano et al. 2004). However, the physiological role of miR-22 editing has not 
been revealed yet. Another primary miRNA found to be edited by ADAR1 and 
ADAR2 isoforms in vitro is pri-miR-142 (Yang et al. 2006b). A-to-I editing of pri-
miR-142 resulted in reduced Drosha processing in HEK293 cells. However, no 
accumulation of edited pri-miR-142 was observed in the nucleus. Edited pri-miR-
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component of RISC, with ribonuclease activity specific to inosine-containing 
dsRNAs (Scadden 2005). However, the relevance of Tudor-SN for in vivo 
degradation of edited pri-miRNAs is still uncertain. ADAR editing of the pri-
miRNA can also inhibit Dicer cleavage (Kawahara et al. 2007a). Editing of pri-
miR-151 by ADAR1 did not affect pri-miRNA to pre-miRNA processing but caused 
inhibition of pre- to mature miR-151 processing as proven by accumulation of 
edited pre-miR-151. The inhibition at the Dicer cleavage step was investigated 
using synthetic pre-miR-151 in vitro. Although there was efficient binding of the 
Dicer–TRBP complex to pre-miR-151, the cleavage of pre- and release of mature 
form was blocked. Analysis of editing sites revealed that only a small proportion 
of the pri-miR-151 transcripts were edited at a specific site. Moreover, high 
frequency of pre-miR-151 editing has been shown in vitro. Therefore, A-to-I 
editing may occur also after processing of pri- to pre-miR-151 (Kawahara et al. 
2007a). Moreover, ADAR editing may interfere with miRNA function by changing 
the ‘‘seed’’ region, which is crucial for target gene binding. The edited isoform of  
 
 
FIGURE 3. Regulation of miRNA processing by ADAR editing. Adenosine deaminases 
acting on RNA (ADARs) can convert adenosine to inosine in pri-miRNA; conversion of pre-
miRNA is also possible, but has not been proven. ADAR editing can lead to blockade in 
Drosha cleavage of pri-miR-142 and degradation of edited pri-miR-142 by a ribonuclease 
Tudor-SN. ADAR editing can also block Dicer processing of pri-miR-151 causing 
accumulation of edited pre-miR-151. 
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miR-376 inhibited a different set of genes than the normal form supporting this 
concept (Kawahara et al. 2007b).  
 Since ADARs are predominantly nuclear enzymes, their targets are most 
likely pri-miRNAs and pre-miRNAs before nuclear export. However, some ADAR 
isoforms shuttle in and out of the nucleus (Desterro et al. 2003) and may edit 
pre-miRNA in the cytoplasm (Kawahara et al. 2007a). Although it is obvious that 
ADAR editing is a regulated event, there is not much known about the relevance 
of ADAR editing and the fate of edited miRNAs. 
Single nucleotide polymorphisms 
Polymorphisms in a miRNA gene may alter miRNA processing by changing the 
stem–loop structure. Although this is not an active processing regulation 
mechanism, it is evident that SNPs do alter the processing efficiency (Fig. 4). 
The first study that identified SNPs in miRNA precursors was performed by Iwai 
and Naraba (2005). However, no effect was observed for the processing 
efficiency of the two alleles of pre-miR-30c-2. The other nine SNPs that were 
identified in this study have not been tested (Iwai and Naraba 2005). Duan et al. 
(2007) systematically identified 323 SNPs that were associated with 227 human 
miRNA genes. Twelve of these SNPs were found in miRNA precursor sequences, 
and one SNP was located in the miR-125a seed sequence. Transfection of 293T 
cells with vectors expressing one of the two miR-125a precursor variants 
revealed that only one of the variants could be processed into mature miRNA. 
The blockade of the other allele occurred at the pri- to pre-miR-125a processing 
step (Duan et al. 2007). Difference in Drosha/DGCR8 processing was also 
proven for the two alleles of miR-146a (rs2910164), miR-502, miR-510, miR-
890, and miR-892b (Jazdzewski et al. 2008; Sun et al. 2009). Possibly, the SNP 
affects the binding efficiency of the Drosha/DGCR8 complex. The T/G SNP in 
miR-934 altered processing efficiency, strand preference, and the mature miRNA 
sequence (Sun et al. 2009). In human lung cancer tissue, similar pre-miR-196a 
levels were observed for both alleles of the C/T SNP (rs11614913), whereas a 
marked difference was observed for the mature miR-196a levels, indicating an 
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suggests interference with the nuclear export or the Dicer processing step of 
pre-miR-196a by the SNP. Together, these studies demonstrate that SNPs in 




FIGURE 4. Influence of SNPs on miRNA processing. SNP variants of miR-125a, miR-
146a, miR-510, miR-196a, and miR-934 are processed differently due to changes in a 
stem structure or processing sites. Major alleles are situated on the left side; minor alleles 
on the right.  




Recent studies have shown that miRNA biogenesis involves a number of tightly 
regulated processing steps that provide an important regulatory mechanism to 
define cellular levels of specific miRNAs. Therefore, biogenesis of miRNAs should 
not be regarded as a linear, unified mechanism. Based on current studies, 
Drosha, Dicer, and terminal loop binding proteins are the main factors involved 
in miRNA processing regulation. Cellular localization and ADAR editing influence 
processing of certain miRNAs, but their overall impact seems to be limited. 
 It is evident that proteins known to regulate transcription (p53, SMADs) or 
mRNA stability (KSRP) can also influence miRNA processing efficiency and 
therefore have the ability to control cellular levels of miRNAs. In some cases, 
complex networks have been reported to regulate processing of specific miRNAs; 
i.e., processing of miR-16, miR-143, and miR-145 is facilitated by p53 and 
inhibited by ERα in a p68/p72-dependent mechanism, and let-7 processing is 
negatively regulated by Lin28 and positively by KSRP. The terminal loop was 
shown to be an important target structure for regulation of miRNA expression by 
binding to activators and/or inhibitors of the miRNA processing machinery. This 
form of regulation may facilitate a much faster response to cellular changes as 
compared to the transcriptional control of miRNA genes. Moreover, the change 
in expression of one miRNA leads to differential expression of many miRNA 
target genes and may provide not only a quick but also a broad response to 
various stimuli.  
 Although knowledge about regulatory proteins is expanding rapidly, future 
studies should focus on identifying additional regulatory proteins. Human 
homologs of proteins regulating miRNA processing in plants, i.e., SERRATE and 
cap binding proteins CBP80/CBP20 (Lobbes et al. 2006; Yang et al. 2006a; Kim 
et al. 2008; Laubinger et al. 2008) need to be studied to define possible parallel 
regulatory functions in the processing of miRNA. 
 It is evident that several mechanisms regulate efficiency of miRNA 
processing. Nevertheless, for some miRNAs, inconsistencies between primary, 
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cells. The mechanisms for these inconsistencies (Table 1) are still unknown. For 
instance, no specific mechanism has been related to the tissue-specific 
expression levels of mature, but not precursor, miR-138 or miR-128 (Table 1; 
Obernosterer et al. 2006; Lee et al. 2008). An overall decrease of miRNA 
expression has been observed in many types of cancer as compared to their 
normal counterparts, and the underlying mechanisms remain unknown (Lu et al. 
2005; Chen and Stallings 2007; Ozen et al. 2008). Inconsistencies between pri- 
and mature miRNAs are most obvious for the so-called polycistronic or miRNA 
clusters and indicate a miRNA-specific regulation. Based on current knowledge, 
it seems likely that the currently known mechanisms that regulate miRNA 
processing are, at least partially, involved in the deregulated miRNA expression 
levels in cancer. However, detailed comparisons between the regulations of 
miRNA processing in cancer cells as compared to their normal counterparts have 
not been performed. Elucidation of putative differences between normal and 
cancer cells and manipulation of these regulatory processes might provide a 
novel approach to restore a normal miRNA profile in cancer cells.  
 
 Undoubtedly, many factors regulating the cellular miRNA levels are still 
unknown. Further unraveling of the mechanisms responsible for regulation of the 
miRNA processing machinery will be an important step in elucidating the 
pathophysiological significance of miRNAs in malignancies and open up new 
venues for treatment. 
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Processing of miRNAs occurs simultaneous with the transcription and splicing of 
their primary transcripts. For the small subset of exonic miRNAs it is unclear if 
the unspliced and/or spliced transcripts are used for miRNA biogenesis. We 
assessed endogenous levels and cellular location of primary transcripts of three 
exonic miRNAs. The ratio between unspliced and spliced transcripts varied 
markedly, i.e. >1 for BIC, <1 for pri-miR-146a and variable for pri-miR-22. 
Endogenous unspliced transcripts were located almost exclusively in the nucleus 
and thus were available for miRNA processing for all three miRNAs. Endogenous 
spliced pri-miRNA transcripts were present both in the nucleus and in the 
cytoplasm and thus were only partly available for miRNA processing. 
Overexpression of constructs containing the 5’ upstream exonic or intronic 
sequence flanking pre-miR-155 resulted in strongly enhanced miR-155 levels, 
indicating that the flanking sequence does not affect processing efficiency. 
Exogenously overexpressed full-length spliced BIC transcripts were present both 
in the nucleus and in the cytoplasm and resulted in enhanced miR-155 levels. 
We conclude that both unspliced and spliced transcripts of exonic miRNAs can be 
used for pre-miRNA cleavage. Splicing and cytoplasmic transport of spliced 
transcripts may present a mechanism to regulate exonic microRNAs levels.  




MicroRNAs (miRNAs) are small (~22nt) noncoding RNA molecules that 
negatively regulate gene expression by binding to the 3’untranslated region 
(3’UTR) of their target mRNAs (Bartel, 2004). MiRNAs play an important role in 
cellular processes like apoptosis, proliferation and differentiation. Altered miRNA 
expression profiles have been associated with various diseases including most, if 
not all, types of cancer (Calin et al., 2004). This suggests that regulation of 
miRNA levels is important for normal cellular functioning. Regulation of the 
miRNA levels may include any of the regulatory mechanisms involved in normal 
gene expression, such as transcriptional or epigenetic control of transcription. 
Additionally, miRNA biogenesis is also regulated at the post-transcriptional level 
(reviewed in Slezak-Prochazka et al., 2010). 
 The first step in miRNA processing, i.e. cleavage of the primary   
transcript (pri-miRNA) by the Drosha/DGCR8 complex, is restricted to the 
nucleus (Denli et al., 2004; Gregory et al., 2004; Han et al., 2004; Landthaler et 
al., 2004). The miRNA stem-loop structures can be located in introns of protein-
coding or noncoding RNA genes, in exons of noncoding genes or in intergenic 
regions (Kim and Nam, 2006). The vast majority of the human miRNAs are 
located in introns. Approximately 10% of the miRNAs, including miR-155, miR-
146a, miR-22, miR-137, miR-34c and let-7b, reside within exons of noncoding 
genes (Kim and Kim, 2007; Rodriguez et al., 2007; Saini et al., 2008). Current 
knowledge about processing of pri-miRNAs has been obtained mainly for intronic 
or intergenic miRNAs (Ballarino et al., 2009; Janas et al., 2011; Kataoka et al., 
2009; Kim and Kim, 2007; Morlando et al., 2008; Pawlicki and Steitz, 2008). 
Processing of intronic miRNAs occurs co-transcriptionally in cooperation with 
splicing of the primary transcript (Janas et al., 2011; Kataoka et al., 2009; Kim 
and Kim, 2007; Morlando et al., 2008; Pawlicki and Steitz, 2008). The 
Microprocessor complex and the spliceosome are associated in one complex, and 
co-produce precursor miRNAs (pre-miRNAs) and spliced transcripts from the 
unspliced pri-mRNA (Kataoka et al., 2009). Splicing is not required for pri-
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promote release of the pre-miRNA from introns of pri-miRNA (Kataoka et al., 
2009). For exonic miRNAs, pre-miRNA release will disrupt the exon of the pri-
miRNA and affect formation of spliced transcripts. Therefore, it is more likely 
that unspliced pri-miRNA transcripts of exonic miRNAs produce either pre-
miRNAs or spliced transcripts. The processing of exonic miRNAs has not yet 
been studied in detail. 
 One well-known exonic miRNA, miR-155, is processed from the transcript 
of the B-cell integration cluster (BIC) gene, also known as the MIR155 host gene 
(MIR155HG) (Lagos-Quintana et al., 2002). The BIC gene consists of three 
exons separated by long (7.6 and 4kb) introns with the stem-loop pre-miR-155 
sequence located in the third exon (Tam, 2001). MiR-155 is crucial for B-cell 
development and regulation of the immune response (Rodriguez et al., 2007; 
Thai et al., 2007; Vigorito et al., 2007). High miR-155 levels are observed in 
many types of cancer, including B-cell malignancies like Hodgkin, primary 
mediastinal and diffuse large B-cell lymphomas (Kluiver et al., 2005; van den 
Berg et al., 2003). In contrast, very low levels of miR-155 were observed in B 
cell-derived Burkitt lymphoma (Kluiver et al., 2006). Eis et al. showed that 
unspliced BIC is located in the nucleus, whereas spliced BIC is located mainly in 
the cytoplasm in two B-cell lymphoma cell lines that both show high miR-155 
levels (Eis et al., 2005). RNA in situ hybridization in primary cases of Hodgkin 
lymphoma and non-Hodgkin lymphoma with high miR-155 levels revealed a 
strong nuclear staining of BIC and no staining in the cytoplasm (Kluiver et al., 
2006; van den Berg et al., 2003).  
 In this study, we investigated processing of exonic miRNAs, with a main 
focus on miR-155. We determined the levels of endogenous unspliced and 
spliced BIC, pri-miR-22 and pri-miR-146a transcripts. We assessed cellular 
localization of endogenous unspliced and spliced BIC, pri-miR-22 and pri-miR-
146a and showed that unspliced transcripts are located predominantly in the 
nucleus while spliced transcripts are partly transported to the cytoplasm. We 
also showed that the 5’ exonic or intronic flanking sequence of pre-miR-155 
does not alter processing efficiency of exogenous BIC transcripts and that upon 
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overexpression also spliced transcripts are efficiently processed to mature miR-
155. 
RESULTS 
The unspliced/spliced transcript ratio is miRNA-specific in B-cell 
lymphoma 
For exonic miRNAs, such as miR-155, miR-22 and miR-146a, both unspliced and 
spliced transcripts include the complete stem-loop pre-miRNA sequence and 
may serve as the primary miRNA template. To discriminate between unspliced 
and spliced transcripts we designed qRT-PCR primer sets specific for unspliced or 
spliced transcripts as indicated in Fig. 1A. We compared the levels of 
endogenous unspliced and spliced transcripts in twenty B-cell lymphoma cell 
lines with variable miRNA levels.  
 Endogenous miR-155 levels were highly variable in B-cell lymphoma cell 
lines. The difference between the cell line with the lowest (ST486) and the 
highest (OCI-Ly3) miR-155 level was ~500 fold (Fig. 1B). In general, cell lines 
with low miR-155 levels also showed low BIC transcript levels. The levels of 
endogenous unspliced BIC transcripts were 1,5 to 73 fold higher than the levels 
of spliced BIC transcripts in 17 out of 20 cell lines irrespective of the miR-155 
levels (Fig. 1B). In two cell lines, the levels of unspliced and spliced BIC 
transcripts were equal. In L540 cells, the spliced BIC transcript levels were 1,5 
fold higher than the levels of the unspliced BIC transcripts. In the two cells lines 
with the lowest miR-155 levels, i.e. ST486 and Ramos, only the unspliced BIC 
transcript was present. Both unspliced and spliced BIC transcript levels showed 
significant correlation with miR-155 levels resulting in R2 of 0.53. The difference 
observed in levels of unspliced and spliced BIC transcripts did not result in a 
significant difference in the slope of the regression lines.  
 MiR-22 levels were low in all analyzed B-cell lymphoma cell lines (Fig. 1C). 
Pri-miR-22 has four alternative splice variants. Transcript variant 3 was almost 
exclusively detected in our panel of B-cell lymphoma cell lines (data not shown). 
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pri-miR-22 transcript levels were higher than unspliced pri-miR-22 transcript 
levels in 9, similar in 9 and lower in 2 of the analyzed cell lines (Fig. 1C). The 
spliced/unspliced pri-miR-22 transcript ratio varied from 0.2 in UHO1 to 8 in 
L540 cells. In SU-DHL-4 cells, only spliced pri-miR-22 transcript was present. No 
significant correlation was observed for either spliced or unspliced pri-miR-22 
transcript levels with mature miR-22 levels. This might be caused by marked 
differences in the efficiency of the pri-miR-22 transcript to miR-22 processing, 
differences in the miR-22 stability, factors regulating the level of mature miR-22 
or limiting amounts of factors involved in the biogenesis of miRNAs.  
 
Cellular localization and processing of primary transcripts of exonic micoRNAs 
 
55 
FIGURE 1. The unspliced/spliced ratio of pri-miRNA transcripts is miRNA-specific 
in B-cell lymphoma cell lines. (A) Schematic overview of the unspliced and spliced BIC, 
pri-miR-22 and pri-miR-146a transcripts and location of the PCR amplicons specific for 
unspliced, spliced transcripts and total (only for BIC) transcripts. Constructs used for miR-
155 overexpression are also denoted. Short constructs, s-exBIC and s-intBIC, constitute of 
pre-miR-155, ~150nt 3’ flanking sequence from exon 3 and 5’ flanking sequence derived 
from exon 2 (s-exBIC) or intron 2 (s-intBIC) of BIC transcript, fl-exBIC covers full-length 
spliced BIC transcript. Figures are not drawn to scale. (B) The endogenous levels of miR-
155, unspliced and spliced BIC transcripts. In 17 out of 20 cell lines the level of unspliced 
BIC transcript was higher than the level of spliced BIC transcripts. Both spliced and 
unspliced BIC showed a similar significant correlation with miR-155 levels. (C) The 
endogenous levels of miR-22, unspliced and spliced pri-miR-22 transcripts. The 
unspliced/spliced transcript ratio is variable between cell lines and neither of the two 
transcripts shows a significant correlation with the miR-22 levels. (D) The endogenous 
levels of miR-146a, unspliced and spliced pri-miR-146a transcripts. In all tested cell lines, 
levels of spliced pri-miR-146a were much higher than unspliced pri-miR-146a transcripts. 
Both unspliced and spliced pri-miR-146a levels significantly correlate with the miR-146a 
levels. However, the slope of the regression line is significantly higher for spliced pri-miR-
146a. Levels of BIC, pri-miR-22 and pri-miR-146a were normalized to HPRT and levels of 
miR-155, miR-22 and miR-146a were normalized to RNU48. 
  MiR-146a levels varied over a 1000-fold range between B-cell lymphoma 
cell lines with the lowest levels being observed in L540 and the highest levels in 
KARPAS-1106P (Fig. 1D). The levels of spliced pri-miR-146a transcripts were 
higher than unspliced pri-miR-146a transcripts for all cell lines. The 
spliced/unspliced pri-miR-146a transcript ratio varied from 14 to 72 fold. In 
L540 cells only the spliced pri-miR-146a transcript was present. Both unspliced 
and spliced pri-miR-146a transcript levels significantly correlated with miR-146a, 
showing R2 of 0.67 and 0.7, respectively. However, the slopes of the curves 
differ significantly (p<0.0001), due to lower unspliced pri-miR-146a transcript 
levels. 
 Thus, for all three exonic miRNAs, both unspliced and spliced primary 
transcripts are present albeit at a variable ratio. For BIC, the unspliced primary 
transcript is predominant, for pri-miR-146a the spliced primary transcripts is 
predominant, whereas for pri-miR-22 the unspliced/spliced transcript ratio varies 
between cell lines. Levels of the mature miRNAs correlated with the levels of 
both unspliced and spliced pri-miRNA transcripts for miR-155 and miR-146a, but 
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Spliced pri-miRNA transcripts are partly transported to the cytoplasm  
To further examine whether unspliced or spliced pri-miRNA transcripts are 
available for miRNA processing, we determined the subcellular localization of 
unspliced and spliced transcripts of BIC, pri-miR-22 and pri-miR-146a by qRT-
PCR of nuclear and cytoplasmic fractions relative to the total fraction (Fig. 2). 
The pri-miRNA transcript levels in the cytoplasm were normalized to tRNA-Lys, 
which showed similar levels in total and cytoplasmic fraction. The pri-miRNA 
transcript levels in the nucleus were normalized to U3, which showed similar 
levels in total and nuclear fraction. To asses subcellular localization of unspliced 
and spliced BIC transcripts, we selected cell lines with low (L428), intermediate 
(Jiyoye) or high (L540) miR-155 levels (Fig. 1A). The same cell lines were used 
for subcellular localization of pri-miR-22 and pri-miR-146a to allow comparison 
between subcellular distributions of pri-miRNA transcripts.  
 Endogenous unspliced BIC transcripts were located exclusively in the 
nuclear fraction (more than 99%) in all three cell lines (Fig. 2). The fraction of 
spliced BIC transcripts located in the nucleus varied from 74% in L428 to 17% in 
Jiyoye cells and 47% in L540. The levels of the spliced and unspliced transcripts 
in cytoplasm and nucleus relative to their levels in the total fraction are shown in 
Supplementary Fig. 1. The highly abundant unspliced BIC transcripts most likely 
serve as the main endogenous primary miR-155 transcript. The spliced BIC 
transcripts that are located in the cytoplasm are not available for processing to 
miR-155 and the functional role of these cytoplasmic spliced BIC transcripts 
remains unclear. 
 Localization of unspliced pri-miR-22 transcripts was predominantly, but 
not exclusively, nuclear in all three cell lines (Fig. 2 and Supplementary Fig. 1). 
88% in L428, 91% in Jiyoye and 97% in L540 of unspliced pri-miR-22 
transcripts were present in the nucleus. The fraction of spliced pri-miR-22 
transcripts that was present in the nucleus was 81% for L428, 53% for Jiyoye, 
and 50% for L540 cells.  
   




FIGURE 2. Cellular localization of unspliced and spliced pri-miRNA transcripts. 
The percentages of spliced and unspliced transcripts of BIC, pri-miR-22 and pri-miR-146a 
were shown in cytoplasmic and nuclear fractions of L428, Jiyoye and L540 cells. For all cell 
lines unspliced transcripts were located almost completely in the nucleus, whereas spliced 
transcripts were also detected in the cytoplasm. Pri-miR-146a was not detectable in L540. 
Transcript levels in the cytoplasm and in the nucleus were calculated relative to the total 
fractions. Average of three independent experiments was presented. P values were 
determined by a Student’s t-test (* p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001, ns 
- not significant). 
  Localization of unspliced pri-miR-146a transcripts was exclusively nuclear 
(above 99%) for both L428 and Jiyoye cells (Fig. 2 and Supplementary Fig. 1). 
In L540 cells, both mature and primary miR-146a transcripts were hardly 
detected, therefore it was not possible to determine the subcellular localization. 
91% of spliced pri-miR-146a transcripts were present in the nucleus in L428 and 
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 Thus, part of the spliced BIC, pri-miR-22 and, to a lesser degree, pri-miR-
146a transcripts are transported to the cytoplasm and as such unavailable for 
processing. Unspliced transcripts show an almost exclusive nuclear localization 
for BIC, pri-miR-22 and pri-miR-146a. Since the levels of spliced pri-miR-22 in 
L540 and Jiyoye cells and pri-miR-146a in Jiyoye and L428 were higher than the 
unspliced transcript levels in these cell lines (Fig. 1C and 1D), spliced pri-miR-22 
and pri-miR-146a may still be the predominant miRNA substrate. 
Exogenous spliced BIC can be processed to miR-155.  
For further analysis we focused on miR-155, because previous studies have 
shown conflicting data concerning BIC to miR-155 processing (Kluiver et al., 
2007; Zhang et al., 2008). The upstream pre-miR-155 flanking sequence is 
different in spliced and unspliced BIC transcripts. To determine if this upstream 
sequence affects the processing efficiency, we assessed the levels of miR-155 
induction upon overexpression of BIC from two short fragments of BIC 
containing the stem-loop region, ~150nt 3’ flanking sequence from exon 3 and 
~150nt 5’ flanking sequence derived either from intron 2 (s-intBIC) or from 
exon 2 (s-exBIC) of the BIC transcript (Fig 1A). In addition, we also 
overexpressed the full-length spliced BIC (fl-exBIC) transcript (Fig. 1A). We 
transduced these three BIC constructs into ST486, Ramos and U-HO1, i.e. cells 
that all have low endogenous miR-155 levels. A high expression of BIC was 
induced using either of the constructs (Fig. 3A), albeit at variable levels. 
Transduction with the short exon spanning BIC construct resulted in the highest 
increase and the full-length spliced BIC construct resulted in the lowest increase 
in total BIC transcript levels (Fig. 3A). Interestingly, the level of miR-155 
induction was similar for all three constructs (Fig. 3B), despite the marked 
differences in total BIC levels. These data indicate that the upstream pre-miR-
155 flanking sequence does not modify processing efficiency and suggest that at 
a certain level of primary miRNA transcript, other factors become limiting or 
regulate the level of mature miR-155.  
 Next, we determined the subcellular localization of BIC transcripts in 
Ramos cells transduced with fl-exBIC. In empty vector control cells, endogenous 
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unspliced BIC transcripts showed a predominantly nuclear localization, whereas 
the endogenous spliced BIC transcripts were not detectable (Fig. 3C). Thus, total 
BIC levels can be completely attributed to the unspliced BIC transcript levels. 
Localization of the overexpressed fl-exBIC was both cytoplasmic and nuclear 
(32% versus 68%). Localization of endogenous unspliced BIC transcripts 
remained predominantly nuclear, i.e. similar to the empty vector control. 
Localization of total BIC resembled the pattern of spliced BIC, since the 
exogenous spliced BIC levels were ~100 fold higher than the endogenous 
unspliced BIC levels. Overexpression of fl-exBIC was followed by a strong 
induction of miR-155 (Fig. 3B), indicating that upon overexpression nuclear 
spliced BIC transcripts can also serve as the primary miR-155 transcript.  
 
FIGURE 3. Processing and cellular localization of exogenous BIC transcripts. 
Levels of total BIC (A) and miR-155 (B) upon overexpression of the three constructs and 
empty vector (EV) in ST486, Ramos and U-HO1 cells. For the three BIC overexpression 
constructs, the increase in total BIC was variable and the highest levels were observed for 
short BIC transcript containing exon 2 derived 5’ pre-miR-155 flanking sequence (s-
exBIC). However, miR-155 induction was similar for all BIC overexpression constructs. (C) 
The percentages of spliced, unspliced and total BIC transcripts in nuclear and cytoplasmic 
fractions of Ramos EV and Ramos full-length spliced BIC (fl-exBIC). For both Ramos EV 
and fl-exBIC, unspliced BIC was located predominantly in the nucleus. Spliced BIC was not 
detectable (ND) in Ramos EV. Upon overexpression of the fl-exBIC construct, spliced BIC 
transcripts were partly exported to the cytoplasm. Localization of total BIC was similar to 
the dominant transcript forms, i.e. unspliced BIC for Ramos EV and spliced BIC for Ramos 
fl-exBIC. Transcript levels in the cytoplasm and the nucleus were calculated relative to the 
total fraction. Average of three independent experiments was presented. P value was 
determined by 1-way ANOVA and by a Student’s t-test for cytoplasmic versus nuclear 
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The unspliced/spliced ratio of BIC transcripts changes upon cellular 
activation  
To investigate whether the ratio between unspliced and spliced BIC transcripts is 
altered upon induction of BIC, we activated three B-cell lymphoma cell lines 
using PMA/Ionomycin. Activation of DG-75, L428 and KM-H2 cells resulted in 3- 
to 13-fold increase in miR-155 levels (Fig. 4A). Induction of unspliced BIC 
transcript levels showed a 1.6 to 5.5 fold increase, whereas spliced BIC 
transcript levels showed a 5.4 to 31 fold increase compared to untreated cells 
(Fig. 4B). Although the unspliced BIC transcript remained the predominant 
transcript, the unspliced/spliced BIC transcript ratio significantly changed in 
favour of the spliced BIC transcript (Fig. 4C). Thus, both processing of unspliced 
BIC transcript to miR-155 and to spliced BIC transcripts are enhanced upon 
activation-induced expression of BIC.  
 
FIGURE 4. Induction of unspliced and spliced BIC transcripts upon cellular 
activation. Fold induction in miR-155 (A), unspliced BIC and spliced BIC transcript (B) 
levels upon PMA/Ionomycin (P/I) treatment. Levels of miR-155 and BIC transcripts in 
untreated cells were averaged and fold induction upon P/I treatment was calculated. In all 
three cell lines, induction of spliced BIC was higher that of unspliced BIC transcripts. (C) 
Unspliced BIC transcripts were predominant in both untreated and P/I-treated cells, 
however unspliced/spliced BIC ratio significantly decreased upon P/I treatment. Sum of 
spliced and unspliced BIC transcript levels was set as 100%. Average of three (DG-75 and 
L428) or four (KM-H2) experiments was presented. P values were determined by a 
Student’s t-test (* p<0.05, ** p<0.01, ns - not significant). 
 
 




Exonic miRNAs constitute a small group of the known human miRNAs. The vast 
majority of exonic miRNAs are located in noncoding RNA genes of which the only 
known function is being a miRNA host gene. In contrast to intronic miRNAs, 
processing of the pri-miRNA transcripts of exonic miRNAs to pre-miRNAs 
interferes with the normal splicing process of the transcript. Exonic miRNAs 
regulate important physiological pathways, i.e. miR-155 and miR-146a are 
crucial regulatory components of the immune response, hematopoiesis and 
carcinogenesis (reviewed in Rusca and Monticelli, 2011; Tili et al., 2009) and 
miR-22 plays a role in carcinogenesis (Alvarez-Diaz et al., 2012; Xu et al., 
2011).  
 In this study, we showed that unspliced pri-miRNA transcripts of exonic 
miRNAs, i.e. miR-155, miR-22 and miR-146a, are located predominantly in the 
nucleus. The spliced transcripts are present both in the nucleus and the 
cytoplasm. Since the first processing step of pri-miRNAs takes place in the 
nucleus (Lee et al., 2002; Yeom et al., 2006), both nuclear unspliced and spliced 
transcripts can serve as pri-miRNA templates. Overexpression constructs 
containing either the exonic 5’ flanking sequence or the intronic 5’ flanking 
sequence of pre-miR-155 both resulted in a marked miR-155 induction. 
Consistent with these findings we also observed a marked induction of miR-155 
upon exogenously overexpressed full-length spliced BIC transcripts. These data 
indicate that the Microprocessor complex can use spliced and unspliced BIC 
transcripts for processing to pre-miR-155.  Since the unspliced BIC transcripts 
are much more abundant and are almost exclusively located in the nucleus, we 
conclude that unspliced nuclear BIC transcripts are the primary template for 
miR-155 processing in B-cell lymphoma. In contrast to pri-miR-155, the spliced 
transcripts are the most abundant form of pri-miR-146a and, for part of the cell 
lines of pri-miR-22. Unspliced pri-miR-146a showed very low levels in all cell 
lines. This might indicate that the unspliced pri-miR-146 is directly used for 
processing to pre-miR-146a or for splicing. The level of spliced pri-miR-146a 
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processing. Alternatively, despite the partial cytoplasmic location, the spliced 
transcripts can still be the most important source for the biogenesis of mature 
miR-146a. Overexpression of miRNAs from constructs that do not contain 
introns show very effective processing to mature miRNAs, similar to our results 
using the BIC constructs. This indicates that although splicing enhances 
processing (Kataoka et al., 2009; Morlando et al., 2008), it is not required to 
allow processing to mature miRNAs. Pawlicki et al. showed that overexpressed 
pri-miRNAs that are artificially prematurely released from the transcription site 
accumulate in the nucleoplasm and are not efficiently processed to pre-miRNA 
(Pawlicki and Steitz, 2008; Pawlicki and Steitz, 2009). These studies implicate 
that spliced pri-miRNA transcripts may be less efficient templates for the miRNA 
processing machinery when released from the transcription site. In vitro 
processing of radiolabeled pri-miRNAs using whole-cell extract or 
immunoprecipitated Microprocessor (Han et al., 2004) indicates that presence at 
the transcriptional start site is not required for release of the pre-miRNA. 
Although we do not know if spliced exonic pri-miRNA transcripts are released 
from the transcription start site before miRNA processing, our data show that 
spliced transcripts can be used for miRNA processing.  
 We observed that induction of BIC using three different constructs was 
variable. However, the induction of mature miR-155 was strikingly similar in the 
three cell lines. Thus, induction of higher BIC transcripts levels did not result in 
higher miR-155 levels. This suggests that the miR-155 levels are regulated in 
these cell lines that are characterized by very low endogenous miR-155 levels. 
Notably, the level of miR-155 obtained with these three constructs was still ~10 
fold lower than the highest observed endogenous miR-155 levels (OCI-Ly3 cell 
line). An alternative explanation could be that factors required for miRNA 
biogenesis become limiting and preclude induction of higher levels.  
 For BIC, we demonstrated that part of the spliced transcripts are exported 
to the cytoplasm and are thus not available for processing. Similarly, spliced pri-
miR-22 and to a lesser degree spliced pri-miR-146a are exported to the 
cytoplasm. Alteration of the efficiency of splicing and nuclear export of spliced 
pri-miRNA transcripts may rapidly change the amount of pri-miRNA available for 
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miRNA processing and therefore serve as a mechanism to regulate mature 
miRNA levels. Consistent with this hypothesis, we observed differences in the 
ratio of unspliced to spliced BIC transcript levels upon PMA/Ionomycin 
treatment. Cellular conditions and external stimuli may thus affect exonic miRNA 
levels by inducing changes to the amount of unspliced pri-miRNA used for 
miRNA processing at the expense of the amount of unspliced transcript available 
for splicing.  
 Both unspliced and spliced exonic miRNA transcripts can be used as 
template for miRNA processing. The level and ratio of spliced and unspliced 
transcripts, their cellular location and the processing efficiency together 
determine which form is the most likely endogenous pri-miRNA. For exonic 
miRNA processing studies it is important to assess total transcript levels and not 
only examine either spliced or unspliced transcripts. Conflicting data as 
presented in the current literature concerning the processing efficiency of BIC 
may, at least partially, be explained by differences in the analyzed transcripts 
(Kluiver et al., 2007; Zhang et al., 2008).  
 Many proteins were reported to inhibit or promote miRNA processing by 
binding to stem-loop of pri-miRNA and/or pre-miRNA (reviewed in Slezak-
Prochazka et al., 2010). These proteins have been identified to regulate both 
intronic and exonic miRNA processing. KH-type splicing regulatory protein 
(KSRP) was shown to enhance miR-155 processing in mouse activated 
macrophages by binding to the terminal loop of both BIC transcript and pre-miR-
155 (Ruggiero et al., 2009). Moreover, monocyte chemoattractant protein 
[MCP]-1-induced protein 1 (MCPIP1) was shown to suppress miRNA processing 
of a panel of miRNAs, including miR-155 and miR-146a, by induction of pre-
miRNA terminal loops cleavage (Suzuki et al., 2011). Some of these proteins, 
like KSRP or hnRNP A1, regulate both miRNA and mRNA processing (Gherzi et 
al., 2010; Michlewski et al., 2008; Trabucchi et al., 2009). These, and possibly 
other, regulatory proteins may thus regulate exonic miRNA levels by promoting 
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 It is unclear whether cytoplasmic spliced transcripts have additional 
functions in the cytoplasm. To date, the only known function of the three 
noncoding genes studied in this paper is being the host gene for the miRNAs. 
Splicing of the transcripts and the subsequent transport to the cytoplasm might 
serve as a mechanism to prevent processing to pre-miRNA (Fig. 5). This is 
supported by the finding that upon inhibition of DGCR8 with shRNA in L1236 
cells we saw a marked induction of the spliced BIC transcript, which resulted in a 
change of the unspliced/spliced BIC transcript ratio from 2.5 to 0.3 (data not 
shown). This indicates that when pre-miRNA processing is inhibited, splicing of 
the unspliced BIC transcript is enhanced. Another possible role of the 
cytoplasmic spliced transcripts is that they may function as competing 
endogenous RNA (ceRNA) transcripts for the mature miRNAs. MiR-155 and miR-
155* sequences are highly complementary and the BIC transcript (MIR155HG) 
is a predicted miR-155 target by the miRanda-mirSVR and PITA algorithms 
(http://www.microrna.org, Betel et al., 2010; 
http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html, Kertesz et al., 
2007). Up to date, various transcripts were shown to function as ceRNA, e.g. 
protein-coding transcripts, pseudogenes, and long noncoding RNAs (Cesana et 
al., 2011; Poliseno et al., 2010; Tay et al., 2011). Spliced pri-miRNA transcripts 
of exonic miRNAs could prevent binding of the mature miRNA to their 
endogenous protein-coding target genes and thereby prevent efficient 
knockdown of the target proteins. This would be a novel mechanism, by which 
cytoplasmic pri-miRNA transcripts function in a negative feedback loop to 
regulate miRNA function.  
 In conclusion, we showed that unspliced BIC, pri-miR-146a and pri-miR-
22 transcripts were predominantly localized in the nucleus, although they were 
not always more abundant than the spliced BIC transcripts. We also showed that 
spliced BIC, pri-miR-146a and pri-miR-22 transcripts are partly localized in the 
cytoplasm and thus not fully available for processing to the mature miRNAs. Pre-
miRNAs and spliced transcripts appear to be two mutually exclusive products of 
unspliced pri-miRNA transcripts of exonic miRNA. Splicing and transport to the 
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cytoplasm may represent a novel mechanism to regulate cellular exonic miRNA 
levels and function. 
 
 
FIGURE 5. Model of processing and function of exonic miRNA primary transcripts. 
The classical miRNA processing and functioning pathway (indicated in dark colors) shows 
that the main pri-miRNA, the unspliced nuclear transcript, is processed to pre-miRNA. Pre-
miRNA is transported to the cytoplasm and further processed to mature miRNA. Mature 
miRNA guides the RNA-induced silencing complex (RISC) to protein-coding miRNA targets 
and inhibits their expression. Unspliced transcripts can also be spliced instead of being 
processed to pre-miRNA. The pre-miRNA stem-loop structure might also be processed 
from the spliced transcripts. Spliced transcript can be transported to the cytoplasm. This 
may represent a mechanism to prevent processing to pre-miRNA.  
MATERIALS AND METHODS 
Cell lines and treatment. Burkitt lymphoma cell lines (Ramos, DG-75, 
NAMALWA, Raji, Jiyoye) were purchased from ATCC (ST486) and DSMZ (other 
cell lines). Diffuse large B-cell lymphoma cell lines (OCI-Ly3, SU-DHL-4, SU-
DHL-6, VER) (Epstein et al., 1978; Tweeddale et al., 1987) were a kind gift of A. 
Epstein (UCLA, CA) (SU-DHL-4 and SU-DHL-6) or were established in our 
laboratory (VER).  Hodgkin lymphoma cell lines (L540, L591, L1236, DEV, KM-
H2, HDLM-2, L428, U-HO1) (Diehl et al., 1982; Diehl et al., 1985; Drexler et al., 
1986; Kanzler et al., 1996; Mader et al., 2007; Schaadt et al., 1980) were 
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Cologne, Germany) (L591, L1236, HDLM-2, L428) and P. Möller (University of 
Ulm, Germany) (U-HO1) or were established in our laboratory (DEV). Primary 
mediastinal B-cell lymphoma cell lines (KARPAS-1106P, MEDB-1) (Copie-
Bergman et al., 2003) were a kind gift of M. Dyer (University of Leicester, UK). 
Cell lines were cultured at 37°C under an atmosphere containing 5% CO2 in 
Iscove's Modified Dulbecco's Medium (OCI-Ly3) or RPMI-1640 (other cell lines) 
medium (Cambrex Biosciences, Walkersville, USA) supplemented with 
ultraglutamine (2 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml; 
Cambrex Biosciences), and 5% (L428), 20% (DEV, ST486, OCI-Ly3) or 10% 
(other cell lines) fetal calf serum (Cambrex Biosciences). DG-75, L428 and KM-
H2 cells were treated for 24h with Phorbol 12-myristate 13-acetate 
(PMA)/Ionomycin (both Sigma-Aldrich, Saint Louis, MO) as previously described 
(Kluiver et al., 2007). The PMA/Ionomycin treatment was performed in triplicate 
(DG-75 and L428) or quadruplicate (KM-H2).  
BIC/miR-155 constructs. The pcDNA3.1(+) plasmid containing full-length 
spliced BIC (fl-exBIC) was described previously (Kluiver et al., 2007). The MXW-
PGK-IRES-GFP vector was a kind gift from C-Z. Chen (Stanford University, CA). 
The full-length spliced fl-exBIC insert was subcloned from the pcDNA3.1(+) 
vector to the MXW-PGK-IRES-GFP vector using PmeI (pcDNA3.1(+) vector) and 
HpaI (MXW-PGK-IRES-GFP vector) restriction enzymes. The miR-155 stem-loop 
and ~150nt flanking sequences were amplified from genomic DNA (s-intBIC) or 
cDNA (s-exBIC) using Taq polymerase. Primer sequences used for PCR were as 
follows, 5’-TGTCACCTCCAGCTTTATAACC-3’ (forward, s-intBIC), 5’-
AACCTACCAGAGACCTTACC-3’ (forward, s-exBIC), 5'-
GGCTTTATCATTTTTCAATCT-3 (reverse, s-intBIC and s-exBIC). An XhoI 
restriction site was added to the forward and an EcoRI site to the reverse primer 
to allow efficient cloning. PCR products were cloned to the retroviral MXW-PGK-
IRES-GFP vector using standard laboratory procedures. The inserts were 
sequenced to confirm the correct sequences.  
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Retroviral transduction. To generate retroviral particles, Phoenix-Ampho 
packaging cells  (Swift et al., 2001) were CaPO4 transfected with 37,5μg of 
MXW-PGK-IRES-GFP constructs (empty vector or vector containing one of the 
BIC constructs) in T75 flasks. Viral particles were harvested after two days and 
concentrated with Retro-X concentrator (Clontech, Saint-Germain-en-Laye, 
France) according to the manufacturer’s protocol. Target cells were transduced 
with the virus by spinning at 2,000rpm for 2hrs. Cells transduced with retroviral 
vectors were sorted for GFP using MoFlo sorter (Dako cytomation). 
RNA isolation from total, nuclear and cytoplasmic fractions. Nuclear and 
cytoplasmic fractions were separated by adding 200µl of lysis buffer (140mM 
NaCl, 1.5mM MgCl2, 10mM Tris-HCl pH8.0, 1mM DTT, 0.5% Nonidet P-40) to 
pellets of ~4 million cells, followed by 5min incubation on ice and centrifugation 
for 3min at 4°C and 100xg. The supernatant was harvested as the cytoplasmic 
fraction. The pellet containing the nuclei was washed twice with lysis buffer. 1ml 
of Qiazol (Qiagen, Carlsbad, USA) was added to the ~200µl of cytoplasmic 
fraction, to the nuclear pellet and to the total cell pellet.  
Quantitative RT-PCR. Total RNA was isolated using Trizol (Invitrogen, 
Carlsbad, USA) according to the manufacturer’s protocol for the cell lines. RNA 
samples were treated with DNase (Ambion, Foster City, CA). For RNA isolation 
from cytoplamic/nuclear/total fractions, we used the miRNeasy kit (Qiagen) 
including a DNase treatment (Qiagen). The RNA concentration was measured 
with a NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific Inc., 
Waltham, USA) and RNA integrity was evaluated by 1% agarose electrophoresis. 
cDNA was synthesized using 500ng input RNA, SuperScript II and random 
primers according to the manufacturers protocol (Invitrogen). The qPCR reaction 
contained SYBRgreen mix (Applied Biosystems, Foster City, USA), 300nM 
primers, and 1ng of cDNA in a total volume of 10µl. Levels of spliced, unspliced 
and total BIC as well as spliced and unspliced pri-miR-22, pri-miR-146a were 
normalized to HPRT. Transcript levels in nuclear fraction were normalized to U3 
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in total fractions were set as 100% and percentage of pri-miRNA transcripts in 
the cytoplasm and in the nucleus were calculated relative to the total fraction. 
Percentages of each transcript in the cytoplasm and in the nucleus were added 
and recalculated to sum up to 100%. For qRT-PCR, we used  the following 
primer sequences: for unspliced BIC, 5’- AGCTTTATAACCGCATGTGCATAC-3’ 
(forward) and 5’- CAGATTTCCCCTTCCTGGTTT-3’ (reverse); for total BIC, 5’- 
AAATTCTTTATGCCTCATCCTCTGA-3’ (forward) and 5’-
AGGCAAAAACCCCTATCACGAT-3’ (reverse); for unspliced pri-miR-22, 5’-
CTGCTCAGATCTTTCCCATTTTC-3’ (forward) and 5’-CCAGGTGAGGGCGTGAGA-3’ 
(reversed); for spliced pri-miR-22, 5’-GGGCTGATCACTGAACTCACATT-3’ 
(forward) and 5’-TGAGGGCGTGAGAGGAACA-3’ (reversed), for unspliced pri-
miR-146a, 5’-ATTTACCAGGCTTTTCACTCTTGTATT-3’ (forward) and 
5’-GGCTTTTCAGAGATGGTGCAA-3’ (reverse); for spliced pri-miR-146a, 
5’-GACAGGAGACAGTAGCACAACGA-3’ (forward) and 
5’-CAGCCAGCGAGCTCCTAAAA-3’ (reverse); primers for spliced BIC, HPRT, 
tRNA-Lys and U3 were described previously (Specht et al., 2001;Taft et al., 
2010;van den Berg et al., 2003). Localization of unspliced or spliced transcript-
specific qRT-PCR products are indicated in Fig. 2A. qRT-PCR for miR-155, miR-
22, miR-146a and RNU48 was performed using miRNA qRT-PCR assays (Applied 
Biosystems, Foster City, USA) as described previously (Gibcus et al., 2009). 
Reverse transcription (RT) primers specific for a miRNA and RNU48 (control) 
were multiplexed in 15µl RT reactions containing 1µl of each RT primer. The 
miRNA levels were normalized to the RNU48 levels. Mean cycle threshold (Ct) 
values for all genes were quantified with the SDS software (version 2.1). 
Relative expression levels were calculated as 2-∆Ct. 
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SUPPLEMENTARY FIGURE 1. Levels of unspliced and spliced pri-miRNA 
transcripts in the cytoplasm and in the nucleus. (A) Unspliced BIC transcripts showed 
significantly higher levels in the nucleus than spliced BIC transcripts and lower levels in the 
cytoplasm. (B) Unspliced pri-miR-22 transcripts were more abundant in the nucleus than 
spliced pri-miR-22 and less abundant in the cytoplasm of Jiyoye and L540 cells. (C) 
Unspliced pri-miR-146a transcripts showed significantly higher levels than spliced pri-miR-
146a in the nucleus for Jiyoye cells. In the cytoplasm lower levels of unspliced pri-miR-
146a were observed compared to levels of spliced transcript for both L428 and Jiyoye 
cells. Levels of pri-miRNA transcripts in the nucleus or the cytoplasm were calculated 
relative to their levels in the total fraction and corrected for the amount of RNA per cell. 
Significance was calculated using 2-way ANOVA and Bonferroni posttest (* p<0.05, ** 
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The oncogenic miR-17~92 cluster contains six miRNAs (miR-17, miR-18a, miR-
19a, miR-20a, miR-19b and miR-92a) that are expressed at variable levels in 
different normal and malignant cell types. We determined the level of the 
primary miR-17~92 transcript, C13ORF25, and the expression pattern of the six 
mature miRNAs in three B-cell subsets, 117 non-Hodgkin lymphoma (NHL) cases 
and 21 NHL cell lines. Within the normal B-cell subsets, significantly higher 
C13ORF25 levels were observed for naïve B cells compared to germinal center B 
cells. In the NHL cases and cell lines, BL showed the highest C13ORF25 levels. 
Among mature miRNAs, miR-92a levels were most abundant in the B-cell 
subsets, in the MCL, BL and CLL cases and all NHL cell lines. In DLBCL cases the 
miR-19b levels were much higher than the miR-92a levels. Comparison of the 
levels of the six mature miR-17~92 miRNAs between the NHL cases and their 
normal B-cell counterparts indicated the highest induction of miR-19b in cases 
and cell lines of the four NHL subtypes. We conclude that in normal B cells, CLL, 
MCL and BL cases miR-92a is the most abundant miRNA of the C13ORF25 
transcript, whereas in DLBCL miR-19b showed the highest expression levels. The 
highest induction in NHL was observed for miR-19b consistent with its known 
oncogenic role.  




MicroRNAs (miRNA) are a class of noncoding RNAs that are processed from 
longer endogenous primary transcripts (pri-miRNA). Each mature miRNA can 
target multiple protein-coding transcripts based on limited sequence homology, 
which can lead to a block in translation or to mRNA degradation. Targeting 
depends on the degree of sequence complementarity between the miRNA and 
target gene. Especially the seed region, i.e. nucleotide 2-7 at the 5’end of the 
miRNA, has been reported to be crucial for effective targeting. Several miRNAs 
are organized into so-called polycistrons that contain multiple miRNA stem loop 
structures in a single primary transcript. Individual miRNAs within such 
polycistronic transcripts contain the same or highly similar seed sequences in a 
proportion of miRNAs. Moreover, shared seed homology can also be observed 
between miRNAs of different or related polycistronic miRNAs (Lewis et al., 
2005). These miRNA seed family members are thought to target overlapping 
sets of genes. 
 Altered expression of miRNAs has been shown in many cancer types and 
miRNAs are located within genomic regions that show recurrent chromosomal 
aberrations in cancer (Klein et al., 2010). Moreover, several animal models 
support a crucial role for miRNAs in tumorigenesis (Li et al., 2012). A rapidly 
increasing number of miRNAs that are involved in many cancer related cellular 
processes, e.g. cell growth, cell death and angiogenesis, have been identified 
supporting a role for miRNAs in tumorigenesis (O'Donnell et al., 2005).  
 One well-known oncogenic polycistron is the miR-17~92 host gene, also 
known as C13ORF25 or Oncomir-1. C13ORF25 is located at 13q31-32 and 
contains six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-
92a). Each of these miRNAs has one or more seed family member in the 
C13ORF25 gene or in one of the two other homologous miRNA clusters (Tanzer 
and Stadler, 2004), i.e. the miR-106a~363 cluster on chromosome X and the 
miR-106b~25 cluster on chromosome 7. Individual miRNAs from the miR-17~92 
cluster have been shown to play a role in various cellular processes such as 
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indicate a role in cancer development. Several members of the miR-17~92 
cluster are overexpressed in B-cell lymphoma (Humphreys et al., 2012; 
Tsuchida et al., 2011) and miR-17~92 has been shown to be the target of the 
13q31-32 amplification in diffuse large B-cell lymphoma (DLBCL) (Ota et al., 
2004) and mantle cell lymphoma (MCL) (Salaverria et al., 2007). Further proof 
that members of the miR-17~92 cluster have oncogenic potential was obtained 
from studies in a MYC mouse model in which expression of miR-17~92 
accelerated lymphomagenesis (He et al., 2005). Besides overexpression induced 
by amplification of the 13q31-32 region, C13ORF25 was also shown to be 
upregulated by MYC (Chang et al., 2008). E2F1, a well known MYC target 
(Matsumura et al., 2003), was targeted by two of the C13ORF25 miRNAs, i.e. 
miR-17-5p and miR-20a (O'Donnell et al., 2005). This indicated a complex 
network between MYC, the E2F family, miR-17-5p and miR-20a (Ji et al., 2011). 
MiR-19a and miR-19b have been shown to be the major oncogenic components 
in the Eµ-myc transgenic mouse model of B-cell lymphoma, this was at least 
partly due to the repression of the tumor suppressor Phosphatase and tensin 
homolog (PTEN) (Mu et al., 2009) 
 The expression of individual members of polycistrons, including 
C13ORF25, has been studied in leukemia cell lines (Yu et al., 2006) and 
revealed marked differences between levels of miRNAs derived from the same 
polycistrons, suggesting variation in processing and/or stability of the individual 
miRNAs. Remarkably, in solid tumors (Li et al., 2012; Tsuchida et al., 2011) as 
well as in lymphoma (Li et al., 2012; Venturini et al., 2007), often only a single 
miRNA or a subset of the miRNAs of the miR-17~92 cluster are differentially 
expressed. 
 In this study, we determined the relative abundance of the six miRNAs of 
the C13ORF25 polycistron in a NHL cohort (n=117) including Burkitt lymphoma 
(BL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and 
diffuse large B-cell lymphoma (DLBCL). The aim of this study is to analyze the 
expression patterns and to determine possible differences in these patterns in B-
cell lymphoma in comparison to normal B-cell subsets and between NHL 
subtypes. 




Levels of C13ORF25 vary in B-cell NHL 
C13ORF25 levels were determined by qRT-PCR in normal B-cell subsets, in 117 
B-cell NHL samples, including 20 MCL, 19 BL, 50 DLBCL and 28 CLL cases, and 
in 21 B-cell NHL-derived cell lines. Within the normal B-cell subsets, a 
significantly higher C13ORF25 level was observed for naïve B cells compared to 
GC B cells (p<0.05) (Fig. 1A). C13ORF25 expression within the 117 NHL 
subtypes revealed marked differences between the four NHL subtypes (Fig. 1B). 
The levels were the highest in BL and the lowest in CLL (9 fold difference) with 
marked differences in expression levels between individual cases of each NHL 
subtype. The BL cases showed a significantly higher C13ORF25 level compared 
to CLL (p<0.001) and MCL (p<0.01). We also observed a significant difference 
between DLBCL and CLL (p<0.001). The overall pattern observed in the NHL cell 
lines was similar to the NHL cases, but the differences between NHL subtypes 
were not significant (Fig. 1C) probably due to smaller group sizes. The BL cell 
lines showed the highest levels of C13ORF25, followed by MCL and CLL cell lines, 
whereas DLBCL cell lines had the lowest levels. 
Different levels of the miR-17~92 cluster members in B-cell NHL  
We next studied the levels of the six individual members of the C13ORF25 
cluster, i.e. miR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a. Each 
B-cell subset showed a similar pattern with the highest level observed for miR-
92a (up to 60% of the total of all miR-17~92 members together) and the lowest 
levels for miR-18a and miR-19b (less than 1%) (Fig. 2A). In all three B-cell 
subsets miR-92a levels were significantly higher than the levels of the other 
miRNAs (p< 0.01). The NHL cases also had significant differences in the levels of 
each of the six miR-17~92 cluster members. For MCL, BL and CLL, miR-92a was 
the most abundant miRNA (60-80%) followed by miR-19b (10-30%). In DLBCL, 
miR-19b was most abundant (~60%), whereas miR-92a levels were much lower 













FIGURE 1. Expression levels of C13ORF25 in normal and malignant B cells. (A) The 
normal B-cell subsets showed a significant difference in the primary miR-17~92 transcript 
levels only between naïve and GC B-cell subsets. (B) The B-cell malignancies showed 
significantly different C13ORF25 levels that were the highest in BL and the lowest in CLL. 
C13ORF25 levels were normalized to an external common calibrator using a comparative 
threshold cycle method to allow comparison of the levels between the four B-cell 
malignancies. (C) In the BL cell lines, the levels of C13ORF25 were significantly higher 
compared to the DLBCL cell lines. P values were determined using a Kruskal-Wallis test. 
(*p<0.05, **p<0.01, ***p<0.001) 
 
FIGURE 2. Expression patterns of miR-17~92 miRNAs in B cells and NHL. (A) In 
the normal B-cell subsets miR-92a levels are significantly higher as compared to the levels 
of the five other miRNAs. (B) The B-cell malignancies MCL, BL and CLL showed the highest 
levels of miR-92a, whereas in DLBCL a higher level was observed for miR-19b. (C) The cell 
lines also showed significant differences within the miR-17~92 cluster with the highest 
levels for miR-92a. P values were determined using a Kruskal-Wallis test.  
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The cell lines derived from the four NHL subsets showed similar expression 
patterns, with miR-92a being the most abundant cluster member (45-73%). 
MiR-19b was the second most abundant in BL and DLBCL (~21%). In MCL, miR-
19b and miR-20a levels were similar (~22%) and were the second/third most 
abundant miRNAs in MCL. In CLL, four of the five remaining miRNAs showed 
similar low levels (3-8%). 
 We next studied the correlation between the levels of the six mature 
miRNAs and the C13ORF25 levels for all NHL cases and cell lines. In the NHL 
cases (Fig. 3A), BL cases showed a significant correlation for five of the six 
miRNAs, i.e. miR-18a (r=0.50, p=0.03), miR-19a (r=0.50, p=0.03), miR-20a 
(r=0.55, p=0.01), miR-19b (r=0,92; p<0.0001) and miR-92a (r=0.70, 
p=0.0008). Correlations for the other NHL subtypes were less pronounced, with 
a significant association observed for miR-92a in MCL, miR-20a in DLBCL, miR-
17 and miR-19a in CLL. In the NHL cell lines (Fig. 3B) only two significant 
associations were observed, which is probably due to the lower number of cell 
lines studied. Both significant associations were observed in BL cell lines, i.e. 
miR-19b (r=0.93, p=0.007) and miR-92a (r=0.82, p=0.003). 
 A possible explanation for the marked differences in expression of 
individual cluster members might be caused by differences in efficiency of the 
qRT-PCR procedure. Therefore, we tested the efficiency of the Taqman miRNA 
assays on serial dilutions of cDNA from the BL-derived CA46 cell line that had a 
relative high expression level of all six cluster members. The efficiency ranged 
from 103% to 109% (Supplementary Fig. 1), with the highest efficiency for miR-
17 and the lowest efficiency for both miR-18a and miR-92a. Thus, based on 
these efficiencies it is highly unlikely that the high miR-92a levels are caused by 
efficiency differences in the qRT-PCR.  
 A second explanation for the observed differences might be a high or 
variable expression of the homologous pri-miR-106a~363 transcript that 
contains two precursor sequences that are highly homologous to the C13ORF25 
precursors of miR-92a and miR-19b and result in identical mature miR-92a and 
miR-19b. To compare both transcripts, qRT-PCR was performed on 7 MCL, 7 BL, 
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C13ORF25, the levels of pri-miR-106a~363 were much lower (range 4 to 20 
fold) (Supplementary Fig. 2). This indicates that it is unlikely that the high levels 
of miR-92a and miR-19b in comparison to the other members of the C13ORF25 
cluster can be explained by expression of the homologous pri-miR-106~363 
cluster. 
 
FIGURE 3. Correlation of C13ORF25 levels with the levels of the six individual 
miRNAs. (A) In the NHL cases correlations were seen in each of the four NHL subtypes. In 
MCL and DLBCL, miR-92a showed a significant correlation with C13ORF25 levels. In BL a 
significant correlation was seen for five out of the six miRNAs whereas in CLL miR-17 and 
miR-19a levels showed significant correlations with C13ORF25 levels. (B) In the NHL cell 
lines only two significant correlations were observed, i.e. for miR-19b and miR-92a in the 
BL cell lines. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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 A third possibility is that factors influencing the processing efficiency or 
stability of the individual miRNAs cause differences in mature miRNA levels. KH-
type splicing regulatory protein (KSRP) and the RNA binding protein 
heterogeneous nuclear ribonucleoprotein A1 (HnRNP A1) have been reported to 
regulate processing of miR-20a and miR-18a, respectively. To identify a possible 
relation between KSRP levels and the levels of miR-20a, we performed qRT-PCR 
on 3 MCL, 12 DLBCL, 6 BL, 9 CLL. No relation was observed between KSRP 
levels and the mature miR-20a levels (data not shown). Immunohistochemical 
staining of HnRNP A1 in NHL cases showed no difference in expression between 
tumors with high or low miR-18a levels (data not shown). 
Fold induction levels in NHL subtypes  
To determine whether the levels of the members of the miR-17~92 cluster are 
deregulated in NHL we studied the fold induction of the miR-17~92 cluster 
members for each NHL subtype in relation to their normal B-cell counterparts 
(Fig. 4). The levels of all miR-17~92 cluster members were increased compared 
to their normal counter parts albeit at variable levels. The strongest fold 
increases were observed for miR-19b in all four NHL subtypes. For NHL cases 
the fold induction for miR-19b ranged from 10-fold for CLL compared to memory 
B cells to 415-fold for MCL compared to naïve B cells. For the cell lines the fold 
increase ranged from 746-fold for CLL compared to memory B cells, to 1344-fold 
for DLBCL compared to GC B cells. For the five other members of the miR-
17~92 cluster the fold increase in comparison to normal B cells ranged from 1 to 
21 fold for the NHL cases and from 5 to 643 fold for the cell lines. Despite the 
marked high levels of miR-92a, there was no apparent fold increase as 
compared to normal B cell subsets. Thus, miR-19b is the most pronounced 













FIGURE 4. Fold induction levels in NHL subtypes. Levels of the mature miRNAs in the 
NHL cases are given relative to the levels of the mature miRNAs in their bormal B-cell 
counterparts.  The cases all showed a significant fold increase in the expression levels of 
miR-19b (p<0.001). The cell lines also showed a significant fold increase in the expression 
of miR-19b (p<0.05). P values were determined using a Kruskal-Wallis test. 
DISCUSSION 
In this study we analyzed the expression pattern of the 6 miRNAs that are 
processed from the noncoding C13ORF25 transcript in NHL. We showed that 
normal B cells and each of the four NHL subtypes have a distinct expression 
pattern for the six miRNAs. MiR-92a was the most abundant miRNA in the 
normal B-cell subsets and three of the four NHL subtypes, whereas miR-19b was 
the most abundant cluster member in DLBCL. In comparison to their normal B 
cell counterparts, all NHL subtypes showed the strongest fold increase for the 
oncogenic miR-19b. 
 MYC and 13q31-32 amplification are two well known mechanisms to 
induce C13ORF25 in NHL (Navarro et al., 2009; O'Donnell et al., 2005; Ota et 
al., 2004; Tagawa et al., 2007). We observed significantly different C13ORF25 
levels in each of the four NHL subtypes. BL cases showed the highest C13ORF25 
levels, which is consistent with the genetic hallmark of BL; a translocation of the 
MYC locus to one of the immunoglobulin loci. The variations in C13ORF25 levels 
observed between and within each NHL subtype are most likely caused by 
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differences in MYC levels and/or the presence of 13q31-32 amplifications in 
individual cases.  
 The most abundant miR-17~92 cluster members in B cells and NHL were 
miR-92a and miR-19b. The miR-106a~363 cluster contains miRNAs that are 
identical to miR-19b and miR-92a derived from the miR-17~92 cluster (Landais 
et al., 2007). In the NHL cases the level of C13ORF25 was always much higher 
than the level of pri-miR-106a~363. Thus, despite the presence of a homologue 
cluster that also contains miR-19b and miR-92a, it is unlikely that the higher 
miR-92a and miR-19b levels in comparison to the four other C13ORF25 
members can be explained by co-expression of the pri-miR-106a~363 cluster. 
We next examined the correlation between the primary miRNA transcript and 
the mature miRNAs to assess possible differences in the biogenesis or stability of 
individual miRNAs. BL showed a good correlation between C13ORF25 and five of 
the six cluster members, in the other NHL subtypes the correlation was less 
obvious. A poor correlation between primary transcript and mature miRNAs has 
been reported for miR-138 in murine brain and murine neuroblastoma cell line 
N2A (Obernosterer et al., 2006), let-7 in neural cell specification (Wulczyn et al., 
2007) and miR-143 and miR-145 in colorectal adenocarcionoma (Michael et al., 
2003). These studies indicate that the levels of primary transcripts do not 
necessarily correlate with the levels of mature miRNAs. 
 Two RNA binding proteins, i.e. KSRP and hnRNP A1, have been shown to 
be involved in biogenesis of certain members of the miR-17~92 cluster. HnRNP 
A1 facilitates processing of miRNA-18a (Guil and Caceres, 2007) and KSRP 
enhances biogenesis of a group of miRNAs including miR-20a and miR-106a 
(Garcia-Mayoral et al., 2007; Trabucchi et al., 2009). We observed no difference 
in hnRNP A1 staining intensity between tumors with high and low miR-18a 
levels, indicating that differences in miR-18a levels are not likely due to 
differences in hnRNP A1 expression. This might in part be caused by the overall 
low miR-18a levels observed in NHL. Since there was no antibody available that 
showed a good staining pattern on FFPE tissue sections, we analyzed KRSP by 
qRT-PCR. KRSP levels showed no relationship to miR-20a expression on a 
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known factors that affect biogenesis of miR-19a, miR-19b or miR-92a. Chaulk et 
al. showed that the tertiary structure of the miR-17~92 transcript in vitro is 
organized in such a way that the miR-92a and miR-19b stem-loops are 
internalized making them less accessible and thus less efficiently processed 
(Chaulk et al., 2011). It would be interesting to analyze the structure of this 
primary transcript in B cells or in NHL cell lines to establish if in this cell type the 
miR-92a and miR-19b stem-loops are more accessible for processing. Moreover, 
it may be speculated that despite lower pri-miR-106a~363 levels, accessibility of 
miR-19b and miR-92a is much better in this transcript, and that a substantial 
proportion of the mature miR-19b and miR-92a miRNAs are derived from this 
transcript despite its lower levels.  
 We observed that miR-92a was the most abundant miRNA in the B-cell 
subsets, the MCL, BL and CLL cases and in the NHL cell lines. MiR-19b usually 
was the second most abundant miRNA in the NHL cases and cell lines. In 
contrast to the MCL, BL and CLL cases, the DLBCL cases showed the highest 
levels for miR-19b. Analysis of the individual DLBCL cases showed that in 49 of 
the 50 cases the miR-19b levels were indeed higher than the miR-92a levels 
(Supplementary Fig. 3). MiR-92a has been shown to be involved in 
carcinogenesis by suppression of angiogenesis by targeting Integrin α5 (ITGA5) 
(Bonauer et al., 2009) and by affecting cellular proliferation in colon and 
hepatocellular carcinoma cell lines (Tsuchida et al., 2011).  MiR-92a is 
overexpressed in a wide variety of cancers, but a role in B-cell lymphomagenesis 
is less evident. MiR-92a is usually not among the consistently overexpressed 
miRNAs in profiling studies in NHL (Lawrie et al., 2009; Malumbres et al., 2009; 
Roehle et al., 2008). He et al. demonstrated that overexpression of a truncated 
miR-17~19b cluster, thus without miR-92a, cooperates with MYC to promote 
lymphomagenesis in mouse models (He et al., 2005). This indicates that miR-
92a is not essential for the oncogenic effect of the miR-17~92 cluster. We 
observed no specific induction of miR-92a in comparison to their normal B cell 
counterparts, despite the high miR-92a levels observed in the majority of the 
NHL cases. Thus, it is unlikely that miR-92a plays a main role in NHL 
lymphomagenesis. 
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 Finally, we assessed the putative oncogenic changes of the mature miRNA 
levels in relation to their normal counterparts. For all four NHL subtypes, miR-
19b showed the highest fold increase ranging from 10- to ~1300-fold. It is 
unclear why only miR-19b and not the closely related miR-19a is induced in the 
NHL cases and cell lines. This might indicate that targets specific for miR-19b 
play a role in lymphomagenesis. MiR-19b, together with miR-19a, accelerated 
the MYC-induced lymphomagenesis in transgenic mice models (Mu et al., 2009; 
Olive et al., 2009). MiR-19a and miR-19b have also been shown to be 
significantly upregulated in Cyclin D1-positive MCL patients (Iqbal et al., 2012).  
Proven targets of miR-19b include protein kinase, AMP-activated, alpha 1 
catalytic subunit (Prkaa1), protein phosphatase 2 (PP2a),  Bcl-2-like protein 11 
(Bim) (Mavrakis et al., 2010), pro-angiogenic protein FGFR2 (Yin et al., 2012) 
and the tumor suppressor gene PTEN (Takakura et al., 2008). PTEN negatively 
regulates the phosphatidylinosiol-3-kinase (PI3K) pathway (Takakura et al., 
2008) and activation of the PI3K pathway is a key element for the malignant 
transformation of MYC expressing germinal center B cells in a BL mouse model 
(Sander et al., 2012). Overall, there is strong evidence that miR-19a and miR-
19b are important oncogenic miRNAs in NHL pathogenesis. The mechanism of 
specific upregulation of miR-19b and not the other members of the miR-17-92 
cluster in NHL compared to normal B cells is not yet known. It is possible that 
miR-19b processing is regulated by an unknown regulatory protein that is 
differential expressed in NHL in comparison to B cells.   
 In conclusion, we showed that miR-92a is the most abundant miRNA of 
the miR-17~92 cluster, in normal B cells, CLL, MCL and BL cases. In DLBCL, 
miR-19b showed the highest levels, and miR-92a was the second most abundant 
miRNA. Despite high miR-92a levels, we observed the highest fold induction for 
miR-19b in all four NHL subtypes in comparison to their normal B-cell 
counterparts, consistent with its known oncogenic role. 
MATERIALS AND METHODS 
B-cell subsets. B cells were purified from human tonsils obtained from children 









Differences in the miR-17~92 miRNA expression pattern in NH 
 
88 
1994). Briefly, mononuclear cells were isolated by Ficoll-Isopaque density 
gradient centrifugation. Monocytes and T cells were depleted by plastic 
adherence and sheep red blood cell (SRBC) rosetting, respectively. The total B 
cell subset was >97% pure as determined by FACS analyses. To sort the 
different B cell sub populations (naive B cells, memory B cells and GC B cells), 
cells were stained with FITC-conjugated anti-human IgD, PE-conjugated anti-
human CD20, and allophycocyanin-conjugated anti-CD38 and sorted using a 
FACS aria (BD Biosciences): naive B cells (CD20+IgD+,CD38-), germinal center 
B cells (CD20+IgD-CD38+) and memory B cells (CD20+IgD-CD38-). 
Patient samples. Formaldehyde Fixed-Paraffin Embedded (FFPE) tissue was 
obtained from 20 cases of MCL, 19 cases of BL, 50 cases of primary stage I and 
II nodal and extranodal DLBCL and 28 cases of CLL from the tissue bank at the 
Department of Pathology, University Medical Center Groningen and the tissue 
bank at the Department of Pathology, The Netherlands Cancer Institute, 
Amsterdam (a gift from Dr. D. de Jong). Each case history was reviewed by a 
hematopathologist and diagnoses were established according to the criteria of 
the World Health Organization classification. Only cases containing a tumor cell 
percentage of >80% were used for RNA isolation and qRT-PCR. All protocols for 
obtaining and studying human tissues and cells were approved by the 
institution’s review board for human subject research. 
 
Cell lines. 21 cell lines were used for the analysis, including 4 MCL cell lines 
(HBL-2, JEKO-1, GRANTA-519 and UPN-1), 7 BL cell lines (Raji, CA46, BL65, 
NAMALWA, DG75, Jiyoye and Ramos), 6 DLBCL cell lines (ROSE, VER, SUDHL6, 
SUDHL4, OCI-Ly3 and SCHI) and 4 CLL cell lines (EHEB, MEC-1, MEC-2 and 
JVM3). The mantle cell lines UPN-1 and HBL-2 were obtained from Dr. W. 
Klapper (Kiel, Germany); JEKO-1, Granta-519 and CLL cell lines JVM-3, MEC-1 
and MEC-2 were obtained from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (DSMZ, Branschweig, Germany). The Burkitt cell lines DG75 
and CA46 were obtained from the American type culture collection (ATCC) (LGC 
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standards, Middlesex, UK). The DLBCL cell lines SU-DHL-4 and SU-DHL-6 were 
obtained from A. Epstein (UCLA, Los Angeles, CA).  
 Cell lines were propagated in DMEM medium containing 10% FBS (Granta-
519), IMDM medium containing 20% (OCI-Ly3) or 10% (MEC-1, MEC-2) FBS or 
RPMI-1640 medium containing 10% FBS (other cell lines) (Cambrex Biosciences, 
Walkersville, USA) supplemented with ultraglutamine (2mM), penicillin 
(100U/ml), streptomycin (0.1 mg/ml; Cambrex Biosciences). Cell lines were 
cultured at 37°C under an atmosphere containing 5% CO2.  
 
Quantitative RT-PCR. RNA isolation from FFPE material of DLBCL, CLL, BL and 
MCL cases was performed as described previously (Robertus et al., 2009). All 
samples were DNAse treated using Turbo DNA free kit (Ambion, USA) according 
to the manufacturer’s instructions. Efficiency of the DNase procedure was 
checked using a multiplex PCR with 5 primer sets specific for different genomic 
DNA loci and subsequent analysis on a 1.5% agarose gel. No PCR products were 
seen confirming the effectiveness of the DNAse treatment. RNA concentrations 
were measured on a NanoDrop® ND-1000 Spectrophotometer (Nano Drop 
Technologies, Wilmington, Delaware, USA). 
 For miRNA-specific cDNA synthesis we used 5ng total RNA, the Taqman 
MicroRNA Reverse Transcription Kit and Taqman miRNA assays for six mature 
miRNAs of the C13ORF25 cluster. The qPCR reaction was carried out on 0.44ng 
cDNA using miRNA specific primers in accordance with the instructions supplied 
by the manufacturer (Applied Biosystems, Foster City, CA, USA). The cDNA 
synthesis for mRNA was primed with random hexamer primers using Superscript 
II (Invitrogen, USA) on 200ng of total RNA. SYBR green (Applied Biosystems) 
was used for the relative quantification of C13ORF25, KSRP with 2ng of cDNA 
input in a 20µl reaction. PCR reactions were performed in triplicate, positive and 
negative controls were included in each run. Primer sequences used for PCR 
were as follows, C13ORF25 forward primer 5’-TGTGATGTTTTGTTGTGGGTTTG-3’; 
reverse primer 5’-AGTGCTTTCTTTCCAAATATAGGC-3’. Pri-miR-106~363 forward 
primer 5’-CAGGGATGAATGGGCAGAG-3’; reverse primer 5’-
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CAGAATACGAATGTGGACAAA-3’; reverse primer; 5’-TCACGTTCCCGGAGGATGT-
3’.  Quantification was performed using Taqman MicroRNA together with the 
7900HT ABI Fast Real-Time PCR system (Applied Biosystems, USA). 
Fluorescence was quantified with the sequence detection system software SDS 
(version 2.1, Applied Biosystems, USA). Mean cycle threshold values (Ct) and 
standard deviations (SD) were calculated for all miRNAs and genes. U6 was 
selected as a housekeeping gene to normalize the mRNA and miRNA levels as it 
showed a uniform expression level in all samples and a sufficiently low threshold 
Ct value. Cases with a Ct value for U6 > 30 were regarded to have bad RNA 
quality and therefore excluded from further analysis. The relative expression 
levels were expressed as 2-ΔCt.  
 Given the large number of NHL samples (n=119), qRT-PCR of the NHL 
cases was performed in separate runs for each of the four subtypes. The 
comparative threshold cycle method was applied using RNA isolated from a 
pediatric tonsil obtained during routine tonsillectomy as endogenous reference 
using the formula 2-ΔΔCt (ΔΔCt = (Ct sample - Ct U6 sample) - (ΔCt Tonsil - ΔCt U6 Tonsil). 
To allow comparison of the levels of the individual members of the miR-17~92 
cluster the sum of the 2-ΔCt values were set at 100%.  
 To determine the efficiency of the miRNA qPCR, a 2x serial dilution of 
cDNA of a cell line with relatively high expression of each of the miRNAs was 
used in a qPCR reaction. The amplification efficiency was calculated based on the 








Immunohistochemistry. HnRNP A1 was stained using ab50492 (Abcam, 
Cambridge, UK) with tris/EDTA pre-treatment and a 1:100 antibody dilution 
followed by detection with labeled GaRPO  followed by RaGPO and DAB substrate 
chromagen solution. Slides were lightly counter-stained with hematoxylin before 
imaging. 
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Data analysis. To determine significant differences in C13ORF25 and individual 
miRNAs levels within each NHL subtype a Kruskal-Wallis test was performed with 
a Dunn’s Multiple Comparison Test and a p-value <0.05 was considered 
significant (GraphPad Prism software, version 5.04). To determine the 
association between the primary transcript and mature miRNA, Pearson and 
Spearman’s rank correlations together with univariate linear regression were 
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SUPPLEMENTARY FIGURE 1. Relative expression of C13ORF25 and pri-miR-
106a~363. In the four NHL subtypes C13ORF25 levels were higher than the levels of the 
homolog pri-miR-106a~363 cluster. 
 
 
SUPPLEMENTARY FIGURE 2. Efficiency of qRT-PCR procedure. Using a sample with 
relative high levels of all six cluster members the PCR efficiency was determined. The 
efficiencies ranged from 103% for miR-92a to 109% for miR-17.  
 
SUPPLEMENTARY FIGURE 3. Expression levels of miR-19b and miR-92a in 
individual DLBCL cases. To determine if the relative high expression of miR-19b in 
contrast to miR-92a is due to extreme outliers, the levels of both miRNAs were compared 
separately for each DLBCL case. Only one DLBCL case showed a higher level of miR-92a 
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MicroRNA (miRNA) sponges are RNA molecules with repeated miRNA antisense 
sequences that can sequester miRNAs from their endogenous targets and thus 
serve as a decoy. Stably expressed miRNA sponges are especially valuable for 
long-term loss-of-function studies and can be used in vitro and in vivo. We 
describe here a straightforward method to generate retroviral miRNA sponge 
constructs using a single directional ligation reaction. This approach allows 
generation of sponges containing more than 20 miRNA binding sites. We provide 
a basis for the design of the sponge constructs with respect to the sequence of 
the miRNA binding site and the sequences flanking the miRNA binding sites. In 
silico validation approaches are presented to test the predicted efficiencies of the 
sponges in comparison to known target genes. In addition, we describe in vitro 
validation experiments to confirm the effectiveness of the miRNA sponges. 
Finally, we describe how the described procedure can be adapted to easily 
generate sponges that target multiple miRNAs simultaneously. In summary, our 
approach allows rapid generation of single or combination miRNA sponges that 
can be used for long-term miRNA loss-of-function studies.  




Several approaches have been described to study the effect of miRNA loss-of-
function in a specific cell type of interest, e.g. using microRNA (miRNA) 
antisense inhibitor oligonucleotides, knockout animal models and miRNA 
sponges or decoys (Brown and Naldini, 2009; Ebert et al., 2007; Kloosterman et 
al., 2007; Krutzfeldt et al., 2005; Park et al., 2010). Inhibitor oligonucleotides 
are effective for short-term (24h – 72h) experiments. However, these synthetic 
oligonucleotides are expensive and not very suitable for long-term experiments 
due to degradation and dilution caused by cell proliferation. MiRNA knockout 
animal models that are the method of choice for functional in vivo studies and 
conditional models allow studying the effect of miRNA knockout in specific cell 
types or at specific time points during development. An important disadvantage 
is the time-consuming procedures and costs to generate knockout animals. 
Moreover, generation of miRNA knockout animals may be technically challenging 
as a large percentage of miRNAs are located within protein-coding genes, are 
part of a miRNA cluster or have multiple copies on the genome. MiRNA sponges 
or decoys are in vivo expressed transcripts that contain multiple high affinity 
miRNA antisense binding sites (MBS). These transcripts can efficiently sequester 
specific miRNAs and, thereby, prevent their binding to endogenous target genes 
(Ebert and Sharp, 2010; Kumar et al., 2008; Papapetrou et al., 2010). The 
experimental application of miRNA sponge technology has met increasing 
interest for in vitro and in vivo applications, indicating that this approach can 
greatly aid to the understanding of miRNA functioning (Chaudhuri et al., 2012; 
Liu et al., 2012; Ma et al., 2011; Otaegi et al., 2011; Zhu et al., 2011).  
 Besides the strategy described by us, two different approaches have been 
described for the generation of miRNA sponges with multiple MBS. The first 
approach is based on the non-directional concatemerization of oligonucleotide 
duplexes followed by a ligation of 5’ and 3’ adapters and ligation into the vector 
of choice (Ebert et al., 2007). This method is relatively inefficient due to the 
non-directional cloning and multiple ligation steps. The second approach uses 
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designed with appropriate restriction enzyme overhangs to allow direct 
directional cloning into a vector (Brown et al., 2007; Papapetrou et al., 2010). A 
disadvantage of this method is that only a limited number of MBS can be cloned, 
which may not be sufficient to sequester all endogenous miRNAs. We have 
developed a novel approach that allows rapid and efficient generation of miRNA 
sponges with varying sizes using a single ligation reaction (Kluiver et al., 2012). 
Effectiveness of the sponges was shown by demonstrating effects on cell growth 
in GFP proliferation assays, modulation of luciferase activity in luciferase 
reporter assays and presence of the sponge transcripts in the Ago2 
immunoprecipitation fraction of cell lines that overexpress the sponge 
constructs. Here, we provide a detailed description of the design and cloning 
strategy to generate miRNA sponge constructs and to validate their 
effectiveness in vitro.  
MATERIALS 
MiRNA sponge design  
Sense and antisense oligonucleotides containing two miRNA binding sites 
separated by a short sequence (“spacer”) and 5’phosphates are ordered PAGE 
purified at a 100nmol scale (IDT, Coralville, IO, USA). The oligonucleotide 
duplexes are designed with overhangs that are compatible with the restriction 
endonuclease SanDI (Fermentas, St. Leon-Rot, Germany) to enable directional 
cloning of multiple oligonucleotide duplexes (Fig. 1a). As a negative control, a 
sponge with a similar design but a scrambled seed sequence (i.e. nucleotide 2-
8) can be used. Combination sponges (combi-sponges) for the simultaneous 
inhibition of multiple miRNAs of interest can be ordered as minigenes (IDT). 
PITA (http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html, Kertesz et 
al., 2007); and STarMir (http://sfold.wadsworth.org/cgi-bin/STarMir.pl, Long et 
al., 2007) software applications are used to predict RNA folding and accessibility 
of the miRNA binding site, as well as the specificity and binding capacity of the 
sponge transcripts.  
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MiRNA sponge cloning 
For the construction of miRNA sponges starting with oligonucleotide duplexes, 
we use the compatible ends of the interrupted palindromic SanDI restriction site. 
To allow cloning and subsequent studies, we adapted the pMSCV-PIG vector 
(Addgene, www.addgene.org, plasmid 21654) by inserting a SanDI restriction 
site containing linker between the XhoI and EcoRI restriction sites yielding 
pMSCV-PIG-sp (Fig. 1b). 
 
FIGURE 1. Example of a MBS oligonucleotide duplex design and a SanDI linker (A) 
Oligonucleotide design used to generate a miR-19 bulged sponge. Shown are the sense 
and antisense sequences of the miR-19 sponge and how the sense strand can bind to miR-
19a and miR-19b. SanDI compatible ends are depicted in bold, the grey box indicates the 
bulge in the miRNA binding site, and the spacer sequence is depicted in italic. (B) The 
linker design used to introduce a SanDI restriction enzyme recognition site in the pMSCV-
PIG vector. A 5’ Xho-I site and a 3’ EcoRI site were added to the ends of the linker for 
efficient subcloning. Besides a SanDI site (bold) for the generation of miRNA sponges, two 
other restriction sites were added to allow flexibility for potential further subcloning. Sp = 
sponge, S = sense, AS = antisense, MBS = miRNA binding site and Phos = phosphate 
group 
 
The pMSCV-PIG-sp vector is prepared for oligonucleotide duplex ligation by 
digestion with SanDI and dephosphorylation with CIAP (1 U/ul, Invitrogen, 
Carlsbad, CA, USA). For ligation of minigenes, the vector should be restricted 
with EcoRI and XhoI (NEB, Ipswich, MA, USA). Digested vectors are gel purified 
using a DNA gel extraction kit (Zymoclean Gel DNA recovery kit, Zymo 
Research, Irvine, CA, USA). For the ligation reaction, T4 DNA ligase is used 
(Invitrogen). Additional material needed for transformation of the ligation 
reaction and screening of colonies include competent E. coli cells, SOC medium, 
waterbath, agar plates with appropriate antibiotic (ampicillin for pMSCV-PIG-sp), 
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5'-TTTATCCAGCCCTCACTCC-3', reverse primer = 5'-TTGTGTAGCGCCAAGTGCC-
3') and PCR machine to screen for insert-containing colonies and a plasmid 
isolation kit. 
In vitro validation of sponge efficiency 
Luciferase assay 
MicroRNA sponge sequences are subcloned into the 3’UTR of the Renilla 
luciferase gene in the psiCHECK2 vector (Promega, Madison, USA). For 
transfection of HEK293 cells, the Amaxa nucleofector I device (Amaxa, 
Gaithersburg, USA) is used with solution V, program Q-01. MiRNA inhibitor 
oligonucleotides are designed as previously described (Kluiver et al., 2012) 
(Exiqon, Vedbaek, Denmark). MiRNA precursors are purchased from Ambion 
(Life technologies, Grand Island, NY, USA). For assessment of Renilla and Firefly 
activity the Dual-luciferase Reporter assay (Promega) is used. Luciferase activity 
is measured on a Luminoskan luminometer (Thermo scientific, Asheville, NC, 
USA). 
Ago2-IP 
Ago2-IP procedure and material details were fully described previously (Tan et 
al., 2009; Tan et al., 2011). The anti-Ago2 antibody clone 2E12-1C9 (Abnova, 
Taipei, Taiwan) is used for the IP procedure. 
METHODS 
MiRNA sponge design  
Oligonucleotide and minigenes composition 
The method of choice for the generation of miRNA sponges may depend on 
number of miRNAs that need to be targeted simultaneously with a single sponge 
construct. For the generation of sponges that target one or two miRNAs, the 
oligonucleotide duplex approach can be used. For the generation of sponges 
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targeting more than two miRNAs, the minigene approach is more efficient (Fig. 
2). As an appropriate negative control for both approaches, one may generate 
the sponge sequence harboring a scrambled miRNA seed-binding region.  
 For the oligonucleotide duplex approach, oligonucleotides are designed 
with two identical MBS, in case one miRNA is inhibited, or two different MBS, in 
case two miRNAs are inhibited simultaneously (Fig. 1A). Each MBS is the 
antisense sequence of the miRNA to be studied, with a central mismatch at 
position 9-12 of the miRNA sequence (“bulge”). This bulge is created by deletion 
of one nucleotide and changing the remaining three nucleotides in such a way 
that chance of base paring (including G-U wobbling) is minimal. The two MBS 
are separated by a short 4-6nt sequence (“spacer”). The 5’ and 3’ ends of the 
oligonucleotide duplex consist of overhangs that are compatible with the SanDI 
restriction endonuclease. This enzyme recognizes a 7-bp interrupted palindromic 
sequence, i.e. 5′-GGGWCCC-3′ (W = A or T), and produces 3nt long 5′ 
protruding ends that will enable directional ligation of the oligonucleotide 
duplexes.  
   
  
 
FIGURE 2. Scheme for the selection of the most appropriate cloning strategy for 
generation of sponges with MBS for one, two, or more than two miRNAs. Sp = 
sponge, LTR = long terminal repeat, PGK = phosphoglycerate kinase, IRES = internal 
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 For the cloning of minigenes, the same approach is applied. For directional 
cloning, 5’-XhoI and 3’-EcoRI sites are added to the minigene design. A pre-
selected number of MBS for each miRNA can be included (see also hints section 
4.4). Increase in the total number of MBS will increase the size and thus also the 
cost of the minigene. Different spacers between MBS may be used and the order 
of MBS can be shuffled. Testing the effects of these variations using in silico 
validation will aid in maximizing the binding efficiency of the miRNA sponge to 
each of the selected miRNAs (see next paragraph). 
In silico validation of sponge specificity and binding efficiency 
To optimize the sequence of the desired sponges, two published algorithms, i.e. 
PITA (Kertesz et al., 2007) and STarMir are used with standard settings (Long et 
al., 2007). For this in silico analysis, the full RNA transcript as generated from 
the vector of interest plus the desired number of MBS is uploaded in the 
program. For our pMSCV-PIG-sp vector this included the end of the psi 
packaging signal up to the start of the PGK promoter resulting in a transcript of 
466bp + the length of the sponge sequence. Based on different RNA folding 
computations, both algorithms predict the effectiveness of the designed MBS in 
the sponges by calculating the difference between the free energy gained by 
binding of the miRNA to the MBS and the free energy lost by unwinding of the 
MBS nucleotides (∆∆G (PITA) and ∆Gtotal (STarMiR)). The PITA algorithm also 
provides information on all other miRNAs that can potentially bind to the sponge 
sequence. The binding energy of the miRNA to the sponge transcript can be 
compared with the binding energy of experimentally proven endogenous targets. 
By varying sequences within the sponge, a design that has a high free energy 
gain upon miRNA binding to most or all MBS and minimal off-target miRNA 
binding can be generated. Variations that can be tested include nucleotide 
composition, length of the spacer sequence and the nucleotide sequence in the 
bulge region (position 9-12) of the MBS. In case the oligonucleotide duplex 
approach is used, one can also vary the nucleotide in the middle of the SanDI 
restriction site (A or T). Care should be taken to ensure the SanDI site in the 
cloning vector is compatible with the A or T choice in the SanDI compatible 
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overhangs of the oligonucleotide duplex. It is important to also test the 
scrambled seed-binding control constructs to rule out the possibility of creation 
of novel off-target effects.   
MiRNA sponge cloning 
Oligonucleotide duplex generation 
Oligonucleotides are dissolved to 50µM in STE-4 (100mM NaCl, 10mM Tris/HCl, 
1mM EDTA, pH 8.0). Sense and antisense oligonucleotides are mixed at a 1:1 
ratio resulting in a final concentration of 25µM for each oligonucleotide. 
Oligonucleotide mixtures are placed in boiling water for 10 minutes and slowly 
cooled to room temperature to allow annealing of the two oligonucleotides (let 
boiling water slowly cool to room temperature in approx. 30 minutes). Store 
oligonucleotide duplexes at -20°C. 
Preparation of cloning vector  
The pMSCV-PIG-sp vector is digested with SanDI according to the reaction 
conditions recommended by the supplier. After completion of the restriction 
enzyme reaction (check small aliquot on 0.7% agarose gel) add 1µl CIAP and 
incubate for an additional 5 minutes at 37°C to dephosphorylate the sticky ends 
of the vector. Enzymes are inactivated by incubation at 65°C for 10 minutes. 
When cloning minigenes, the pMSCV-PIG-sp vector should be digested with 
EcoRI and XhoI. Gel-purify the restricted and dephosphorylated vector using a 
DNA gel extraction kit. After purification, the DNA concentration is measured on 
a NanoDrop. 
Ligation reaction 
For ligation of sponge oligonucleotide duplexes into the vector, a vector/insert 
ratio of 1:300 or 1:1000 is recommended. A higher ratio results in an average 
longer insert size at the cost of a lower number of clones. The number of MBS 
we obtained varied between 2-16 (average 6) for a ratio of 1:300 and 2-22 
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and oligonucleotide duplexes required for the ligation the following formula is 
used: ng insert = { (bp insert * ng vector) / bp vector } * ratio. For efficient 
ligation, a minimum of 50-100ng of digested vector is recommended. Ligation 
reactions are performed in 10µl with 1μl 5U/μl T4 DNA ligase in the buffer 
supplied by the manufacturer. In addition, it is recommended to perform ligation 
control reactions to be able to determine whether the prepared vector is 
efficiently digested and dephosphorylated (see troubleshooting section, 5.1). For 
the minigene cloning strategy, inserts with 5’XhoI – 3’EcoR1 overhangs are 
ligated at a standard 1:3 ratio into the pMSCV-PIG-sp vector. The ligation 
reaction is performed by incubation at room temperature for 30 minutes. 
Approximately 10ng DNA (vector + insert) of the ligation reaction is used for 
standard transformation to E. coli and at least two different amounts of the 
transformed bacteria culture are plated on agar plates.  
TABLE 1. Expected number of MBS per clone upon ligations with different vector/insert 
ratios.  
Ratio vector/insert # MBS/insert Median # MBS/insert 
Mean # MBS/insert 
1:3 2-8 2 3.2 
1:100 2-10 5 5.5 
1:300 2-16 6 6.0 
1:1000 2-22 6 7.5 
Check presence and length of insert 
As a rapid screen to select clones with the desired number of MBS, a colony PCR 
can be done. Mark the selected colonies and pick part of the colony with a sterile 
toothpick and re-suspend the bacteria in 100μl water. Boil samples for 10 
minutes, spin tubes and use 1ul of the supernatant as template DNA for an 
insert PCR using primers that flank the multiple cloning site. Run PCR products 
on an agarose gel. The size of the PCR product indicates the number of MBS 
present in the selected clone (empty vector PCR product for pMSCV-PIG-sp is 
144bp). Select the clones with the desired insert sizes, grow bacteria on a large 
scale and isolate plasmid DNA (Qiagen, Venlo, the Netherlands). These clones 
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are submitted for Sanger sequencing to confirm the insert sequence (LGC 
genomics, Berlin, Germany).  
In vitro validation of sponge efficiency 
Luciferase assay 
To validate the effectiveness of the sponge transcript to bind to the desired 
miRNA, the entire sponge is subcloned into the 3’UTR of the Renilla luciferase 
gene of the dual-luciferase reporter vector psiCHECK2 using XhoI and PmeI 
restriction sites. HEK293 cells or other easy to transfect cells can be used for 
these experiments. One million HEK293 cells are transfected with 2μg of each 
construct with or without miRNA precursor (100nM) or inhibitor (20μM). Harvest 
cells after 24 hours and make cell lysates for luciferase measurement according 
to the manufacturer’s protocol. Renilla and Firefly activities are measured in 
duplicate for each transfection and each transfection is performed at least in 
triplicate to obtain robust results. A decreased Renilla to Firefly luciferase ratio is 
expected upon transfection with the miRNA precursor, while transfection with 
the miRNA inhibitor should lead to an increase in the Renilla to Firefly luciferase 
ratio. 
Ago2-IP 
To confirm that the miRNA containing RISC complexes are bound to the miRNA 
sponge transcripts, an Ago2 immunoprecipitation can be performed. Sponge 
transcripts should be enriched in the IP fraction similar to endogenous miRNA 
targets. The immunoprecipitation of Ago2-containing protein-RNA complexes is 
described in detail elsewhere (Tan et al., 2011). In short, 15-30 million cells 
that express the miRNA and the miRNA sponge of interest are lysed. The 
cleared supernatant is incubated with sepharose beads coated with Ago2 
or IgG control antibody at 4°C overnight. After washing, total, flow-
through and immunoprecipitated fractions are harvested for protein and 
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IP fraction and thus confirm effectiveness of the IP procedure.  QRT-PCR 
of the sponge transcripts is performed to determine enrichment in the 
Ago2 IP fraction as compared to the IgG control IP, the total cell lysate 
and the IP flow-through fractions. 
HINTS  
Targeting seed-families 
Several miRNAs have seed family members at different genomic loci that most 
likely have a large overlap in their target genes and thus have similar functions. 
In general, the miRNA sequences of these seed family members are highly 
similar and oligonucleotides may be designed in such a way that all members 
can be targeted simultaneously. If this is not possible, two slightly different MBS 
can be made within the oligonucleotide to enable optimal binding of all individual 
miRNA seed family members. The sponge approach thereby allows an effective 
loss-of-function analysis of entire seed families.  
Generation of combi-sponges 
For the generation of combi-sponges that target two unrelated miRNAs, a 
strategy similar to the single sponge procedure can be followed. The principle 
difference is that the oligonucleotides contain two different miRNA binding sites. 
For the generation of sponges with binding sites for multiple miRNAs, e.g. MBS 
for all miRNAs of a specific miRNA cluster; it may be more convenient to use a 
minigene approach. In this way the number of binding sites for each miRNA can 
be easily selected. Also for these constructs, the binding efficiency and 
availability of each binding site should be checked using the STarMir and/or PITA 
software.  
Bulged or perfect MBS sponges 
Bulged miRNA sponges are reported to be more effective for the sequestration of 
miRNAs than perfect antisense sponges (Ebert et al., 2007; Gentner et al., 
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2009; Haraguchi et al., 2009). Consistent with these findings we also showed 
that miR-19 bulged MBS sponges are effective inhibitors of miR-19 driven 
proliferation while miR-19 perfect MBS sponges are not (Kluiver et al., 2012). 
This difference may be caused by degradation of the sponge transcripts due to 
endonucleolytic cleavage activity of the Ago2 complex upon perfect binding of 
the miRNA to its binding site. Thus, perfect MBS may be more suitable for the 
induction of degradation of a transcript upon binding of the miRNA.   
Number of MBS per sponge 
Several factors may influence the number of MBS in a sponge needed for 
maximal miRNA inhibition for a specific cell type, i.e. the miRNA expression 
levels, the miRNA sponge transcript levels and the miRNA binding efficiency of 
the MBS of endogenous targets. We showed that when comparing miR-19 
sponges with 2, 6 or 12 MBS, 6 MBS appeared to be sufficient for maximal miR-
19 mediated inhibition of WEHI-231 cell growth (Kluiver et al., 2012). In a study 
utilizing neuroblastoma cells, a miRNA sponge construct containing 12 miR-9 
MBS was reported to be more effective than 6 or 24 miR-9 MBS (Otaegi et al., 
2011). Thus, for each experimental setting the optimal or minimal number of 
MBS needed may vary and should be determined experimentally. The fact that 
increasing the number of MBS in the sponge construct does not, by definition, 
correlate with increased effectiveness of functional miRNA sequestration may be 
explained by increased sponge transcript degradation caused by the high 
number of MBS. In our experience sponges with 6-12 MBS are a good starting 
point for testing functional effects of long-term miRNA inhibition.  
TROUBLESHOOTING 
Ineffective cloning results 
If no or only a few colonies are obtained, vector preparation, ligation efficiency 
or the transformation procedure might have failed. To check the efficiencies of 
each of these steps the following negative and positive controls can be 
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a very few colonies to confirm that the vector was efficiently digested. To test 
the dephosphorylation step, a ligation reaction without insert can be performed 
which again should yield no or only a few colonies upon transformation. To test 
the T4-DNA-ligase, a ligation reaction with digested vector which has not been 
dephosphorylated can be performed. After transformation a high number of 
colonies (>500) should be obtained. To test transformation efficiency, a control 
circular plasmid vector can be transformed and this should yield a high number 
of colonies (>1,000). For optimal transformation, an aliquot of the ligation 
reaction containing a maximum of 10ng of DNA (plasmid and oligonucleotide 
duplex) should be used (too much DNA input is toxic and will result in a lower 
number of colonies). To increase the efficiency of the ligation reaction in 
general, the vector concentration can be increased from 50ng to 200ng per 10μl 
ligation reaction. To increase the number of colonies the vector/oligonucleotide 
duplex ratio can be lowered to 1:100. However, this will result in a decrease of 
the average insert size (Table1).  
Sponges have no (obvious) functional effect 
When there is a known functional readout for the miRNA of interest and no or 
little effect is observed upon overexpression of the sponge this may indicate 
ineffective sequestration of the miRNAs by the sponge. A sponge containing 
more MBS may be tested or a new sponge with an altered design of the 
oligonucleotide duplexes can be tested. In addition, the expression level of the 
sponge transcript may be checked in relation to the level of the endogenous 
miRNA. In case the expression levels of the sponge are low and the levels of the 
endogeneous miRNAs of interest are high, testing different promoters for the 
sponge transcript may help to achieve an optimal balance between the 
expression level of the sponge and the edogeneous miRNA. Suitable strong 
promoters include PGK, EF1α, MSCV, SFFV and CMV promoters (Hong et al., 
2007). Selection of the most optimal promoter depends on the cell type of 
interest and the application. 
 In case the miRNA loss-of-function phenotype is not known, it may be 
difficult to determine the effectiveness of the sponge. To ensure effective 
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binding of the miRNAs to the sponge a luciferase reporter assay may be 
performed or enrichment of the sponge transcripts in the Ago2-IP fraction 
following Ago2 immunoprecipitation may be tested.  
SUMMARY 
We describe a method that allows straightforward generation of retroviral miRNA 
sponges with a selected number of MBS that can target one or more miRNAs 
simultaneously. We also provide in silico and in vitro approaches to verify the 
(putative) effectiveness of miRNA binding to the miRNA sponges. The practical 
guidelines to generate miRNA sponges described here will contribute to our 
understanding of the role of miRNAs in diverse biological processes. 
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MiR-155 is an important regulator of B-cell development and deregulation of 
miR-155 contributes to B-cell lymphomagenesis. High miR-155 levels are 
observed in several types of lymphoma, including Hodgkin lymphoma. In 
contrast, Burkitt lymphoma is characterized by very low miR-155 levels. To 
determine the function of miR-155 in B-cell lymphoma, we studied the effect of 
miR-155 induction on BL cell growth and identified miR-155 target genes in BL 
and HL. Overexpression of miR-155 enhanced growth of ST486 BL cells but not 
of Ramos BL cells in a GFP competition assay. Ago2-RIP-Chip in miR-155-
transduced or empty vector-transduced cells revealed 54 miR-155 target genes 
in ST486 and 15 in Ramos cells. Besides the higher number of targets, also the 
fold enrichments were much higher in miR-155-ST486 as compared to miR-155-
Ramos. In silico validation of the 54 genes identified in ST486 cells indicated 
that 32% of the genes were predicted as miR-155 targets by TargetScan and 
77% contained the 6-mer miR-155-binding motif in the 3’UTR. We confirmed 
miR-155 targeting for the 5 most enriched genes, i.e. DET1, TBRG1, TRIM32, 
HOMEZ and PSIP1, and a known miR-155 target, JARID2, using luciferase 
reporter assays in ST486 cells. Inhibition of miR-155 in KM-H2 HL cells using a 
sponge construct revealed that DET1, TBRG1, TRIM32, HOMEZ and JARID2 are 
also targeted by endogenous miR-155 in KM-H2 cells. To determine if the 
identified miR-155 target genes were involved in the observed enhanced growth 
of ST486 cells upon miR-155 overexpression, we inhibited the 6 selected genes 
by shRNA constructs and showed that inhibition of TBRG1 enhanced growth of 
ST486 cells. In conclusion, we identified novel miR-155 targets in BL and HL and 
showed that miR-155 promotes growth of BL cells by targeting the TBRG1 gene. 




MicroRNAs (miRNAs) constitute a subgroup of short (~22nt) single-stranded 
RNAs that belong to the family of noncoding RNAs (Bartel, 2004). MiRNAs are 
transcribed as longer primary transcripts (pri-miRNAs) that contain one or more 
hairpin-structures which are processed by the Microprocessor complex in the 
nucleus (Cai et al., 2004; Denli et al., 2004; Gregory et al., 2004). The resulting 
precursor miRNAs (pre-miRNAs) are transported to the cytoplasm by Exportin-5 
and further processed by Dicer to the mature miRNAs (Bohnsack et al., 2004; 
Grishok et al., 2001; Hutvagner et al., 2001; Yi et al., 2003). Mature miRNAs 
are bound by one of the Argonaute (Ago) proteins and incorporated into the 
RNA-induced silencing complex (RISC) (Hutvagner and Zamore, 2002; 
Mourelatos et al., 2002). The miRNA guides the RISC to protein-coding RNA 
transcripts (mRNAs) based on partial sequence homology and inhibits their 
translation or induces RNA degradation (Eulalio et al., 2008; Filipowicz et al., 
2008). MiRNAs regulate expression of more than 30% of all human genes 
(Bartel, 2009) including genes that play important roles in fundamental cell 
biological processes like differentiation, proliferation and apoptosis. In line with 
their obvious importance to regulate and maintain cellular and physiological 
homeostasis, deregulation of miRNA levels has been linked to pathological 
conditions such as development and progression of cancer.  
 The well-known oncogenic miR-155 is an important regulator of diverse 
aspects of the immune response including B-cell development. MiR-155 is 
processed from the transcript of the B-cell integration cluster (BIC) gene (Lagos-
Quintana et al., 2002). Most germinal center (GC) B cells express BIC and miR-
155 in the course of the GC response (Thai et al., 2007). The role of miR-155 for 
normal B-cell development was demonstrated in miR-155-deficient mice that  
have reduced numbers of germinal centre B cells, abolished antibody affinity 
maturation and fail to generate memory B cells (Rodriguez et al., 2007; Thai et 
al., 2007; Vigorito et al., 2007). Deregulation of miR-155 expression has been 
shown to contribute to the pathogenesis of hematological malignancies by 
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155 transgenic mice in which overexpression of miR-155 driven by the B-cell-
specific Eµ-enhancer induced pre-B-cell lymphoma (Costinean et al., 2006). 
Recently, Babar et al. showed that induction of miR-155 in lymphoid tissues of 
mice caused disseminated lymphoma characterized by a clonal, transplantable 
pre-B-cell population (Babar et al., 2012). Withdrawal of miR-155 lead to tumor 
regression, partly due to increased apoptosis of the malignant cells, 
demonstrating that the tumor cells were dependent on miR-155. MiR-155 levels 
were shown to be high in GC B cell-derived lymphomas like Hodgkin lymphoma 
(HL), primary mediastinal and diffuse large B-cell lymphomas (Kluiver et al., 
2005; van den Berg et al., 2003). In contrast, very low levels of miR-155 were 
observed in GC B-cell derived Burkitt lymphoma (BL) (Kluiver et al., 2006) 
suggesting a tumor suppressive function in this B-cell lymphoma subtype. This 
was supported by the finding that miR-155 targeted activation-induced cytidine 
deaminase (AID) and that miR-155 downregulation resulted in an increased 
number of AID-mediated MYC translocations in B cells (Dorsett et al., 2007). 
The hallmark of Burkitt lymphoma is the (8;14) translocation which involves the 
MYC and one of the immunoglobulin gene loci (Taub et al., 1982). Thus, low 
miR-155 levels may be required to drive AID-mediated formation of the MYC/Ig 
translocations in BL. These findings demonstrate that both high and low miR-155 
levels may be beneficial for lymphomagenesis depending on the target gene 
repertoire and deregulation of miR-155 is a common feature in different 
lymphoma subtypes. 
 To understand the function of miR-155 in B-cell lymphomas, it is crucial to 
identify genes that are targeted by miR-155. In this study, we show that 
overexpression of miR-155 in BL derived cell lines leads to enhanced growth of 
the ST486 cells, whereas no effect was observed in Ramos cells. We 
subsequently identified miR-155 target genes in both ST486 and Ramos cells 
and found 54 targets in ST486 and 15 in Ramos. Six selected genes were 
validated as miR-155 targets and five of them, i.e. DET1, TBRG1, TRIM32, 
HOMEZ and JARID2, were shown to be targeted by endogenous miR-155 in 
Hodgkin lymphoma cells. Inhibition of TBRG1, which is a miR-155 target in 
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ST486 but not in Ramos, caused increased growth of ST486 cells similar to the 
miR-155 overexpression phenotype.  
RESULTS 
MiR-155 confers growth advantage in ST486 Burkitt lymphoma cells 
To determine the effect of miR-155 in BL cell lines, we overexpressed miR-155 
in two EBV-negative BL-derived cell lines, i.e. ST486 and Ramos. These cell lines 
were chosen based on their very low endogenous miR-155 levels and similar 
response to anti-IgM treatment. Upon miR-155 overexpression, we observed a 
200-400 fold increase in miR-155 levels in both miR-155-ST486 and miR-155-
Ramos compared to empty vector (EV)-transduced cells (Fig. 1A). These levels 
were ~3 fold lower than the endogenous miR-155 levels observed in the 
Hodgkin lymphoma cell line KM-H2 (Fig. 1A). Next, we determined the effect of 
miR-155 overexpression on growth of ST486 and Ramos cells in a GFP 
competition assay. We observed a growth advantage of GFP+ miR-155-ST486 
cells compared to GFP- wild-type ST486 cells (Fig. 1B). In 3 weeks, the GFP+ 
miR-155-ST486 cell fraction increased ~2 fold over the GFP- wild-type cell 
fraction. In contrast, overexpression of miR-155 did not result in any difference  
 
FIGURE 1. Overexpressed miR-155 enhanced growth of ST486 but not Ramos 
cells. (A) Levels of miR-155 were strongly increased in miR-155-ST486 and miR-155-
Ramos cells compared to empty vector (EV) control. Endogenous miR-155 levels in KM-H2 
HL cells were ~3 fold higher. (B) ST486 cells showed a 2 fold increase in the percentage of 
GFP+ cells after 22 days in comparison to GFP- cells. (C) Ramos cells showed no difference 
in cell growth. The GFP+ percentage in EV control remained stable in both cell lines. 
Changes in the percentage of GFP+ cells were calculated as the fold increase/decrease 
relative to the percentage of GFP+ cells at day 4. An average of three independent GFP 
competition assay experiments was presented. P value was determined by linear 
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in growth between GFP+ and GFP- Ramos cells (Fig. 1C). Empty vector control did 
not cause any difference in the percentage of GFP+ cells. Thus, these two Burkitt 
lymphoma cell lines respond differently to overexpression of miR-155, despite the 
similar high miR-155 levels.  
High-throughput identification of endogenous miRNA targets 
To determine the miRNAs target genes in ST486 and Ramos cells, we 
characterized the miRNA targetome of ST486 and Ramos cells using the RIP-
Chip approach (Tan et al., 2009). We used an antibody against endogenous 
Ago2 to immunoprecipitate (IP) RISC together with the miRNA target 
transcripts. Enrichment of Ago2 in the Ago2-IP fraction and depletion of Ago2 in 
the flowthrough (FT) fraction was confirmed in both cell lines by Western blot 
(Supplementary Fig. 1A). In addition, we also showed efficiency of the IP 
procedure by enrichment of miR-155 and miR-19b in the Ago2-IP fraction, but 
not in the negative control IgG-IP fraction when compared to the total fraction 
(Supplementary Fig. 1B). RNA samples isolated from the total and IP fractions of 
ST486 and Ramos cells were analyzed on the Agilent microarray platform. The 
miRNA-targetome was defined by the transcripts that were more than two fold 
enriched in the IP fraction compared to the total fraction (Table 1). The miRNA 
targetome included 12,5% and 16,5% of all analyzed probes in ST486 cells and 
Ramos cells, respectively. 
TABLE 1. Number of probes in miRNA targetome of ST486 and Ramos cells 
Enrichment ST486 (n=14,468*) 
Ramos (n=11,928*) 
# probes IP/T>2 1,804 (12.5%) 1,969 (16.5%) 
 IP/T>4 664 (4.6%) 743 (6.2%) 
 IP/T>8 239 (1.7%) 269 (2.3%) 
*Number of probes that are flag present and show consistent signals for Cy3 and Cy5 
 
 To identify miRNAs that contribute to the targetome in ST486 and Ramos 
cells, we performed a gene set enrichment analysis (GSEA) (Subramanian et al., 
2005) comparing gene abundance levels in IP and total fractions. The most 
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enriched gene set for both cell lines was the miR-17 seed family binding motif 
(Fig. 2A). This is consistent with the high abundance of the miR-17 seed family 
members in ST486 and Ramos and the overall high percentage of miR-17 
targets in the human genome as predicted by TargetScan. The 20 most enriched 
gene sets in IP vs total fraction included 14 miRNA binding motifs in ST486 and 
17 in Ramos cells (Supplementary Table 1).  
 
FIGURE 2. Enrichment of the miR-17 seed family and miR-155 binding motives in 
the Ago2-IP fraction compared to the total fraction. (A) miR-17 family binding motif 
was the most enriched gene set in the IP of ST486 and Ramos cells. (B) miR-155 binding 
motif was the 13th most enriched gene sets in miR-155-ST486. In miR-155-Ramos and 
the EV-transduced cells, the miR-155 binding motif was not among the top-20 most 
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Identification of miR-155 target genes 
To identify the genes that were targeted by miR-155 in miR-155-ST486 and 
miR-155-Ramos cells, we compared the targetomes of miR-155 and EV-
transduced cells. Targetomes of miR-155-ST486 and miR-155-Ramos consisted 
of a similar number of probes as compared to their EV-transduced controls 
(Supplementary Table 2). The most enriched gene set in the IP fraction of miR-
155-ST486 and miR-155-Ramos was the miR-17 seed family binding motif (Fig. 
2A). EV and miR-155 transduced cells shared 16 and 17 of the top-20 most 
enriched gene sets in ST486 and Ramos, respectively (Supplementary Table 1). 
In miR-155-ST486 the miR-155-binding motif was the 13th most enriched gene 
set with a false discovery rate (FDR) <0.001 (Fig. 2B). In contrast, the miR-155-
binding motif was not within the 20 most enriched gene sets for EV-ST486 or 
any of the transduced Ramos cell lines.  
 To identify the miR-155-specific targets we determined which probes are 
more than two-fold stronger enriched in the IP fraction of miR-155 compared to 
EV-transduced cells. We identified 64 probes that fulfilled this condition in ST486 
and 18 probes in Ramos cells. Out of the 64 probes identified in ST486, 61 
probes belonged to 54 genes and 3 probes did not correspond to any known 
gene. The fold enrichment in the targetome of miR-155-ST486 compared to EV-
ST486 ranged from 2.0 to 12.6 fold. In silico validation indicated that 26 of the 
54 identified genes (48%) contained an 8-mer miR-155 binding site 
(AGCATTAA) and 43 genes (80%) contained a 6-mer miR-155 binding site 
(GCATTA) in the 3’UTR. 18 of the 54 genes (33%) were predicted to be miR-155 
targets by TargetScan (Supplementary Table 3). This percentage was strongly 
increased as compared to the ~1.7% predicted miR-155 targets among all 
expressed genes. For Ramos cells, 15 of the 18 probes were assigned to known 
genes. The enrichment fold in the targetome of miR-155-Ramos compared to 
EV-Ramos ranged from 2.0 to 2.6 fold. Two of the genes (13%) contained an 8-
mer and 9 genes (60%) contained a 6-mer miR-155 binding site 
(Supplementary Table 4). Three of the 15 genes (20%) were predicted to be 
miR-155 targets by TargetScan. Five of the miR-155 target genes are identified 
in both ST486 and Ramos cells. Three of these genes showed similar fold 
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enrichment in both cell lines, whereas the fold enrichment for De-etiolated-1 
(DET1) and PC4 and SF2 interacting protein 1 (PSIP1) was much higher in 
ST486 cells (Fig. 3A).  
MiR-155 target genes validation 
We selected six miR-155 target genes for validation, i.e. one known target gene, 
Jumonji AT rich interactive domain 2 (JARID2), and the five genes that were 
most enriched in the targetome of miR-155-ST486 cells, i.e. DET1, Transforming 
growth factor beta regulator (TBRG1), Tripartite motif-32 (TRIM32), Homeobox 
leucine zipper (HOMEZ) and PSIP1. Four of the six genes, TBRG1, TRIM32, 
HOMEZ and JARID2, were ST486-specific miR-155 target genes and two genes, 
DET1 and PSIP1, were found both in ST486 and in Ramos (Fig. 3A). We first 
compared the endogenous levels of the six selected genes in wild-type ST486 
and Ramos cells (Fig. 3B). The levels of TBRG1, HOMEZ, JARID2, DET1 and 
PSIP1 were similar for ST486 and Ramos cells, whereas the TRIM32 level was 
substantially lower in Ramos cells. Thus, the lack of TRIM32 enrichment in the IP 
fraction of miR-155-Ramos cells can be explained by its very low expression 
level.  
 We performed luciferase reporter assay in ST486 cells to validate the six 
selected genes as miR-155 target genes. The 3’UTRs of TBRG1, TRIM32, 
JARID2, DET1 and PSIP1 genes and the coding sequence of HOMEZ contained 
miR-155 binding sites that were cloned into the psiCHECK2 luciferase vector 
(Fig. 3C). Co-transfection of the resulting luciferase constructs with a miR-155 
precursor to ST486 wt cells resulted in significantly decreased relative luciferase 
levels, ranging from 15 to 53%, compared to co-transfection with negative 
control precursors (Fig. 3D). Western blot analysis for the most enriched gene in 
the targetome of miR-155-ST486 cells, i.e. DET1, revealed a 2 fold decrease in 
DET1 protein level in miR-155-ST486 compared to EV-ST486 cells (Fig. 3E, F). 
Thus, we confirmed that TBRG1, TRIM32, HOMEZ, JARID2, DET1 and PSIP1 are 
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FIGURE 3. Validation of miR-155 target genes. (A) Venn diagram showing the overlap 
between  miR-155 target genes in ST486 and Ramos cells upon overexpression of miR-155 
as identified by AGO2-RIP-CHIP. Genes selected for validation are presented in the boxes. 
Fold enrichment in IP/T ratio in miR-155 compared to EV cells is indicated. (B) Transcript 
levels of TBRG1, TRIM32, HOMEZ, JARID2, DET1 and PSIP1 were measured by qRT-PCR in 
wild-type ST486 and Ramos cells. TRIM32 levels were much lower in Ramos compared to 
ST486 cells. (C) Schematic overview of 3’UTR regions with the positions of the predicted 
miR-155 binding sites indicated by the arrows (8-mer and 6-mer sites) in 3’UTRs. For 
HOMEZ, no miR-155 binding sites were predicted in the 3’UTR, but two putative sites were 
observed in the coding region. For TBRG1 and PSIP1, the 3’UTR of the isoforms containing 
the miR-155 binding sites are shown (ENST00000441174 and NM_021144, respectively). 
(D) Luciferase reporter assay for six selected genes in ST486 cells revealed reduced 
Renilla luciferase (RL) / Firefly luciferase (FL) ratios for all six genes. Thus, TBRG1, 
TRIM32, HOMEZ, JARID2, DET1 and PSIP1 are validated miR-155 target genes in ST486 
cells. Ratios were calculated for cells co-transfected with the psiCHECK2 construct and 
either synthetic miR-155 precursor or a negative control (NC). Luciferase ratio for miR-155 
precursor relative to negative control was calculated for each construct. P values were 
calculated with Student’s t-test (*p<0.05, **p<0.001, ***p<0.01). (E) DET1 protein level 
was decreased in miR-155-ST486 compared to EV-ST486. (F) Quantification of the 
Western blot for DET1 relative to GAPDH. EV-ST486 was set as 1, the average of 2 
experiments was shown. 
TBRG1, TRIM32, HOMEZ, JARID2 and DET1 are targeted by endogenous 
miR-155 in Hodgkin lymphoma 
We next investigated whether the six validated miR-155 target genes are also 
targeted by endogenous miR-155 in HL cells. We inhibited miR-155 using a 
retroviral vector containing a miR-155 sponge with 14 binding sites (Kluiver et 
al., 2012) in KM-H2 HL cells that have high endogenous miR-155 level (Fig. 1A). 
We performed Ago2-RIP-Chip in KM-H2 cells transduced with EV (EV-KM-H2) or 
miR-155 sponge (miR-155AS-KM-H2) to identify the miR-155 targets 
(Supplementary Table 5). The IP/T ratio for TBRG1, TRIM32, HOMEZ, JARID2 
and DET1 decreased in miR-155AS-KM-H2 cells, whereas there was no 
difference in the IP/T ratios for PSIP1. These results indicate that TBRG1, 
TRIM32, HOMEZ, JARID2 and DET1 are targeted by endogenous miR-155 in KM-
H2 cells. For comparison we also show the increase in IP/total ratio observed in 













FIGURE 4. Five of the six validated miR-155 target genes are also targeted by 
endogenous miR-155 in HL. (A) IP/T ratio of the six miR-155 target genes was 
increased in miR-155-ST486 with compared to EV-ST486. (B) IP/T ratio of in five of the six 
genes was decreased in miR-155AS-KM-H2 compared to EV-KM-H2. IP/T ratios were 
calculated from expression levels as determined by the gene expression microarrays.  
Inhibition of TBRG1 phenocopy miR-155 overexpression in ST486 cells 
To show the relevance of these six validated miR-155 target genes we generated 
12 shRNA constructs directed against these six genes. Effectiveness of the 
shRNA constructs was determined by qRT-PCR (Supplementary Fig. 2). 
Inhibition of TRIM32, HOMEZ, JARID2, DET1 and PSIP1 decreased growth of 
ST486 cells during GFP competition assay for at least one of the two shRNA 
constructs (Supplementary Fig. 2). For TBRG1, there are 11 transcript variants 
in the Ensemble database (Supplementary Table 6). Only 3 of the 11 variants 
contain the miR-155 binding site, i.e. ENST00000441174, ENST00000284290 
and ENST00000529543 (Supplementary Table 6). Deng et al. assessed levels of 
7 of the 11 transcripts and showed that isoforms ENST00000441174 and 
ENST00000473629 were most abundant in the Burkitt lymphoma cell line MutuI 
(Deng et al., 2011) (Fig. 5A). The Agilent platform contains two probes for 
TBRG1, i.e. one probe that binds to both abundant isoforms (probe 1) and one 
probe that is specific for the protein-coding isoform that contains the miR-155 
binding site (probe 2). Consistent with the findings of Deng et al. (2011) we 
observed that probe 1 showed much higher signals than probe 2 (Fig. 5B). Probe 
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1 was not enriched in the IP, whereas probe 2 was 5.4 fold enriched in the IP 
fraction. Thus, miR-155 binds specifically to the protein coding isoform. We used 
three shRNAs to inhibit TBRG1, one was specific for the protein-coding isoform 
and the other two were targeting most TBRG1 isoforms. Inhibition of the 
protein-coding TBRG1 isoform resulted in enhanced growth of ST486 cells, 
whereas inhibition of the other isoforms revealed no change or a decrease in 
growth of ST486 cells (Fig. 5C). Thus, inhibition of the protein-coding isoform of 




FIGURE 5. Specific inhibition of the protein-coding isoform of TBRG1 caused 
increase of ST486 cell growth. (A) Schematic overview of two most abundant TBRG1 
isoforms. Position of the miR-155 binding site (miR-155BS), the region targeted by the 
shRNAs and the location of the two microarray probes were indicated. (B) Signal intensity 
measured by probe 1 was much higher than the signal intensity measured by probe 2. The 
protein-coding isoform detected specifically by probe 2 was strongly enriched in the 
targetome of miR-155-ST486 cells, whereas the common probe was not enriched. (C) 
shRNA-1 that specifically inhibits the protein-coding isoform induced a growth advantage 
of ST486 cells in a GFP competition assay. shRNA-2 resulted in decreased cell growth and 














MiR-155 and the miR-155 primary transcript, BIC, are among the most studied 
miRNAs in B-cell lymphoma. Over the past few years many target genes 
involved in functioning of normal hematopoietic cells have been identified. In the 
context of B-cell lymphoma, it is frequently not clear which target genes are 
relevant for the pathogenesis of a specific B-cell lymphoma subtype. In this 
study we showed that upon overexpression of miR-155 in BL cells, growth of 
ST486 cells was enhanced, whereas growth of Ramos cells was not affected. 
Phenotype copy experiments revealed that TBRG1 is involved in the enhanced 
growth observed upon miR-155 overexpression in ST486 cells. 
 We selected two commonly used BL cell lines for the functional studies 
that have similar miRNA and gene expression profiles (data not shown) and both 
show very low miR-155 levels. Nevertheless, ST486 and Ramos cells responded 
differently to overexpression of miR-155 and Ago2-RIP-Chip analysis upon miR-
155 induction resulted in the identification of a larger and more enriched set of 
miR-155 target genes in ST486 than in Ramos cells. The differences in targeting 
were not caused by differences in endogenous expression levels of the target 
genes, because the endogenous levels were similar for 5 out of 6 genes. For 
TRIM32 we observed low expression levels in Ramos cells compared to ST486 
cells which might explain the absence of TRIM32 in the IP fraction of Ramos 
cells. Besides similar endogenous transcript levels, also the induced miR-155 
levels were similar in both cell lines making it unlikely that the miR-155 levels 
were insufficient to target these genes in Ramos cells. However, we did see a 
slightly higher enrichment of miR-155 in the IP fraction of ST486 as compared to 
Ramos cells (Supplementary Fig. 1), which might in part explain differences in 
miR-155 targeting and phenotype.  
 We selected six miR-155 target genes for validation and confirmed 
effective targeting in ST486 BL cells for all. One gene, JARID2, was a known 
target, whereas TRIM32, DET1, HOMEZ, PSIP1 and TBRG1 were novel miR-155 
targets. In contrast to the observed miR-155 effect on growth of ST486 cells, 
inhibition of five of the target genes revealed either no or a growth inhibitory 
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effect. Only inhibition of TBRG1 phenocopied the observed effect upon miR-155 
overexpression in ST486 cells. 
 JARID2 was previously shown to inhibit apoptosis in chicken B-cell 
lymphoma (Bolisetty et al., 2009) and cardiomyocyte proliferation by regulating 
Cyclin D1, D2 and D3 (Jung et al., 2005). TRIM32 and DET1 have been shown to 
be involved in the ubiquitinylation pathway and the subsequent degradation of 
proteins. TRIM32 is a member of the ubiquitination-related tripartite motif 
(TRIM) family and was shown to ubiquitinylate MYC, inhibit proliferation and 
enhance differentiation of mouse neuronal progenitors (Schwamborn et al., 
2009). Overexpression of TRIM32 in mouse embryonic fibroblast cell line, NIH 
3T3, resulted in accelerated proliferation (Kano et al., 2008). Another 
established function of TRIM32 is enhancement of activity of certain miRNAs, 
including the cell differentiation-promoting miRNA let-7a. DET1 is a component 
of the E3 ubiquitin ligase DCX DET1-COP1 complex, which is involved in c-Jun 
ubiquitination and degradation. Inhibition of DET1 induced apoptosis of human 
osteosarcoma cells (Wertz et al., 2004). This is consistent with the growth 
inhibition that we observed upon DET1 inhibition in ST486 cells. HOMEZ did not 
have a miR-155 binding site in the 3’UTR, and consistent with this we observed 
no effect in the luciferase reporter construct upon cloning of this 3’UTR region 
(data not shown). However, the two putative miR-155 binding sites in the 
coding region were validated by the luciferase reporter assay. In general, the 
majority of the miRNA binding sites are found in the 3’UTR and the remaining 
binding sites are located in the 5’UTR or in the coding region (Chi et al., 2009). 
The cellular function of HOMEZ is not well characterized, but based on the 
protein domains it is predicted to function as a transcription factor (Bayarsaihan 
et al., 2003). Inhibition of HOMEZ decreased growth of ST486 cells, suggesting 
that it may be involved in regulation of genes involved in growth of Burkitt 
lymphoma cells. PSIP1 encodes two protein isoforms, i.e. p52 and p75, which 
are generated by alternative splicing. Only the Psip1/p52 has a miR-155 binding 
site in the 3’UTR and consistent with this we indeed observed enrichment of the 
probe that recognizes this isoform in the IP fraction, whereas the probe for the 
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involved in alternative splicing (Pradeepa et al., 2012). Tissue specific 
expression patterns of Psip1/p52 and Psip1/p75 are consistent with different 
regulation of these two proteins and support different cellular functions.  
 For TBRG1 only one probe detecting two out of eleven isoforms was 
enriched in the IP fraction, which was consistent with the putative miR-155 
binding site that was present in the 3’UTR of these isoforms. These isoforms are 
not the dominant isoforms in our BL cells as was apparent from the lower probe 
signals in the microarrays. In Mutu1 BL cells, Deng et al. showed that the 
protein-coding isoform containing the miR-155 binding site constitutes only 
~35% of all detected TBRG1 transcripts (Deng et al., 2011). In addition, the 
authors showed that also for some other genes a non-dominant isoform is 
targeted by miRNAs, which is consistent with our findings. Inhibition of the 
protein-coding isoforms of TBRG1 using an shRNA construct phenocopied the 
enhanced growth of ST486 cells as observed for miR-155 overexpression. The 
two other shRNA constructs, targeting most isoforms, showed either no or a 
growth inhibitory effect. This indicates that the protein-coding isoform of TBRG1 
is involved in the growth stimulating effect of miR-155 in ST486 cells. This is 
consistent with growth inhibitory role of TBRG1 protein described by Tomkins et 
al. (Tompkins et al., 2007). They showed that TBRG1 was linked to ARF-MDM2-
p53 signaling in several ways. The level of TBRG1 protein was downregulated by 
MDM2-mediated ubiquitination. TBRG1 in cooperation with alternative reading 
frame (ARF) protein induced G1-phase arrest in human osteosarcoma cells. 
Moreover, both TBRG1 and ARF were shown to increase p53 activity (Tompkins 
et al., 2007). Microarray studies indicated that TBRG1 was downregulated in 
various types of cancer, including diffuse large B cell lymphoma and chronic 
lymphocytic leukemia (Tompkins et al., 2007). This is consistent with the high 
miR-155 levels found in many types of cancer and supports our findings 
regarding to the role of TBRG1 in growth of ST486 cells.  
 Dorsett et al. showed that low miR-155 in B cells results in increased level 
of the miR-155 target gene AID and this enhanced the frequency of MYC 
translocations (Dorsett et al., 2008). Since MYC translocations are the hallmark 
of BL, it might be anticipated that low miR-155 levels are especially crucial at 
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the initiation step of the malignant transformation of the germinal center 
precursor B cells. This might explain why we do see an oncogenic effect of high 
miR-155 levels in an established Burkitt lymphoma cell lines. Our data show that 
the effect of miR-155 modulation may be different even between similar cell 
types such as ST486 and Ramos. It may be speculated that the balance between 
the target gene transcript levels and the efficiency of regulation by miR-155 and 
probably other miRNAs determines the final outcome of miR-155 modulation.  
 In conclusion, we identified six miR-155 target genes in BL cells with 
overexpression of miR-155 and showed that five of these genes are also 
targeted by endogenous miR-155 in HL cells. Induction of miR-155 enhances 
growth of ST486 BL cells and this phenotype involves inhibition of the TBRG1 
gene. 
MATERIAL AND METHODS 
Cell lines. The ST486 and Ramos BL cell lines and the KM-H2 HL cell line were 
cultured at 37°C under an atmosphere containing 5% CO2 in RPMI-1640 medium 
(Cambrex Biosciences, Walkersville, USA) supplemented with ultraglutamine 
(2mM), penicillin (100U/ml), streptomycin (0.1mg/ml; Cambrex Biosciences), 
and 20% (ST486) or 10% (Ramos, KM-H2) fetal calf serum (Cambrex 
Biosciences). Cell lines were purchased from ATCC (ST486) or DSMZ (Ramos, 
KM-H2). 
DNA constructs. To overexpress miR-155, the pre-miR-155 and 
~150ntflanking sequences were amplified from genomic DNA using Taq 
polymerase and primers listed in Supplementary Table 7. A XhoI restriction site 
was added to the forward and an EcoRI site to the reverse primer to allow 
directional cloning to the retroviral MXW-PGK-IRES-GFP vector (Mao and Chen, 
2007) using standard laboratory procedures. The MXW-PGK-IRES-GFP vector 
was a kind gift from C-Z. Chen (Stanford University, CA). To inhibit miR-155, a 
miR-155 sponge construct was generated as previously described (Kluiver et al., 
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pMSCV-PIG vector (Addgene). The 3’ UTR of DET1, TRIM32, JARID2, PSIP1, 
TBRG1 and the ~300nt fragment of HOMEZ in the coding sequence containing 
the potential miR-155-binding sites were amplified from genomic DNA using the 
primers listed in Supplementary Table 7. A NotI restriction site was added to the 
forward and a SstI to the reverse primers to enable cloning of the PCR products 
in the psiCHECK2 vector (Promega, Madison, WI). To inhibit DET1, TRIM32, 
JARID2, PSIP1, TBRG1 and HOMEZ, shRNA sequences were selected from shRNA 
library (TRC, Broad Institute, http://www.broadinstitute.org/rnai/trc/lib). 
Sequences of the shRNA oligo’s are listed in Supplementary Table 8. XhoI and 
EcoRI sites were added to enable cloning to the retroviral pMDH1-PGK-GFP 2.0 
vector (Mao and Chen, 2007). The pMDH1-PGK-GFP 2.0 vector was a kind gift 
from C-Z. Chen (Stanford University, CA). All inserts were verified by 
sequencing. 
 
Retroviral transductions. To generate retroviral particles, Phoenix-Ampho 
packaging cells (Swift et al., 2001) were CaPO4 transfected using 37,5μg of 
retroviral vector in T75 flasks. Viral particles were harvested after two days and 
concentrated with Retro-X concentrator (Clontech, Saint-Germain-en-Laye, 
France) according to the manufacturer’s protocol. Target cells were transduced 
with the virus by spinning at 2,000rpm for 2hrs. Cells transduced with retroviral 
vectors were sorted for GFP+ cells using MoFlo sorter (Dako cytomation). 
Quantitative RT-PCR. Total RNA from total, FT and IP fractions was isolated 
using miRNeasy kit (Qiagen, Carlsbad, USA). Total RNA from other samples was 
isolated using Trizol (Invitrogen, Carlsbad, USA) according to the manufacturer’s 
protocol for the cell lines. The RNA concentration was measured with a 
NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, 
USA) and RNA integrity was evaluated by 1% agarose electrophoresis. qRT-PCR 
for miR-155, miR-19b and RNU48 (control) was performed using miRNA qRT-
PCR assays (Applied Biosystems, Foster City, USA) as described previously 
(Gibcus et al., 2009). Reverse transcription (RT) primers specific for a miR-155, 
miR-19b and RNU48 were multiplexed in 15µl RT reactions containing 1µl of 
each RT primer. MiR-155 and miR-19b levels were normalized to the RNU48 
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levels. To determine the levels of TBRG1, TRIM32, HOMEZ, JARID2, DET1, 
PSIP1, cDNA was synthesized using 500ng input RNA, SuperScript II and 
random primers according to the manufacturer’s protocol (Invitrogen). The qPCR 
reaction contained a final concentration of 1x qPCR MasterMix Plus (Eurogentec, 
Liege, Belgium), 1x Gene expression assay (Applied Biosystems, Foster City, 
USA), and 1ng of cDNA in a total volume of 10µl. The following gene expression 
assays were used: Hs00262345_m1 (TBRG1), Hs00705875_s1 (TRIM32), 
Hs01866743_s1 (HOMEZ), Hs01004460_m1 (JARID2), Hs00894490_m1 (DET1), 
Hs01045711_g1 (PSIP1) (All Applied Biosystems). Gene expression levels were 
normalized to HPRT levels. Mean cycle threshold (Ct) values were determined 
with the SDS software (version 2.1). Relative expression levels were calculated 
as 2-∆Ct. 
Transfection of cell lines and luciferase assay. Luciferase assay was 
performed using Promega Dual-Luciferase Reporter Assay System (Promega, 
Madison, WI) as described previously (Gibcus et al., 2009). Briefly, two million 
ST486 cells were transfected with 4µg of each psiCHECK2 construct and co-
transfected with 100nM miR-155 precursor (Ambion) or negative control #1 
(Ambion) using Amaxa nucleofector device, program A23 (Amaxa, Gaithersburg, 
MD). Cell lysates were made 24 hours after transfection. For each transfection, 
the Renilla and Firefly luciferase activities were measured in duplicate, the 
Renilla over Firefly (R/L) luciferase ratio for miR-155 precursor was calculated 
and compared to negative control (set at 100%). Transfections were performed 
in triplicate and standard deviations were calculated. To determine significance 
of difference in the R/F ratio between miR-155 precursor and negative control 
#1 a Student’s t-test was performed. 
Western Blot. Cell lysates were prepared, separated on polyacrylamide gels 
and transferred onto nitrocellulose membranes using standard protocols. Mouse 
anti-DET1 antibody (clone 3G5, Genentech, San Francisco, CA) was diluted to a 
concentration of 1µg/ml in 5% milk in Tris-buffered saline with Tween-20 
(TBST). Immunoblots were incubated with primary anti-DET1 antibody at 4ºC 
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peroxidase was used. Chemiluminescence was detected with the ChemiDoc MP 
scanner and protein bands were visualized and quantified with Image Lab 4.0.1 
software (both BioRad, Veenendaal, NL). To detect protein levels of TBRG1, 
TRIM32 and JARID2, we tested the following antibodies: anti-TBRG1, clone 
11E12, kindly provided by D. Quelle (The University of Iowa, Iowa) and clone 
18951-1-AP purchased from Proteintech Manchester, UK; anti-TRIM32, clone 
10326-1-AP (Proteintech); anti- JARID2,  antibody was kindly provided by D. 
Reinberg (NYU School of Medicine Smilow Research Center, NY). However, we 
were not able to obtain reliable immunoblot results for these three proteins.  
FACS analysis. For GFP competition assays, ST486 and Ramos cells were 
transduced with the MXW-PGK-IRES-GFP empty vector or miR-155 containing 
construct. For GFP competition assays with shRNAs, ST486 cells were 
transduced with the pMDH1-PGK-GFP 2.0 empty vector of shRNA containing 
construct (Supplementary Table 8). GFP expression was measured on a FACS 
Calibur flow cytometer (BD PharMingen) at day 3 or 4 post-transduction and 
monitored for three weeks tri-weekly. The percentage of GFP positive cells at 
day 3 or 4 was set to 1 and a fold difference per measurement was calculated.  
 
Ago2-RIP-Chip procedure. Immunoprecipitation of Ago2-containing RISC 
complexes was performed as described previously (Tan et al., 2009). Briefly, 
cleared lysate of 10-20 million cells was incubated with protein G Sepharose 
beads (GE Healthcare) coated with anti-Ago2 antibody (Clone 2E12-1C9, 
Abnova, Taiwan) at 4°C overnight. Anti-IgG antibody was used as a negative 
control (Millipore BV, Amsterdam, The Netherlands). After washing the beads, 
RNA was harvested for microarray and qRT-PCR analysis and protein lysates 
were prepared for Western blot. Western blot for Ago2 was performed as 
described previously (Tan et al., 2009). Total RNA was isolated with miRNeasy 
Kit (Qiagen) according to manufacturer’s protocol. RNA from total and Ago2-IP 
fractions of miR-155-ST486, EV-ST486, miR-155-Ramos, EV-Ramos, miR-
155AS-KMH2 and EV-KMH2 cells was used for microarray analysis. Labelling and 
hybridization was performed using two-color Quick Amp Labeling Kit (ST486 and 
Ramos) and Low Input Quick Amp Labeling Kit (KM-H2), according to 
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manufacturer’s protocol (Agilent, Santa Clara, USA). Briefly, 60-100ng of RNA 
from total and Ago2-IP samples was used for cDNA synthesis, followed by cRNA 
amplification and Cy3 and Cy5 labelling. cRNA was purified with RNeasy Kit 
(Qiagen) and quantified on NanoDropTM 1000 Spectrophotometer (Thermo 
Fisher Scientific Inc.). Equal amounts of Cy3 and Cy5-labelled cRNA were 
combined and hybridized at 65°C overnight on the 44k Human Whole Genome 
Oligo Microarray. Next, slides were washed and scanned with GenePix 4000B 
(Agilent). Scanned images were used for Agilent Feature Extraction software 
version 10.5., converted into Linear and Lowess normalized data. Quality control 
report was generated for each microarray. Using GeneSpring GX version 9.0 
(Agilent), quantile normalization of the signals was performed separately for 
Ramos, ST486 and KM-H2 samples. Next, probes not detected in more than half 
of the samples and probes that were inconsistent (more than 2 fold different) in 
Cy3 and Cy5 replicates of the same sample were filtered out. The averaged 
signals for Cy3 and Cy5 replicates were used to calculate the IP/T ratio for each 
sample.  
 
Gene Set Enrichment Analysis. To determine which genes sets are 
significantly enriched in the Ago2-IP in comparison to the total fraction in miR-
155-ST486, EV-ST486, miR-155-Ramos and EV-Ramos, we performed a Gene 
Set Enrichment Analysis using The Molecular Signatures Database (GSEA; 
http://www.broad.mit.edu/gsea, Subramanian et al., 2005). If more than one 
probe was assigned for a certain gene, we selected the probe with the highest 
fold enrichment in the IP/T ratio in miR-155-ST486 or miR-155-Ramos 
compared to EV controls. This selection resulted in 9,047 genes submitted for 
analysis for ST486 and 7,809 genes for Ramos.  
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SUPPLEMENTARY TABLE 1. 20 most enriched gene sets in EV-ST486, miR-155-ST486, 
EV-Ramos and miR-155-Ramos  
 
Position in GSEA 
Gene set ST486  
Ramos 
 EV miR-155  EV 
miR-155 
GCACTTT,MIR-17-5P,MIR-20A,MIR-106A,MIR-106B,MIR-20B,MIR-519D 1 1  1 1 
ACACTAC,MIR-142-3P 2 3  11 12 
AGCACTT,MIR-93,MIR-302A,MIR-302B,MIR-302C,MIR-302D,MIR-372,MIR-
373,MIR-520E,MIR-520A,MIR-526B,MIR-520B,MIR-520C,MIR-520D 
3 2  4 4 
CTACTGT,MIR-199A 4 8  10 9 
GTGCAAT,MIR-25,MIR-32,MIR-92,MIR-363,MIR-367 5 4  3 3 
TGAATGT,MIR-181A,MIR-181B,MIR-181C,MIR-181D 6 6  7 7 
TTTGCAC,MIR-19A,MIR-19B 7 7  5 5 
AAGCACT,MIR-520F 8 10  16 15 
ACTTTAT,MIR-142-5P 9 11  6 6 
NAGASHIMA_NRG1_SIGNALING_UP 10 9    
TGCACTT,MIR-519C,MIR-519B,MIR-519A 11 5  2 2 
KIM_WT1_TARGETS_UP 12 14    
TTGCCAA,MIR-182 13     
BONCI_TARGETS_OF_MIR15A_AND_MIR16_1 14     
TGCACTG,MIR-148A,MIR-152,MIR-148B 15 12  8 10 
TGTTTAC,MIR-30A-5P,MIR-30C,MIR-30D,MIR-30B,MIR-30E-5P 16 20    
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_DN 17 18    
ATAAGCT,MIR-21 18     
TACTTGA,MIR-26A,MIR-26B 19 15  18 18 
AMIT_EGF_RESPONSE_40_HELA 20     
AGCATTA,MIR-155  13    
NAGASHIMA_EGF_SIGNALING_UP  16    
ACATATC,MIR-190  17    
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP  19    
DAZARD_RESPONSE_TO_UV_NHEK_DN    9 8 
TTGCACT,MIR-130A,MIR-301,MIR-130B    12 11 
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN    13 16 
CACTTTG,MIR-520G,MIR-520H    14  
DACOSTA_UV_RESPONSE_VIA_ERCC3_DN    15 13 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_UP    17  
ATTACAT,MIR-380-3P    19  
TGCTGCT,MIR-15A,MIR-16,MIR-15B,MIR-195,MIR-424,MIR-497    20 19 
ATGCTGC,MIR-103,MIR-107     14 
GTACTGT,MIR-101     17 
CTTTGCA,MIR-527     20 
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SUPPLEMENTARY TABLE 2. Similar numbers of probes were identified in the miRNA-
targetomes of EV and miR-155-transduced ST486 and Ramos cells. 
 ST486 (n=14,468*) 
 Ramos (n=11,928*) 
Enrichment EV miR-155 
 EV miR-155 
# probes IP/T>2 1,804 (12.5%) 1,833 (12.7%)  1,969 (16.5%) 1,927 (16.2%) 
 IP/T>4 664 (4.6%) 701 (4.8%)  743 (6.2%) 751 (6.3%) 
 IP/T>8 239 (1.7%) 226 (1.6%)  269 (2.3%) 263 (2.2%) 
*Number of probes that were flag present and showed consistent signals in Cy3 and Cy5 
signals. 
SUPPLEMENTARY TABLE 3. MiR-155 target genes in miR-155-ST486 cells identified with 
Ago2-RIP-Chip. 









# 6-mer3 in 
3'UTR 
DET1* NM_017996 A_23_P26184 17.5 1.4 12.6 + 1 3 
TBRG1 NM_032811 A_23_P98463 11.6 2.2 5.4 + 1 2 
TRIM32 NM_012210 A_23_P112311 2.1 0.4 5.2 + 1 1 





PSIP1* NM_021144 A_23_P256384 9.8 2.4 4.1 + 1 2 
C14orf159 BC009182 A_24_P58177 2.0 0.6 3.7  0 1 
CCDC126 NM_138771 A_23_P168592 4.0 1.1 3.7  1 3 
MAX NM_145114 A_23_P436138 2.1 0.6 3.7  0 0 
PSKH1 NM_006742 A_23_P390596 11.7 3.3 3.5 + 1 1 
BRWD1 NM_018963 A_24_P190541 3.5 1.1 3.3 + 0 2 
ZNF578 NM_001099694 A_23_P339601 5.0 1.5 3.3  1 1 
IER5 NM_016545 A_23_P86330 3.4 1.1 3.1  0 1 
TCF4 NM_003199 A_23_P27332 3.1 1.0 3.1 + 2 4 
SAR1A NM_020150 A_23_P127175 4.6 1.5 3.0  0 0 
KLHL5 NM_015990 A_23_P121527 3.9 1.3 3.0  1 3 
TBC1D14 NM_020773 A_24_P120352 2.3 0.8 3.0  1 1 
JARID2 NM_004973 A_23_P214876 6.8 2.2 3.0 + 2 2 
PRDM15 AY063456 A_32_P145989 2.8 1.0 3.0  1 2 
ZNF845 NM_138374 A_32_P207428 6.2 2.1 2.9  1 2 
USPL1* NM_005800 A_24_P338757 6.4 2.2 2.9  0 1 
DPY19L1 NM_015283 A_23_P358628 3.4 1.2 2.8  1 3 
ARRDC2 NM_001025604 A_23_P130965 2.1 0.7 2.8  0 1 
FAM119A NM_145280 A_23_P209337 2.6 1.0 2.7  0 0 
PHKB NM_001031835 A_23_P206532 2.2 0.8 2.7  0 1 
TAB2 NM_015093 A_23_P19702 7.1 2.7 2.6 + 1 2 
ERI2 NM_080663 A_23_P129717 6.6 2.5 2.6  0 0 
PICALM NM_007166 A_23_P147995 2.2 0.9 2.6  0 4 
ZFP36* NM_003407 A_23_P39237 19.4 7.6 2.6  0 1 
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SUPPLEMENTARY TABLE 3 continued 
VAMP3* NM_004781 A_24_P370887 20.2 7.9 2.5  0 3 
CENPI NM_006733 A_23_P252292 2.1 0.8 2.5  0 0 
BACH1 NM_206866 A_23_P211047 14.5 5.8 2.5 + 1 3 
RHEB NM_005614 A_23_P134247 3.8 1.5 2.5 + 0 1 
PHC2 NM_198040 A_23_P423864 2.6 1.1 2.4 + 1 1 
ZNF320 NM_207333 A_32_P540407 6.1 2.5 2.4  1 2 
PLEKHB2 NM_001100623 A_24_P873414 4.6 1.9 2.4  1 1 
C5orf15 NM_020199 A_23_P81650 3.2 1.3 2.4  0 0 
ARFIP1 NM_001025595 A_24_P166094 2.3 1.0 2.4  0 1 
CLUAP1 NM_024793 A_23_P77714 2.6 1.1 2.3  1 1 
RNF26 NM_032015 A_23_P64630 2.2 1.0 2.3  1 1 
PPA2 NM_176869 A_24_P214625 3.0 1.3 2.2  0 0 
PANK1 NM_148977 A_23_P127054 3.7 1.7 2.2 + 0 1 
GALT NM_000155 A_24_P12865 2.4 1.1 2.1  1 1 
TPD52 NM_001025252 A_23_P216257 2.6 1.2 2.1  0 1 
ZNF137 NR_023311 A_23_P208238 3.1 1.5 2.1  0 0 
CD58 NM_001779 A_23_P138308 3.8 1.9 2.1  0 2 
CSRP2 NM_001321 A_23_P44724 10.8 5.2 2.0  1 2 
LIN9 NM_173083 A_23_P301995 2.2 1.1 2.0  0 1 
DCTN6 NM_006571 A_23_P43049 8.8 4.3 2.0  0 0 
FGF7 NM_002009 A_23_P14612 10.7 5.3 2.0 + 1 2 
KIAA1715 CR936742 A_32_P127248 2.6 1.3 2.0 + 0 2 
MARK2 NM_004954 A_24_P914495 3.3 1.6 2.0 + 0 1 
CSNK1G2 NM_001319 A_24_P99963 3.2 1.6 2.0 + 1 1 
MFSD5 NM_032889 A_23_P72850 5.0 2.5 2.0  0 0 
LNX2 NM_153371 A_23_P402287 3.4 1.7 2.0 + 1 1 
*present on miR-155-Ramos miR-155 target list,
1
TS-miR-155 target predicted by TargetScan 6.2, 
2
8-
mer sequence – AGCATTAA, 
3
6-mer sequence – GCATTA, 
4
8-mer and 6-mer in CDS 
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NR_002776 A_24_P117301 13.5 5.1 2.6  NA
4
  NA 
DET1* NM_017996 A_23_P26184 4.1 1.5 2.6 + 1 3 
SLC23A2 NM_203327 A_24_P254278 3.3 1.3 2.6  0 0 
VAMP3* NM_004781 A_24_P370887 9.0 3.6 2.5  0 3 
USPL1* NM_005800 A_24_P338757 5.0 2.0 2.5  0 1 
ZFP36* NM_003407 A_23_P39237 11.1 4.6 2.4  0 1 
AKTIP NM_001012398 A_32_P224840 7.2 3.0 2.4  0 1 
ZBTB4 NM_020899 A_23_P100654 34.4 15.1 2.3  0 0 
SNAP23 NM_003825 A_23_P206177 3.3 1.5 2.2  0 0 
SETD7 NM_030648 A_24_P251841 2.5 1.2 2.1 + 0 4 
STK38 NM_007271 A_24_P63727 2.8 1.4 2.0  0 1 
FAM82A2 NM_018145 A_24_P296280 3.9 1.9 2.0  0 0 
RC3H2 NM_018835 A_23_P94636 2.8 1.4 2.0  0 3 
PSIP1* NM_021144 A_23_P256384 4.6 2.3 2.0 + 1 2 
OAZ3 NM_016178 A_23_P432583 5.3 2.7 2.0   0 0 
*present on miR-155-ST486 miR-155 target list,
1
TS-miR-155 target predicted by TargetScan 6.2, 
2
8-mer 
sequence – AGCATTAA, 
3
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RICTOR NM_152756 A_32_P193322 7.2 17.0 0.42 + 1 3 
OOEP NM_001080507 A_32_P14762 1.0 2.3 0.42  1 1 
SMC4 NM_005496 A_23_P91900 1.4 3.1 0.47  0 0 
ASPH NM_032466 A_24_P18105 5.3 10.9 0.49  0 2 
TMTC3 NM_181783 A_24_P141804 4.9 9.9 0.49  0 1 
EPG5 NM_020964 A_24_P392146 5.5 11.2 0.49  0 0 
RBBP6 NM_032626 A_23_P342053 1.0 2.0 0.51  0 3 
SLC25A25 NM_001006641 A_23_P9435 1.7 3.3 0.52  0 0 
PDE4B NM_001037341 A_24_P325333 4.1 7.7 0.53  0 0 
GCNT2 NM_001491 A_24_P397489 6.8 12.6 0.54  0 0 
ISCA1 NM_030940 A_24_P387609 2.2 3.9 0.56  0 0 
DNA2 NM_001080449 A_24_P366107 4.6 8.2 0.57  0 0 
PKN2 NM_006256 A_24_P387869 40.3 70.0 0.58 + 1 1 
JARID2* NM_004973 A_23_P214876 3.7 6.5 0.58 + 2 2 
HIF1AN NM_017902 A_23_P46964 1.4 2.5 0.58  0 0 
ZNF174 NM_003450 A_24_P193600 1.3 2.3 0.58  0 0 
SETD8 NM_020382 A_32_P82807 2.2 3.8 0.59  0 0 
SLC30A1 U68494 A_24_P937095 3.5 5.8 0.60  0 1 
TBRG1* NM_032811 A_23_P98463 3.7 6.2 0.60 + 1 2 
AKAP11 NM_016248 A_23_P204929 11.3 18.7 0.60  0 0 
ZNF776 AK095607 A_23_P378499 2.5 4.1 0.60  0 1 
SYNJ1 NM_203446 A_23_P324718 9.5 15.6 0.61  0 1 
FAM108C1 NM_021214 A_23_P369701 3.1 5.0 0.61  0 0 
BET1 NM_005868 A_23_P59700 1.3 2.1 0.62  0 1 
DET1* NM_017996 A_23_P26184 3.4 5.5 0.62 + 1 3 
MORF4L1 NM_206839 A_32_P164314 1.5 2.4 0.62  0 0 
PANK3 CR612518 A_24_P311845 14.5 23.1 0.63  0 1 
SLC2A3 NM_006931 A_24_P81900 7.8 12.3 0.63  0 0 
POLK NM_016218 A_23_P386450 2.9 4.7 0.63  0 0 
HDAC4 NM_006037 A_23_P210048 2.1 3.3 0.63 + 1 2 
C6orf204 NM_001042475 A_32_P49832 5.1 8.1 0.64  0 0 
DCAF8 NM_015726 A_23_P200143 1.5 2.3 0.64  0 0 
BICD1 BC010091 A_24_P916586 1.3 2.0 0.64  0 0 
ABCC5 NM_005688 A_23_P212665 7.7 11.9 0.64  0 0 
RB1CC1 NM_014781 A_23_P9056 2.4 3.7 0.64  0 0 
HOMEZ* NM_020834 A_23_P76829 1.6 2.5 0.64  0 0 
BRWD1 NM_001007246 A_24_P861009 1.8 2.7 0.65  0 0 
TCF7L2 NM_001198525 A_24_P921823 5.3 8.2 0.65 + 1 2 
UBE2D1 NM_003338 A_24_P364025 2.7 4.2 0.65  0 0 
ZNF729 NM_001242680 A_24_P161696 20.9 32.1 0.65  0 0 
TMEM127 NM_017849 A_24_P80181 1.9 2.9 0.65  0 0 
TBC1D20 NM_144628 A_23_P354193 2.6 4.0 0.65  0 1 
*present on miR-155-ST486 miR-155 target list,
1
TS-miR-155 target predicted by TargetScan 6.2, 
2
8-mer 
sequence – AGCATTAA, 
3
6-mer sequence – GCATTA 
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shRNA-1 shRNA-2 shRNA-3 
001 00000441174* 4004 Protein coding Yes Yes Yes Yes 
011 00000531667 552 Protein coding No No No Yes 
201 00000375005 1483 Protein coding No No Yes Yes 
003 00000284290 4461 
Nonsense mediated 
decay 
Yes No Yes Yes 
004 00000452080 730 
Nonsense mediated 
decay 
No No Yes No 
005 00000529543 2142 
Nonsense mediated 
decay 
Yes No No Yes 
009 00000530731 1571 
Nonsense mediated 
decay 
No No Yes Yes 
007 00000438907 842 Processed transcript No No Yes Yes 
002 00000473629 1634 Retained intron No No Yes Yes 
006 00000491010 2308 Retained intron No No No Yes 
008 00000531033 1809 Retained intron No No No No 
* CCDS8448 
SUPPLEMENTARY TABLE 7. Primer sequences used for cloning.  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
miR-155 TGTCACCTCCAGCTTTATAACC GGCTTTATCATTTTTCAATCT 
DET1 GTGCCTCACCAGAGCCAGAT CACTTAGTTCTCCCAGGAACAG 
TRIM32 GAGAAATTATCAGTTTCTTCTGC GTTCAACATCATTTTAATGACC 
JARID2 AACGCCCGTGGTCGATTTAT TATTATTAAACCTTGTAGTACAAAC 
TBRG1 ACAAGAAGGGATCAGATGCCACATCG  GAAAGAGGCCTTCAGTGTTTG 
PSIP TTGGGCTCAAAGCATTAATC TTTGGTTACAGTTTCATTCTT 
HOMEZ ATGGCATAGGTACTGCTTCC GAGTTATGCCGTAGCCCTTG 
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SUPPLEMENTATY TABLE 8. shRNA sequences. 



















shTBRG1-1 -S TCGAGACTGGAAGTTCTGAAGAAACTCGAGTTTCTTCAGAACTTCCAGTTTTTTG 





*S-sense strand, AS-antisense strand 




SUPPLEMENTARY FIGURE 1. Ago2, miR-19b and miR-155 are enriched in Ago2-IP 
fraction in ST486 and Ramos cells. (A) Analysis of the IP efficiency by Western blotting 
for Ago2 protein. Ago2 was pulled down when anti-Ago2 antibody was used and not when 
IgG1 negative control antibody was used. (B) IP efficiency of the Ago2-RISC complex 
analyzed by qRT-PCR for miR-19b and miR-155. Both miRNAs were pulled down with anti-
Ago2 antibody and not with IgG1 negative control antibody. MiRNA levels were normalized 
to RNU48. MiR-155 levels could only be measured in miR-155-transduced samples, since 
the levels in EV-transduced samples were not detectable. 
 
SUPPLEMENTARY FIGURE 2. GFP competition assay of cells transduced with 
shRNAs against five validated miR-155 target genes. Percentage of GFP+ cells was 
normalized to day 3 and fold increase or decrease within 21 days was shown. For TRIM32, 
JARID and DET1, one shRNAs caused decrease in percentage of GFP+ ST486 cells, 
whereas the other shRNA construct had no effect. For HOMEZ, both shRNAs showed an 
growth inhibitory effect. For PSIP1 the shRNA construct also resulted in growth inhibition 
of ST486 cells. The average of 2 or 3 experiments was presented. P value was determined 
by linear regression (**p<0.01, **** p<0.0001). Decrease in mRNA level of selected 
genes upon shRNA presented in a table as a ratio between mRNA level in GFP+ cells with 
shRNA compared to GFP+ cells with EV. None of the shRNAs induced a phenotype similar 
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SUMMARY AND DISCUSSION 
MiRNAs are effective gene expression regulators that play crucial roles in many 
cellular processes, such as apoptosis, proliferation and differentiation. 
Deregulated miRNA levels are observed in many diseases including cancer and 
have been causatively implicated in the cancer pathogenesis. The mechanisms 
causing altered miRNA levels or the genes affected by miRNA deregulation are 
often unknown. The aim of the research project presented in this thesis was to 
elucidate key aspects of the regulation of miRNA biogenesis (chapter 2-4) and 
consequences of altered miR-155 levels (chapter 5-6) in B-cell lymphoma. 
Regulation of miRNA biogenesis 
MiRNA levels are regulated at the transcriptional and post-transcriptional level. 
At the transcriptional level, the regulation of expression is often similar to that of 
protein-coding genes and includes regulation of expression by transcription 
factors, methylation, etc. A very important additional step in the regulation of 
miRNA expression is the processing from the primary transcript to the mature 
miRNA. In chapter 2, we discuss currently known mechanisms involved in 
regulation of miRNAs processing and we indicate that most regulatory factors 
are specific for individual miRNAs or for a subgroup of the miRNAs. Several 
tissue-specific mechanisms have been identified that result in either enhanced or 
inhibited miRNA processing. Regulatory mechanisms, as currently known from 
the literature, are described for a group of ~30 miRNAs. We speculate that in 
addition to the miRNAs specifically addressed in this chapter, many more 
miRNAs are being regulated during processing. 
 MiR-155 is one of the most studied oncogenic miRNAs that has a 
presumed regulated processing in B-cell lymphoma, although no regulating 
factors have been identified so far. MiR-155 belongs to a small group of exonic 
miRNAs that are characterized by location of the stem-loop structure in exons of 
non-protein-coding genes. Processing of miR-155 and two additional exonic 
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 We assessed levels and subcellular localization of unspliced and spliced primary 
transcripts in B-cell lymphoma cell lines. We showed that unspliced transcripts 
are predominantly nuclear, whereas spliced transcripts are partly transported to 
the cytoplasm and are, as such, unavailable for processing by the 
Microprocessor complex. These results indicate that splicing and nuclear export 
can serve as a mechanism to prevent processing of exonic miRNAs. Upon 
stimulation of B-cell lymphoma cells the unspliced/spliced transcript ratio of BIC 
(pri-miR-155) decreased, indicating that external stimuli may affect the 
efficiency of pri-miRNA splicing and nuclear export, and thereby regulate the 
levels of exonic miRNAs.  
 A second oncogenic miRNA cluster that is frequently deregulated in B-cell 
lymphoma is the miR-17~92 cluster that consists of six miRNAs, i.e. miR-17, 
miR-18a, miR-19a, miR-20a, miR-19b and miR-92a. In chapter 4, we 
investigated the expression pattern of these six miRNAs in 117 non-Hodgkin 
lymphoma (NHL) cases and in 21 NHL cell lines. We show that miR-92a is the 
most abundant miRNA in three of the four subtypes of the NHL cases, all NHL 
cell lines and in the normal B-cell subsets. Only in diffuse large B-cell lymphoma, 
miR-19b levels were higher than the miR-92a levels. Comparison of the 
individual miRNA levels in NHL as compared to their normal counterparts 
showed that miR-19b is the most significantly induced miR-17~92 cluster 
member. This suggests that either the processing efficiency or the stability of 
miR-19b is increased in NHL. The observed miR-19b induction is consistent with 
the known oncogenic role of miR-19b in lymphomagenesis. 
Identification of microRNA-155 target genes 
Studying the cellular function of specific miRNAs often includes their inhibition or 
overexpression in the cell type of interest. Transfection of small precursor-like 
molecules or anti-sense oligo’s is effective only for short-term experiments. To 
achieve long-term induction or inhibition of specific miRNAs, viral vectors are 
commonly used. For overexpression of miRNAs, cloning of the stem-loop region 
with the 100-150nt 3’ and 5’ flanking region is generally effective to induce the 
miRNA of interest. Effective strategies for inhibition of highly abundant miRNAs 
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or all members of a specific seed family are technically more challenging. In 
chapter 5, we describe a straightforward and rapid method to generate 
constructs with antisense miRNA sequences against single miRNAs, multiple 
miRNAs or seed families. These so-called miRNA sponges were generated 
starting from short oligo’s that were ligated to concatamers of variable sizes and 
cloned in a selected vector. We demonstrate that these miRNA sponges 
efficiently sequester miRNAs, inhibit their function and, as such, can be used for 
in vitro or in vivo loss-of-function studies.  
 To study the role of miR-155 and identify its target genes, we 
overexpressed miR-155 in two Burkitt lymphoma cell lines, ST486 and Ramos 
(chapter 6). Both cell lines have very low endogenous miR-155 levels compared 
to the levels in germinal center B cells. Interestingly, we observed an enhanced 
growth of ST486 cells upon miR-155 overexpression, but not of Ramos cells. 
Using Ago2-RIP-Chip we identified 54 and 15 miR-155 target genes in ST486 
and Ramos cells, respectively. The lower number of target genes and the lower 
fold enrichment of the miR-155 targets in the Ago2-IP fraction observed for miR-
155-transduced Ramos cells suggest a differential targeting efficiency in these 
two cell lines. We selected four ST486-specific miR-155 targets, TBRG1, TRIM32, 
HOMEZ, JARID2, and two common targets, DET1 and PSIP1, for further 
validation. All six genes were confirmed as miR-155 targets in a luciferase 
reporter assay. Next, we investigated whether these miR-155 targets were also 
targeted in Hodgkin lymphoma cells with high endogenous miR-155 levels. Five 
of the six selected target genes showed diminished abundance in the miRNA 
targetome of cells transduced with miR-155 sponge compared to cells 
transduced with empty vector. This suggests that these five genes are also 
targeted by endogenous miR-155 in Hodgkin lymphoma cells. To determine if we 
can copy the growth promoting phenotype observed in ST486 cells upon miR-
155 overexpression, we inhibited TBRG1, TRIM32, HOMEZ, JARID2, DET1 and 
PSIP1 using shRNA constructs. Inhibition of TBRG1 resulted in growth 
enhancement suggesting that TBRG1 is involved in growth promoting phenotype 
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 In conclusion, in this thesis we investigated mechanisms involved in 
regulation of miRNA processing and proposed a novel mechanism to regulate 
processing of exonic miRNAs by nuclear export of spliced pri-miRNA transcripts. 
We also showed differential processing of miR-17~92 cluster members and 
specific upregulation of miR-19b in NHL. In the second part, we investigated the 
effect of miRNA modulation on B-cell lymphoma cells and we described method 
to inhibit miRNAs by miRNA sponges. Finally, we identified novel miR-155 
targets in B-cell lymphoma and showed that miR-155 induced cell growth by 
targeting the TBRG1 gene. 
FUTURE PERSPECTIVES 
In the past 10 years, the miRNA research field has greatly expanded and 
knowledge regarding miRNA processing, target gene recognition and functioning 
has been gained. Despite these developments it is also clear that there are still 
many questions that need to be answered to fully understand miRNA biology. 
Identification of miRNAs with (de)regulated processing 
In this thesis we discussed miRNAs that undergo regulated processing. 
Specifically, we investigated processing of miR-155 and the miR-17~92 cluster. 
The group of miRNAs regulated at the processing level is likely to be much larger 
than currently described in the literature. An indication for regulated processing 
is an inconsistency between primary and mature miRNA levels. We started 
analysis of pri-miRNAs and mature miRNAs levels in 12 samples of normal B 
cells and B-cell lymphoma to gain a global insight in the number of miRNAs that 
are potentially regulated at the processing level.  
 The incomplete characterization of a significant subset of the primary 
miRNA transcripts makes it challenging to reliably analyze their expression 
levels. Many miRNAs are localized in introns of protein coding genes and 
commercially available probes that mostly detect spliced transcripts are not 
suitable for detection of such pri-miRNAs. Potential problems that may affect 
detection of primary miRNA transcripts of miRNAs are that (1) the exact length 
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and transcriptional start site of intergenic pri-miRNAs transcripts is frequently 
unknown; (2) it is unknown if the spliced or unspliced transcripts serve as 
templates for the biogenesis of exonic miRNA; (3) many intronic miRNAs are 
transcribed from a promoter that is different from the promoter used by the 
protein-coding host gene and this might lead to different transcript sizes; (4) 
some mature miRNAs can be transcribed from multiple loci on the genome. All 
these aspects complicate the design of a good platform to determine the 
expression levels of pri-miRNA transcripts. To address these putative 
complicating factors we designed a custom gene expression array containing 
probes that cover the stem-loop region and sequences flanking the stem-loop 
regions of all pri-miRNA transcripts (Fig. 1A). For data analysis we selected the 
probe that showed the highest signal for each stem-loop region. Probes 
corresponding to 974 miRNAs were present on both the mature and the pri-
miRNA arrays and were detectable for the pri-miRNA and/or mature miRNA in at 
least 1 of the 12 samples. Comparison of the levels of pri-miRNAs and mature 
miRNAs revealed a significant positive correlation for only 39 miRNAs, whereas a 
significant inversed correlation was observed for 35 miRNAs (Table 1). 
  The group of miRNAs with a positive correlation contained all six 
members of the miR-17~92 cluster with a Pearson correlation coefficient that 
ranged from 0.77 to 0.92 (p< 0.01). This was consistent with the positive 
correlation observed for these six miRNAs and the C13ORF25 transcript levels in  
TABLE 1. Correlation between pri-miRNA and mature miRNA. 
 #miRNAs Pearson correlation p-value 
Significant positive correlation 39 0.57- 0.92 <0.05 
Positive correlation 121 0-0.56 >0.05 
Significant negative correlation 35 -0.94- -0.58 <0.05 
Negative correlation 99 -0.57-0 >0.05 
Only pri-miRNA detected* 629 - - 
Only mature miRNA detected* 51 - - 
Total 974   
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NHL cases and cell lines (chapter 4). MiR-155 levels were also positively 
correlated with BIC transcript levels and showed a Pearson correlation coefficient 
of 0.56 (p=0.055). This is in accordance with the positive miR-155 - BIC 
correlation observed in B-cell lymphoma cell lines (chapter 3). For the vast 
majority of the analyzed miRNAs, i.e. 629 (65%), we only detected the pri-
miRNA transcripts and not the mature miRNAs. This suggests that most of the 
primary transcripts are expressed, but not processed to mature miRNAs in B 
cells or B-cell lymphoma. Another explanation might be that the mature miRNAs 
are unstable or actively degraded. 
 DGCR8 is an essential component of the Microprocessor complex and 
therefore required for miRNA processing (Han et al., 2006; Landthaler et al., 
2004). Inhibition of DGCR8 should prevent miRNA biogenesis and thus result in 
an increase of pri-miRNA levels. In our initial experiment with an shRNA against 
DGCR8 in HL cell line we observed enhanced levels for only a small fraction 
(n=53) of the pri-miRNA transcripts (Fig. 1B). The lack of enhanced pri-miRNA 
levels for the vast majority of the transcripts is not caused by a global shift in 
pri-miRNA levels during normalization procedures, since we observed no 
difference for the protein-coding transcript levels that were also present on the 
array. The efficiency of DGCR8 inhibition was shown by 2.4 fold decrease in 
DGCR8 transcript levels (Fig. 1C) and 3 fold decrease in miR-155 levels (Fig. 
1D). 
 There was a striking overlap, i.e. 33 of the 53 (62%), between the 
miRNAs that showed enhanced pri-miRNA levels upon DGCR8 inhibition and the 
miRNAs that showed a positive correlation between the mature and primary 
transcript levels. Probes for all six members of the miR-17~92 cluster as well as 
miR-155 showed 15 to 65 fold higher transcript levels upon shDGCR8 and were 
among the top ten most affected probes.  
 At present, we cannot explain why the correlation between primary and 
mature miRNA levels is so poor and why the levels of most pri-miRNA transcripts 
are not enhanced upon DGCR8 inhibition. This poor correlation might represent 
a mechanism for the cells to achieve tissue-specific miRNA expression patterns. 
This would mean that pri-miRNAs are abundantly expressed, but need auxiliary  
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FIGURE 1. Inhibition of DGCR8 affect only fraction of pri-miRNAs. (A) Up to 6 
probes were designed for each miRNA stem-loop (indicated in red), i.e. 2 probes that 
cover stem-loop region, 2 probes located within 100nt stem-loop flanking sequence and 2 
probes located in the region 100-200nt from stem-loop structure. (B) Comparison of levels 
of pri-miRNAs (indicated in black) in L1236 cells transduced with lentiviral vector 
containing shDGCR8 versus scrambled control. Correlation of protein-coding gene levels 
was indicated in color. All transcripts were detected by Agilent custom gene expression 
array. Levels of DGCR8 (C) and miR-155 (D) were decresed upon DGCR8 inhibition 
measured by qRT-PCR relative to HPRT and RNU48 levels, respectively. 
tissue-specific proteins to regulate processing by the Microprocessor complex. To 
identify the proteins that are bound to specific pri-miRNAs, immunoprecipitation 
of the Microprocessor complex and the subsequent identification of the proteins 
in different cell types need to be performed. On the other hand, it might be that 
a 2.4 fold inhibition of DGCR8 is not sufficient to effectively inhibit biogenesis of 
pri-miRNA transcripts. It would be interesting to investigate whether the same 
set of pri-miRNAs is affected in different tissue types and whether the correlation 
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these preliminary findings it is tempting to speculate that only a minority of the 
actively transcribed pri-miRNAs is processed to mature miRNAs. This implies 
that regulation of miRNA biogenesis might be a much more general phenomenon 
than currently anticipated. 
Identification of miRNA target genes in B-cell lymphoma 
In the studies described in this thesis, a clear phenotype of enhanced miR-155 
levels was observed in one of two BL cell lines. One of the identified miR-155 
targets, TBRG1, phenocopied this effect. To further study the relevance of 
TBRG1 in the pathogenesis of B-cell lymphoma it would be interesting to 
determine TBRG1 protein expression patterns in B-cell lymphoma cases with 
high and low miR-155 levels. In addition, it would be of interest to study the 
effect of enhanced TBRG1 expression in HL cell lines and study the effect of 
TBRG1 shRNA constructs in the Ramos BL cell line that did not show a 
phenotype upon miR-155 induction. It is clear that miR-155 modulation may 
have different effects in various subtypes of B-cell malignancies. To unravel 
these cell type-specific miR-155 functions the miR-155 targetomes should be 
studied in different stages of B-cell development and in different B-cell 
lymphoma subtypes. It is intriguing, why some genes are very efficiently 
targeted by specific miRNAs in one cell type, whereas they are not regulated by 
the same miRNAs in other cell types despite being expressed at high levels. 
Comparison of the miRNA targetomes of normal B cells to that of malignant B 
cells will allow indentification of the target genes that are related to the 
malignant transformation. However, it is challenging to obtain enough normal 
GC B cells for efficient immunoprecipitation of endogenous Ago2. Analogous to 
miR-155 and the previously analyzed miR-17 family target genes, several other 
miRNAs that are important for lymphomagenesis, such as miR-150, miR-21 and 
miR181b (Kotani et al., 2010), should be modulated in B-cell lymphoma cells 
and subjected to Ago2-RIP-Chip.  
 In this thesis we used anti-Ago2 antibody for immunoprecipitation of the 
RISC and the subsequent identification of miRNA target genes. However, Ago1, 
3 and 4 can also be a part of the RISC complex and the four isoforms are 
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generally redundant (Azuma-Mukai et al., 2008; Liu et al., 2004; Meister et al., 
2004). In B-cell lymphoma, we showed that Ago1 and Ago2 are expressed at 
high levels, whereas Ago3 and Ago4 are much less abundant (Tan et al., 2009). 
Nevertheless, it would be of interest to investigate the miRNA targetome using 
antibodies for all Ago isoforms separately or use a pan-Ago antibody for the RIP-
Chip. 
 Studies described in this thesis have been performed with miRNA and 
gene expression microarray analysis using the Agilent platform. In future 
studies, it would be advisable to use RNA-sequencing instead of gene expression 
arrays. For identification of miRNA target sequence by Ago2-RIP-Chip, RNA-seq 
analysis will allow specific identification of alternative splice isoforms that may 
be differentially regulated by miRNAs as shown for targeting of TBRG1 by miR-
155. Targeting of specific transcript isoforms by a miRNA has been suggested to 
represent a more common phenomenon (Deng et al., 2011). Also for miRNA 
profiling studies small-RNA-seq should be implemented to allow identification of 
novel miRNAs that are important for B-cell lymphoma. In addition, this will 
provide specific information concerning sequence variations of the miRNAs. 
Moreover, small-RNA-seq of the RIP-Chip fraction, also allows to specifically 
identify the miRNAs that are indeed loaded into the RISC and this may facilitate 
discrimination of true novel miRNAs from RNA degradation products. Recent 
technical developments such as HITS-CLIP, PAR-CLIP and CLASH attempt to 
improve methods to experimentally link miRNAs to their cellular target genes 
(Chi et al., 2009; Hafner et al., 2010; Kudla et al., 2011). This will facilitate 
identification of cell type-specific miRNA-target gene combinations, without 
modulation of miRNA levels. 
 At present, the only antisense miRNA-based therapy which is a subject of 
clinical trials is directed against miR-122 and aims to block hepatitis C virus 
replication and viremia (Elmen et al., 2008; Jopling et al., 2005; Sarasin-
Filipowicz et al., 2009). Modulation of miRNA levels also has a great potential in 
anti-cancer therapy. Mice overexpressing miR-155 and miR-21 develop miRNA-
dependent lymphomas, and removal or inhibition of these miRNAs leads to 
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oncogenic miRNAs (Babar et al., 2012; Medina et al., 2010). Therefore, these 
miRNAs present promising candidates for antisense therapy to treat B-cell 
lymphoma patients. In this respect, it would be valuable to study the potential of 
miRNA sponges described in chapter 5 to inhibit miRNAs in vivo. Tightly 
controlled modulation of miRNA levels in combination with predictable outcome 
of such modulations, i.e. the affected miRNA target genes, will enable the 
application of miRNA modulating agents in anti-cancer therapy in future studies.  
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MicroRNAs (miRNAs) zijn korte, ~22 nucleotiden (nt), RNA moleculen die 
betrokken zijn bij de regulatie van genexpressie en daarmee een cruciale rol 
spelen in een groot aantal cellulaire processen, zoals apoptose, proliferatie en 
differentiatie. Veranderingen in het expressie patroon van miRNAs zijn 
kenmerkend voor allerlei ziektebeelden en ook tumoren worden gekenmerkt 
door een afwijkend miRNA expressiepatroon. Functionele in vitro en in vivo 
studies hebben aangetoond dat deze afwijkende miRNA expressie patronen 
causaal geassocieerd zijn met het ontstaan van kanker. Echter, de mechanismen 
die betrokken zijn bij de veranderingen in het miRNA expressie patroon en de 
genen die daardoor worden gereguleerd zijn vaak nog niet bekend. Het doel van 
deze promotie studie was om factoren betrokken bij de regulatie van de miRNA 
biogenese te onderzoeken (hoofdstuk 2-4) en om de effecten van een miRNA 
dat frequent verhoogd tot expressie komt in B-cel lymfomen, miR-155,  te 
onderzoeken (hoofdstuk 5-6). 
Regulatie van de miRNA biogenese 
De expressie van miRNAs in de cel kan op transcriptioneel en post-
transcriptioneel niveau gereguleerd worden. Op het niveau van transcriptie zijn 
de regulerende mechanismen gelijk aan de mechanismen die ook de expressie 
van eiwit coderende genen reguleren, waarbij transcriptiefactoren en methylatie 
een belangrijke rol spelen. Post-transcriptioneel wordt de expressie van miRNAs 
in belangrijke mate gereguleerd door de biogenese van de functionele mature 
miRNAs uit de langere primaire transcripten. In hoofdstuk 2 wordt een overzicht 
gegeven van de factoren waarvan bekend is dat ze de biogenese van mature 
miRNAs kunnen beïnvloeden. Deze factoren oefenen direct of indirect invloed uit 
op de activiteit / specificiteit van de twee enzym complexen die betrokken zijn 
bij de biogenese. Ook kunnen ze door binding aan de "stem" of aan de "loop" 
van het primaire of precursor miRNA transcript de biogenese beïnvloeden. Tot 
op heden zijn er voor in totaal zo’n 30 verschillende miRNAs verschillende 




In hoofdstuk 3 hebben we de biogenese onderzocht van een relatief kleine groep 
van miRNAs die in exonen van niet coderende genen liggen. Voor deze groep 
van miRNAs kan het transcript met of zonder intronen dienen als template voor 
de biogenese van de mature miRNAs. Voor miRNAs die in de intronen liggen van 
coderende of niet coderende genen kunnen splicing en de eerste stappen van de 
miRNA biogenese tegelijkertijd plaats vinden. We hebben ons onderzoek gericht 
op drie miRNAs: miR-22, miR-146a en miR-155, die in exonen liggen van niet 
coderende genen. We hebben eerst gekeken naar de intracellulaire locatie van 
de primaire (pri-)miRNA transcripten met en zonder intronen. Hieruit bleek dat 
de intron houdende pri-miRNA transcripten bijna exclusief in de kern 
gelokaliseerd zijn, terwijl de pri-miRNA transcripten na splicing van de intronen 
gedeeltelijk in de kern zitten en gedeeltelijk in het cytoplasma. Aangezien de 1e 
stap voor de biogenese uitsluitend in de kern plaats vindt, is het aannemelijk dat 
de intron-houdende pri-miRNA transcripten de belangrijkste bron voor de miRNA 
biogenese zijn. De verhouding tussen de hoeveelheid transcript voor en na 
splicing kan variëren onder invloed van stimulatie, wat er op kan duiden dat de 
miRNA biogenese gereguleerd kan worden door het veranderen van de balans 
tussen splicing in combinatie met het nucleair export of miRNA biogenese. 
Overexpressie van een transcript zonder intronen resulteerde echter wel in een 
duidelijk toename van de hoeveelheid mature miRNA. Dit betekent dat het 
transcript zonder intronen wel degelijk gebruikt kan worden voor de miRNA 
biogenese mits in voldoende mate aanwezig in de kern. 
In hoofdstuk 4 hebben we een aantal karakteristieken van het miR-17~92 
transcript in B-cel lymfomen onderzocht. Dit oncogene miRNA cluster bevat de 
“stem-loop” structuren voor 6 miRNAs, miR-17, miR-18a, miR-19a, miR-20a, 
miR-19b and miR-92a. Er zijn twee iso-vormen van dit transcript, waarbij de 
stem-loop structuren zich kunnen bevinden in het exon van de ene iso-vorm en 
in het intron van de andere iso-vorm. Opmerkelijk is dat de expressie van de 
mature miRNAs in de cel sterk kan verschillen, terwijl ze allen afkomstig zijn van 
hetzelfde primaire transcript. We hebben de hoeveelheid van de zes miRNAs 
bepaald in drie B cel maturatie stadia, 117 B cel lymfomen en in 21 B cel 
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lymfoom cellijnen. In normale B cel subsets en drie B cel lymfoom subtypen was 
de expressie van miR-92 10 tot 100x hoger dan de 5 andere miRNAs. Alleen bij 
het diffuus groot cellig B cel lymfoom was de expressie van miR-19b het hoogst. 
In vergelijking met de normale voorloper cellen lieten alle lymfoom subtypen 
een sterke toename zien van met name miR-19b, terwijl geen toename werd 
gezien van miR-92. Ook voor de andere vier miRNAs werden geen verhoogde 
expressie niveaus gevonden ten opzichte van de normale B cellen. De sterke 
inductie van miR-19b is consistent met de oncogene effecten van dit miRNA 
zoals aangetoond in muis modellen. Onze data duiden erop dat er een sterke 
regulatie is van de hoeveelheid mature miRNAs, dit kan bereikt worden door 
verschillen in de processing efficiency van de zes precursor miRNAs en/of door 
verschillen in de stabiliteit van de mature miRNAs.   
miRNA-155 target genen 
In hoofdstuk 5 beschrijven we een methode waarmee we op een efficiënte 
manier de functie van miRNAs kunnen remmen door productie van antisense 
transcripten met meerdere bindingsplaatsen voor de miRNA(s) van interesse. De 
antisense transcripten worden op een zodanige manier ontwikkeld dat ze een 
variabel aantal bindingsplaatsen gericht tegen een of meerdere miRNAs kunnen 
bevatten. De antisense transcripten worden tot overexpressie gebracht door 
klonering in een virale vector en infectie in het celtype van interesse. We laten 
op verschillende manieren, waaronder reporter testen en functionele testen, zien 
dat deze zogenaamde spons vectoren effectief zijn in B cel lymfoom cellijnen. De 
methode is gebaseerd op concatemerisatie van dubbelstrengs oligo’s die twee 
miRNA bindingsplaatsen bevatten met daar tussen een korte willekeurige 
sequentie. De 1-staps ligatie reactie met een oligo-vector ratio variërend van 
1:10 tot 1:1000 resulteert in constructen met een variabel aantal oligo’s en dus 
ook een variabel aantal miRNA bindingsplaatsen. De spons vectoren kunnen op 
deze manier efficiënt gemaakt worden gebruikt worden om het effect van miRNA 




Om de oncogene rol van miR-155 verder te bestuderen hebben we in hoofdstuk 
6 dit miRNA tot overexpressie gebracht in twee Burkitt lymfoom cellijnen, ST486 
and Ramos. Deze twee cellijnen hebben een lage endogene miR-155 expressie 
in vergelijking met de normale voorloper cellen. In een cel proliferatie test 
toonden we aan dat in ST486 cellen miR-155 een groei voordeel opleverde, 
terwijl in Ramos cellen geen effect werd gezien op de groei snelheid. Door 
immuunprecipitatie van het RNA-induced silencing complex in cellen met 
overexpressie van miR-155, en de daarop volgende gen expressie profiling 
konden we 54 miR-155 target genen in ST485 en 15 in Ramos aan tonen. Voor 
zes genen hebben we vervolgens aanvullende functionele studies uitgevoerd om 
te kijken of een van deze genen betrokken was bij het miR-155 fenotype in 
ST486. TBRG1, TRIM32, HOMEZ en JARID2 werden alleen in ST486 gevonden 
als zijnde miR-155 targets, terwijl DET1 en PSIP1, in zowel ST486 als ook in 
Ramos als target genen voor miR-155 werden geïdentificeerd. Voor zes 
geselecteerde genen hebben we middels een luciferase test binding door miR-
155 bevestigd. Voor DET1 konden we ook op eiwit niveau aantonen dat er 
regulatie door miR-155 plaats vond. Remming van miR-155 in een Hodgkin 
lymfoom cellijn met hoge endogene miR-155 niveaus, bevestigde binding van 
miR-155 voor vijf van de zes genen. Cel proliferatie testen met shRNAs tegen 
alle zes genen in ST486 lieten voor vijf genen geen effect of geen groei remming 
zien. Voor TBRG1 zagen we groei stimulerend effect, vergelijkbaar met het 
effect zoals gevonden voor miR-155. Dit onderzoek toont aan dat het groei 
stimulerende effect van miR-155 op zijn minst gedeeltelijk kan worden 
toegeschreven aan het remmen van TBRG1 in ST486 cellen. 
 
Samenvattend, laten we in dit proefschrift zien hoe de miRNA biogenese 
gereguleerd kan worden voor een specifieke groep van miRNAs die gelokaliseerd 
zijn in exonen van niet voor eiwit coderende genen. Verder laten we zien dat er 
in B cel lymfomen een sterke regulatie is van de miRNA expressie niveaus van 
miRNAs die afkomstig zijn van hetzelfde primaire miR-17~92 miRNA transcript. 
in alle B cel lymfoom subtypen werd overexpressie van het oncogene miR-19b 
gevonden. In het tweede deel van dit proefschrift hebben we een methode 
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ontwikkeld om op een effectieve manier miRNAs te kunnen remmen. Daarnaast 
hebben we de rol van miR-155 onderzocht in B cel lymfomen en aangetoond dat 
TBRG1 een belangrijk target gen is voor de oncogene rol van miR-155.  






Slezak-Prochazka I, Kluiver J, de Jong D, Halsema N, Poppema S, Kroesen BJ, 
van den Berg A. 2012. Cellular localization and processing of primary transcripts 
of exonic microRNAs. PLoS One, provisionally accepted. 
Kluiver J, Slezak-Prochazka I, van den Berg A. 2012. Studying MicroRNAs in 
Lymphoma. Methods in Molecular Biology  971, in press. 
Kluiver J, Slezak-Prochazka I, Smigielska-Czepiel K, Halsema N, Kroesen BJ, 
van den Berg A. 2012. Generation of miRNA sponge constructs. Methods 58: 
113-117. 
Kluiver J, Gibcus JH, Hettinga C, Adema A, Richter MK, Halsema N, Slezak-
Prochazka I, Ding Y, Kroesen BJ, van den Berg A. 2012. Rapid generation of 
microRNA sponges for microRNA inhibition. PLoS One 7(1):e29275. 
Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A. 2010. MicroRNAs, 





Every journey starts with a first step. My first step in Groningen was 5 years ago 
when I started my internship and I immediately knew that I wanted to do my 
PhD here. I would like to thank my promoter Prof. Anke van den Berg for giving 
me this opportunity. Anke, you showed me how to be a good scientist and how 
to make, sometimes difficult, decisions and cherish small successes. You made 
me believe in myself. You also knew when to push me and when to let go. I 
admire how you can do so much so quickly and always think logical.  
I would like to acknowledge my co-promoters Dr. Bart-Jan Kroesen and 
Dr. Joost Kluiver. Bart-Jan, I admire your writing skills and ability to put 
thoughts into exactly the right words. Thank you also for your easy-going 
attitude. Joost, I learned a lot from you on how to design experiments and 
analyze data. I enjoyed our work-related and less work related conversations. 
Thank you for your help with solving my countless scientific and daily-life 
problems and for cheering me up when I needed it.  
I would also like to express my gratitude to Prof. Gerald de Haan, Prof. 
Philip Kluin and Prof. Jan Jacob Schuringa. I appreciate that you accepted to be 
members of my reading committee and spent your valuable time on reading my 
thesis.  
My utmost thanks go to all present and former members of the “miRNA 
group”. It was a pleasure to work with you. Johan, you were an inspiring and 
motivating supervisor during my internship and as a colleague later on. I 
admired how you came up with new fascinating ideas and so passionately talked 
about them. Jan-Lukas, I am grateful that you shared your project that resulted 
in my chapter 4. I like your English sense of humor and stories about your 
daughter. Debora, you were a huge help in the lab, especially in the last 
months. You were understanding when I needed to have everything done before 
yesterday and enthusiastic when something worked out.  I am very happy that 
you agreed to be my paranimf. Nancy, I appreciate especially your help with 
microarrays, how you calmed me down when I was jittery over pipetting 




without you… Gertrud, you made me smile every time I saw you. Thank you that 
you were eager to help and that you put so much heart into whatever you did. 
Bea, I appreciate your help with Western Blots and RNA isolations. Melanie, 
thank you for spending your holidays on handling the massive amount of work I 
had for you. Rikst-Nynke, you introduced me to the lab during my internship, 
patiently answered all my beginners questions and were so kind to me. Geert, 
your experience with qRT-PCR analysis and microarrays was very helpful and I 
am grateful for teaching me how to handle the plating robot. Chris, thank you 
for the 3 months when you handled the things I didn’t have time for and for 
your Friday afternoon jokes. Pytrick, thanks for work discussions and sharing 
reagents. 
I am also thankful to the co-authors and collaborators. Prof. Sibrand 
Poppema, thank you for your expert opinion on my research. I very much 
enjoyed the two Allersmaborg meetings, where we could discuss our projects 
from a global point of view in a very friendly atmosphere. Klaas, your help with 
designing and analyzing custom arrays is highly appreciated. I learnt a lot from 
you and Martijn about analysis of large datasets in a systematic way. Ye Ding, 
thank you for your expertise on designing miRNA sponges and for taking me for 
Chinese dinner in Vancouver.  
I would also like to acknowledge Lydia and Arjan from the Malignant 
Lymphoma group. Lydia, thank you for your kind words just in the right time 
and for the delicious carrot cake on my farewell party. I also very much enjoyed 
the multicultural meeting with you and the PhD students at your place. Arjan, I 
appreciate your stimulating questions during my presentations.  
I would also like to say that thank you to all the people from the DNA and 
O&O labs (Mirjam, Lorian, Weird, Klaas, Sippie, Inge, Jenny, Sicco, Eric, Sharon, 
Annelies, Hans, Rianne and others). I very much enjoyed working with you. You 
helped me whenever I had doubts and created a very nice working environment 
(and the labs were so well organized!). 
A special thanks to fellow PhD students. Wouter, I liked talking to you 
about serious and not serious issues. I know that you keep a list of things I 
shouldn’t have said… Sietse, thanks for your help with translating Dutch letters. 
Dankwoord 
171 
To my fellow foreign PhD students (Lu Ping, Chuanhui, Kushi, Ali, Mina, Yuxuan, 
Huang Xin, Richard, Zheng Liang, Rea, Achmed, Nato, Li Jun), I appreciate that 
we could talk about differences in our cultures, try traditional food (at Lydia’s 
and Anke’s place) and discuss difficulties that we encounter as foreigners.  Lu 
Ping, you gave me some good pieces of advice when I was starting my PhD. 
Thank you for establishing Ago2-RIP-Chip technique in our lab. As you can see it 
works well! Kushi, I enjoyed listening to your stories about Indian weddings. Ali, 
you had a good conclusion, namely that Iranian and Polish people are very 
similar. Chuanhui, Huang Xin, Richard, I hope you are doing well in China. 
Kushi, Ali, Yuxuan, Zheng Liang, Rea, Achmed, Mina, Nato, Li Jun, good luck 
with your projects and I am looking forward to getting your dissertations!  
I am also grateful to Geert, Henk and Roelof-Jan from FACS facility for 
patiently sorting my “difficult” cells and squeezing my sorts in the very busy 
sorting schedule. Big thanks to my two German students, Ann-Christin and 
Julian. You were great students and thanks to you I realized that I like teaching. 
Thank you Jan and Roel for help with computers and thanks to the secretaries 
from our department for being helpful and efficient.  
I am also grateful to Prof. Hanna Rokita for mentoring me during my 
studies at the Jagiellonian University and encouraging me to participate in the 
Erasmus program. 
Thank you to my Polish lunch team (Marta, Kasia, Paulina). Girls, thank 
you for always being there for me. You were like a family. Marta, I wish you all 
the best with your work as scientist/doctor/fitness instructor. I enjoyed our 
Friday evening outings. I will never forget that you drove all the way to 
Eindhoven and we made it 1 minute before the gate at the airport closed. Kasia, 
thank you for our long evening coffee chats. It was nice to have someone with 
similar problems and sometimes very different point of view. Good luck with 
your and Marcin’s defense! Paulina, you were a great flatmate and I loved your 
sarcastic comments. Marta and Kasia, it is great that you are willing to be my 
paranimfen! 
I would like to thank my family. Mamo i Tato, dziękuję Wam za to, że 




co robię powinnam robić najlepiej jak potrafię (Mum and Dad, thank you for 
teaching me to follow my dreams and change dreams into plans and that 
whatever I do I should do my best). Kora, I could always call you when I felt 
lonely. Bartek, without your constant support, love, friendship and ability to 
make me laugh I couldn’t finish it. I am so happy that we proved ourselves that 
long-distance relationship can work out! 
I smile to my computer when writing these acknowledgements and 
recalling all the nice memories. It is time to move on, but the people I met in 
Groningen will always be in my mind and heart. Thank you all! 
 
